Omnicomm Systems (OMCM) 10-K/A 8 Sep 14 2013 FY Annual report (amended) Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 28, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'OMNICOMM SYSTEMS INC	'	'
Document Type	'10-K	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Common Stock, Shares Outstanding	'	90,104,659	'
Entity Public Float	'	'	$15,980,081
Amendment Flag	'false	'	'
Entity Central Index Key	'0001034592	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
CURRENT ASSETS	'	'
Cash	$1,160,720	$873,315
Accounts receivable, net of allowance for doubtful accounts of $65,341 and $84,210, respectively	1,599,568	1,240,898
Prepaid expenses	146,907	131,942
Total current assets	2,907,195	2,246,155
Property and equipment, net	607,433	481,803
Intangible assets, net	270,242	0
Goodwill	675,710	0
Prepaid stock compensation	169,375	0
Other assets	82,501	51,153
TOTAL ASSETS	4,712,456	2,779,111
CURRENT LIABILITIES	'	'
Accounts payable and accrued expenses	2,540,956	2,124,365
Notes payable, current portion	37,500	0
Deferred revenue, current portion	2,866,356	3,732,240
Line of credit	3,500,000	0
Convertible notes payable, related parties, current portion, net of discount	0	160,000
Convertible notes payable, current portion, net of discount	75,000	75,000
Patent settlement liability, current portion	962,500	962,500
LONG TERM LIABILITIES	'	'
Notes payable, long term, net of current portion	614,486	651,987
Notes payable, related parties, long term, net of current portion, net of discount of $447,666 and $656,524, respectively	4,568,213	3,830,355
Deferred revenue, long term, net of current portion	1,385,017	987,328
Convertible notes payable, related parties, net of current portion	9,125,000	8,965,000
Convertible notes payable, net of current portion	465,000	465,000
Patent settlement liability, long term, net of current portion	963,124	1,223,715
TOTAL LIABILITIES	36,173,335	31,752,411
SHAREHOLDERS' (DEFICIT)	'	'
Preferred stock	0	0
Common stock - 250,000,000 shares authorized, 90,104,659 and 86,598,659 issued and outstanding, respectively, at $0.001 par value	90,105	86,599
Additional paid in capital - preferred	4,717,804	4,717,804
Additional paid in capital - common	37,334,358	36,645,589
Accumulated other comprehensive (loss)	-87,604	-69,092
Accumulated deficit	-73,519,917	-70,358,575
TOTAL SHAREHOLDERS' (DEFICIT)	-31,460,879	-28,973,300
TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT)	4,712,456	2,779,111
Series B Preferred Stock [Member]	'	'
SHAREHOLDERS' (DEFICIT)	'	'
Preferred stock	0	0
Series C Preferred Stock [Member]	'	'
SHAREHOLDERS' (DEFICIT)	'	'
Preferred stock	0	0
Series A Preferred Stock [Member]	'	'
SHAREHOLDERS' (DEFICIT)	'	'
Preferred stock	4,125	4,125
Series D Preferred Stock [Member]	'	'
SHAREHOLDERS' (DEFICIT)	'	'
Preferred stock	250	250
Conversion Feature Liability, Related Parties [Member]	'	'
CURRENT LIABILITIES	'	'
Derivative liabilities, current	2,979,392	2,240,782
Conversion Feature Liability [Member]	'	'
CURRENT LIABILITIES	'	'
Derivative liabilities, current	146,814	46,541
Warrant Liability, Related Parties [Member]	'	'
CURRENT LIABILITIES	'	'
Derivative liabilities, current	5,799,946	6,095,153
Warrant Liability [Member]	'	'
CURRENT LIABILITIES	'	'
Derivative liabilities, current	144,031	192,445
Total current liabilities	$19,052,495	$15,629,026

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
			Series B Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Series C Preferred Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]
Allowance for doubtful accounts (in Dollars)	$65,341	$84,210	'	'	'	'	'	'
Notes payable related parties noncurrent, discount (in Dollars)	447,666	656,524	'	'	'	'	'	'
Preferred stock, par value (in Dollars per share)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000	230,000	230,000	747,500	747,500	5,000,000	5,000,000
Preferred stock, shares undesignated (in Dollars)	3,772,500	3,772,500	'	'	'	'	'	'
Preferred stock, shares issued	'	'	0	0	0	0	4,125,224	4,125,224
Preferred stock, shares outstanding	'	'	0	0	0	0	4,125,224	4,125,224
Preferred stock, liquidation preference (in Dollars)	'	'	$0	$0	$0	$0	$4,125,224	$4,125,224
Common stock, shares authorized	250,000,000	250,000,000	'	'	'	'	'	'
Common stock, shares issued	90,104,659	86,598,659	'	'	'	'	'	'
Common stock, shares outstanding	90,104,659	86,598,659	'	'	'	'	'	'
Common stock, par value (in Dollars per share)	$0.00	$0.00	'	'	'	'	'	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues	$13,887,520	$14,818,479
Reimbursable revenues	444,320	733,784
Total revenues	14,331,840	15,552,263
Cost of goods sold	2,560,191	2,762,081
Reimbursable expenses-cost of goods sold	351,022	451,576
Gross margin	11,420,627	12,338,606
Operating expenses	'	'
Salaries, benefits and related taxes	8,758,276	8,335,565
Rent and occupancy expenses	894,121	881,503
Consulting services	157,905	152,297
Legal and professional fees	265,251	278,427
Travel	534,135	442,030
Telephone and internet	187,078	165,877
Selling, general and administrative	851,642	931,269
Bad debt expense	11,131	-58,234
Depreciation expense	230,323	377,680
Amortization expense	7,720	232,117
Total operating expenses	11,897,582	11,738,531
Operating income/(loss)	-476,955	600,075
Other income/(expense)	'	'
Interest expense	-150,410	-116,531
Interest expense, related parties	-2,339,702	-2,108,749
Interest income	9	237
Change in derivative liabilities	-95,121	-6,123,302
Loss on sale of fixed assets	0	-22,106
Transaction gain/(loss)	-5,041	1,220
(Loss) before income taxes	-3,067,220	-7,769,156
Income taxes	-94,122	-63,814
Net (loss)	-3,161,342	-7,832,970
Preferred stock dividends in arrears	'	'
Preferred stock dividends	-206,261	-229,517
Net (loss) attributable to common stockholders	-3,367,603	-8,062,487
Net (loss) per share	'	'
Basic and diluted (in Dollars per share)	($0.04)	($0.09)
Weighted average number of shares outstanding	'	'
Basic and diluted (in Shares)	87,969,202	86,522,332
Cost of Goods Sold, Including Reimbursable Expenses [Member]	'	'
Cost of goods sold	2,911,213	3,213,657
Preferred Class A [Member]	'	'
Preferred stock dividends in arrears	'	'
Preferred stock dividends	($206,261)	($229,517)

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive (Loss) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Net (loss) attributable to common stockholders	($3,367,603)	($8,062,487)
Other comprehensive (loss)	'	'
Change in foreign currency translation adjustment	-18,512	-15,378
Other comprehensive (loss)	-18,512	-15,378
Comprehensive (loss)	($3,386,115)	($8,077,865)

Consolidated_Statement_of_Shar

Consolidated Statement of Shareholders' (Deficit) (USD $)	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	Additional Paid In Capital, Preferred [Member]	Common Stock [Member]	Additional Paid In Capital, Common [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
Balances at December 31, 2011 at Dec. 31, 2011	$4,125	$0	$0	$250	$4,717,804	$86,482	$36,572,099	($62,525,605)	($53,714)	($21,198,559)
Balances at December 31, 2011 (in Shares) at Dec. 31, 2011	4,125,224	0	0	250,000	'	86,481,495	'	'	'	'
Employee stock option expense	'	'	'	'	'	'	65,744	'	'	65,744
Foreign currency translation adjustment	'	'	'	'	'	'	'	'	-15,378	-15,378
Issuance of common stock in lieu of accrued interest	'	'	'	'	'	42	7,821	'	'	7,863
Issuance of common stock in lieu of accrued interest (in Shares)	'	'	'	'	'	42,164	'	'	'	'
EmployP5P5 stock option P5xP5rcisP5	'	'	'	'	'	75	-75	'	'	0
EmployP5P5 stock option P5xP5rcisP5 (in Shares)	'	'	'	'	'	75,000	'	'	'	'
Net loss for the period	0	0	0	0	0	0	0	-7,832,970	0	-7,832,970
Ending Balance at Dec. 31, 2012	4,125	0	0	250	4,717,804	86,599	36,645,589	-70,358,575	-69,092	-28,973,300
Ending Balance (in Shares) at Dec. 31, 2012	4,125,224	0	0	250,000	'	86,598,659	'	'	'	'
Employee stock option expense	'	'	'	'	'	'	83,875	'	'	83,875
Foreign currency translation adjustment	'	'	'	'	'	'	'	'	-18,512	-18,512
Restricted stock issuance	'	'	'	'	'	1,225	221,275	'	'	222,500
Restricted stock issuance (in Shares)	'	'	'	'	'	1,225,000	'	'	'	'
Issuance of common stock in lieu of accrued interest	'	'	'	'	'	'	'	'	'	0
EmployP5P5 stock option P5xP5rcisP5	'	'	'	'	'	11	-11	'	'	0
EmployP5P5 stock option P5xP5rcisP5 (in Shares)	'	'	'	'	'	11,000	'	'	'	'
Shares issued for Purchase of Promasys	'	'	'	'	'	2,270	383,630	'	'	385,900
Shares issued for Purchase of Promasys (in Shares)	'	'	'	'	'	2,270,000	'	'	'	'
Net loss for the period	0	0	0	0	0	0	0	-3,161,342	0	-3,161,342
Ending Balance at Dec. 31, 2013	$4,125	$0	$0	$250	$4,717,804	$90,105	$37,334,358	($73,519,917)	($87,604)	($31,460,879)
Ending Balance (in Shares) at Dec. 31, 2013	4,125,224	0	0	250,000	'	90,104,659	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss	($3,161,342)	($7,832,970)
Adjustment to reconcile net loss to net cash (used in) operating activities	'	'
Change in derivative liabilities	95,121	6,123,302
Interest expense from derivative instruments	609,000	475,621
Loss from sale of fixed assets, net	0	14,606
	0	7,863
Employee stock option expense	83,875	65,744
Amortization of prepaid compensation	53,125	0
Provision for doubtful accounts	11,131	-58,234
Depreciation and amortization	238,043	609,797
Changes in operating assets and liabilities	'	'
Accounts receivable	-153,514	101,280
Prepaid expenses	-14,966	25,421
Other assets	-31,348	-17,484
Accounts payable and accrued expenses	775,251	663,530
Patent settlement liability	-260,591	-194,032
Deferred revenue	-697,548	-158,356
Net cash (used in) operating activities	-2,453,763	-173,912
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Proceeds from sale of property and equipment	0	50,000
Payments to acquire business, net of cash acquired	-386,545	0
Purchase of property and equipment	-353,775	-157,882
Net cash (used in) investing activities	-740,320	-107,882
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Repayments of notes payable	0	-131,800
Proceeds from revolving line of credit	3,500,000	0
Net cash provided by/(used in) financing activities	3,500,000	-131,800
Effect of exchange rate changes on cash and cash equivalents	-18,512	-15,378
Net increase/(decrease) in cash and cash equivalents	287,405	-428,972
Cash and cash equivalents at beginning of period	873,315	1,302,287
Cash and cash equivalents at end of period	1,160,720	873,315
Cash paid during the period for:	'	'
Income taxes	94,122	63,814
Interest	835,154	1,331,956
Non-cash transactions	'	'
Common stock issued for the acquisition of Promasys B.V.	385,900	'
Notes Payable Issued for Existing Notes Payable [Member]	'	'
Non-cash transactions	'	'
Debt conversion, Notes Issued	3,501,366	0
Promissory Notes Issued for Accrued Interest [Member]	'	'
Non-cash transactions	'	'
Debt conversion, Notes Issued	529,000	0
Promasys B.V. [Member]	'	'
Non-cash transactions	'	'
Common stock issued for the acquisition of Promasys B.V.	$385,900	$0

Note_1_Organization_and_Nature

Note 1 - Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Nature of Operations [Text Block]	'
	NOTE 1:               ORGANIZATION AND NATURE OF OPERATIONS
	OmniComm Systems, Inc. (“OmniComm” or the “Company”) is a healthcare technology company that provides Web-based electronic data capture (“EDC”) solutions and related value-added services to pharmaceutical and biotech companies, clinical research organizations, and other clinical trial sponsors principally located in the United States, Europe and Asia. Our proprietary EDC software applications; TrialMaster®; TrialOne®; Promasys® and eClinical Suite, allow clinical trial sponsors and investigative sites to securely collect, validate, transmit, and analyze clinical trial data.
	Our ability to compete within the EDC industry is predicated on our ability to continue enhancing and broadening the scope of solutions offered through our EDC software and services.  Our research and development (“R&D”) efforts are focused on developing new and complementary software solutions, as well as enhancing our existing software solutions through the addition of increased functionality.    During the years ended December 31, 2013 and December 31, 2012 we spent approximately $2,403,504 and $2,337,904, respectively, on R&D activities, which is primarily comprised of salaries to our developers and other R&D personnel and related costs associated with the development of our software products.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

'

Significant Accounting Policies [Text Block]

'

NOTE 2:                SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION

The Company’s accounts include those of all its wholly-owned subsidiaries, which are more fully described in the Company’s Annual Report filed on Form 10-K with the Securities and Exchange Commission, and have been prepared in conformity with (i) accounting principles generally accepted in the United States of America; and (ii) the rules and regulations of the United States Securities and Exchange Commission.  All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated in consolidation.

ESTIMATES IN FINANCIAL STATEMENTS

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and footnotes thereto.  Significant estimates incorporated in our financial statements include the recorded allowance for doubtful accounts, the estimate of the appropriate amortization period of our intangible assets, the evaluation of whether our intangible assets have suffered any impairment, the allocation of revenues under multiple-element customer contracts, royalty-based patent liabilities, the value of derivatives associated with debt issued by the Company and the valuation of any corresponding discount to the issuance of our debt.  Actual results may differ from those estimates.

RECLASSIFICATIONS

Certain reclassifications have been made in the 2012 financial statements to conform to the 2013 presentation.  These reclassifications did not have any effect on our net loss or shareholders’ deficit.

FOREIGN CURRENCY TRANSLATION

The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830-30, Foreign Currency Matters—Translation of Financial Statements. The reporting currency for the Company is the U.S. dollar. The functional currency of the Company’s subsidiaries, OmniComm Europe GmbH in Germany, OmniComm Spain S.L. in Spain and Promasys B.V. in the Netherlands is the Euro. The functional currency of the Company's subsidiary, OmniComm Ltd. in the United Kingdom is the British Pound Sterling. Accordingly, the assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using the exchange rate in effect at each balance sheet date. Revenue and expense accounts of the Company’s foreign subsidiaries are translated using an average rate of exchange during the period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income (loss) as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are primarily related to intercompany accounts that have been determined to be temporary in nature and accordingly, are recorded directly to the statement of operations.  We record translation gains and losses in accumulated other comprehensive income as a component of stockholders’ equity. We recorded a translation loss of $18,512 for the year ended December 31, 2013 and a translation loss of $15,378 for the year ended December 31, 2012.

REVENUE RECOGNITION POLICY

The Company derives revenues from software licenses and services of its EDC products and services which can be purchased on a stand-alone basis. License revenues are derived principally from the sale of term licenses for the following software products offered by the Company: TrialMaster, TrialOne, Promasys and eClinical Suite (the “EDC Software”). Service revenues are derived principally from the Company's delivery of the hosted solutions of its TrialMaster and eClinical Suite software products, and consulting services and customer support, including training, for all of the Company's products.

The Company recognizes revenues when all of the following conditions are satisfied: (1) there is persuasive evidence of an arrangement; (2) the product or service has been provided to the customer; (3) the collection of fees is probable; and (4) the amount of fees to be paid by the customer is fixed or determinable.

The Company operates in one reportable segment which is the delivery of EDC Software and services to clinical trial sponsors.  The Company segregates its revenues based on the activity cycle used to generate its revenues.  Accordingly, revenues are currently generated through four main activities. These activities include hosted applications, licensing, professional services and maintenance-related services.

Hosted Application Revenues

The Company offers its TrialMaster and eClinical Suite software products as hosted application solutions delivered through a standard Web-browser, with customer support and training services. To date, hosted applications revenues have been primarily related to TrialMaster.

Revenues resulting from TrialMaster and eClinical Suite application hosting services consist of three components of services for each clinical trial: the first component is comprised of application set up, including design of electronic case report forms and edit checks, installation and server configuration of the system.  The second component involves application hosting and related support services as well as billable change orders which consist of amounts billed to customers for functionality changes made. The third stage involves services required to close out, or lock, the database for the clinical trial.

Fees charged and costs incurred for the trial system design, set up and implementation are amortized and recognized ratably over the estimated hosting period.  Work performed outside the original scope of work is contracted for separately as an additional fee and is generally recognized ratably over the remaining term of the hosting period. Fees for the first and third stages of the service are billed based upon milestones.  Revenues earned upon completion of a contractual milestone are deferred and recognized over the estimated remaining hosting period.   Fees for application hosting and related services in the second stage are generally billed quarterly in advance.  Revenues resulting from hosting services for the eClinical Suite products consist of installation and server configuration, application hosting and related support services. Services for this offering are generally charged as a fixed fee payable on a quarterly or annual basis. Revenues are recognized ratably over the period of the service.

Licensing Revenues

The Company's software license revenues are earned from the sale of off-the-shelf software.  From time-to-time a client might require significant modification or customization subsequent to delivery to the customer.  The Company generally enters into software term licenses for its EDC Software products with its customers for 3 to 5 year periods, although customers have entered into both longer and shorter term license agreements.  These arrangements typically include multiple elements: software license, consulting services and customer support. The Company bills its customers in accordance with the terms of the underlying contract. Generally, the Company bills license fees in advance for each billing cycle of the license term which typically is either on a quarterly or annual basis. Payment terms are generally net 30 days.

In the past the Company has sold perpetual licenses for EDC Software products in certain situations to existing customers with the option to purchase customer support, and may in the future do so for new customers based on customer requirements or market conditions. The Company has established vendor specific objective evidence of fair value for the customer support. Accordingly, license revenues are recognized upon delivery of the software and when all other revenue recognition criteria are met. Customer support revenues are recognized ratably over the term of the underlying support arrangement.  The Company generates customer support and maintenance revenues from its perpetual license customer base.

Professional Services

The Company may also enter into arrangements to provide consulting services separate from a license arrangement. In these situations, revenue is recognized on a time-and-materials basis. Professional services can be deemed to be as essential to the functionality of the software at inception and typically are for initial trial configuration, implementation planning, loading of software, building simple interfaces and running test data and documentation of procedures.  Subsequent additions or extensions to license terms do not generally include additional professional services.

Maintenance Revenues

Maintenance includes telephone-based help desk support and software maintenance. The Company generally bundles customer support with the software license for the entire term of the arrangement. As a result, the Company generally recognizes revenues for both maintenance and software licenses ratably over the term of the software license and support arrangement. The Company allocates the revenues recognized for these arrangements to the different elements based on management's estimate of the relative fair value of each element.  The Company generally invoices each of the elements based on separately quoted amounts and thus has a fairly accurate estimate of the relative fair values of each of the invoiced revenue elements.

The fees associated with each business activity for the years ended December 31, 2013 and December 31, 2012, respectively are:

For the year ended

Revenue activity

31-Dec-13

31-Dec-12

Set-up fees

$

3,369,670

$

4,990,378

Change orders

475,680

249,673

Maintenance

4,584,594

5,270,913

Software licenses

2,911,509

3,364,324

Professional services

2,207,181

996,081

Hosting

783,206

680,894

Total

$

14,331,840

$

15,552,263

COST OF REVENUES

Cost of revenues primarily consists of costs related to hosting, maintaining and supporting the Company’s application suite and delivering professional services and support. These costs include salaries, benefits, bonuses and stock-based compensation for the Company’s professional services staff. Cost of revenues also includes outside service provider cost.  Cost of revenues is expensed as incurred.

CASH AND CASH EQUIVALENTS

Cash equivalents consist of highly liquid, short-term investments with maturities of 90 days or less.  The carrying amount reported in the accompanying consolidated balance sheets approximates fair value.

ACCOUNTS RECEIVABLE

Accounts receivable are judged as to collectability by management and an allowance for bad debts is established as necessary. The allowance is based on an evaluation of the collectability of accounts receivable and prior bad debt experience.  The Company had recorded an allowance for uncollectible accounts receivable of $65,341 and $84,210 as of December 31, 2013 and December 31, 2012, respectively.

The following table summarizes activity in the Company's allowance for doubtful accounts for the years presented.

December 31, 2013

December 31, 2012

Beginning of period

$

84,210

$

142,444

Bad debt expense

11,131

(58,234

)

Write-offs

(30,000

)

-0-

End of period

$

65,341

$

84,210

CONCENTRATION OF CREDIT RISK

Cash and cash equivalents and restricted cash are deposited with major financial institutions and, at times, such balances with any one financial institution may be in excess of FDIC-insured limits. As of December 31, 2013, $793,016 was deposited in excess of FDIC-insured limits.  Management believes the risk in these situations to be minimal.

Except as follows, the Company has no significant off balance sheet risk or credit risk concentrations. Financial instruments that subject the Company to potential credit risks are principally cash equivalents and accounts receivable. Concentrated credit risk with respect to accounts receivable is limited to creditworthy customers. The Company's customers are principally located in the United States and Europe.   The Company is directly affected by the overall financial condition of the pharmaceutical, biotechnology and medical device industries and management believes that credit risk exists and that any credit risk the Company faces has been adequately reserved for as of December 31, 2013.  The Company maintains an allowance for doubtful accounts based on accounts past due according to contractual terms and historical collection experience. Actual losses when incurred are charged to the allowance. The Company's losses related to collection of accounts receivable have consistently been within management's expectations.  As of December 31, 2013, the Company believes no additional credit risk exists beyond the amounts provided for in our allowance for uncollectible accounts.  The Company evaluates its allowance for uncollectable accounts on a monthly basis based on a specific review of receivable aging and the period that any receivables are beyond the standard payment terms. The Company does not require collateral from its customers in order to mitigate credit risk.

One customer accounted for 11% during the year ended December 31, 2013 or approximately $1,551,100, respectively. One customer accounted for 19% and another accounted for 16% of our revenues during the year ended December 31, 2012 or approximately $2,909,300 and $2,503,100, respectively.  The following table summarizes the number of customers who individually comprise greater than 10% of total revenue and/or total accounts receivable and their aggregate percentage of the Company's total revenue and gross accounts receivable for the years presented.

Revenues

Accounts Receivable

For the years ended

Number of

Percentage of

Number of

Percentage of accounts

customers

total revenues

customers

receivable

31-Dec-13

1

11%

2

23%

31-Dec-12

2

35%

3

54%

The table below provides revenues from European customers for the years ended December 31, 2013 and December 31, 2012, respectively.

European revenues

For the year ended

31-Dec-13

31-Dec-12

European revenues

% of Total revenues

European revenues

% of Total revenues

$

1,847,305

12.90%

$

1,545,730

9.90%

The Company serves all of its hosting customers from third-party web hosting facilities located in the United States. The Company does not control the operation of these facilities, and they are vulnerable to damage or interruption. The Company maintains redundant systems that can be used to provide service in the event the third-party web hosting facilities become unavailable, although in such circumstances, the Company's service may be interrupted during the transition.

PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost.  Additions and betterments are capitalized; maintenance and repairs are expensed as incurred.  Depreciation is calculated using the straight-line method over the asset’s estimated useful life, which is 5 years for leasehold improvements, computers, equipment and furniture and 3 years for software.  Gains or losses on disposal are charged to operations.

ASSET IMPAIRMENT

Acquisitions and Intangible Assets

We account for acquisitions in accordance with ASC 805, Business Combinations (“ASC 805”) and ASC 350, Intangibles- Goodwill and Other (“ASC 350”). The acquisition method of accounting requires that assets acquired and liabilities assumed be recorded at their fair values on the date of a business acquisition. Our consolidated financial statements and results of operations reflect an acquired business from the completion date of an acquisition.

The judgments that we make in determining the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact net income in periods following an asset acquisition. We generally use either the income, cost or market approach to aid in our conclusions of such fair values and asset lives. The income approach presumes that the value of an asset can be estimated by the net economic benefit to be received over the life of the asset, discounted to present value. The cost approach presumes that an investor would pay no more for an asset than its replacement or reproduction cost. The market approach estimates value based on what other participants in the market have paid for reasonably similar assets. Although each valuation approach is considered in valuing the assets acquired, the approach ultimately selected is based on the characteristics of the asset and the availability of information.

Long-lived Assets

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount and the asset’s residual value, if any. In turn, measurement of an impairment loss requires a determination of fair value, which is based on the best information available. We use quoted market prices when available and independent appraisals and management estimates of future operating cash flows, as appropriate, to determine fair value.

DEFERRED REVENUE

Deferred revenue represents cash advances received in excess of revenue earned on on-going contracts.  Payment terms vary with each contract but may include an initial payment at the time the contract is executed, with future payments dependent upon the completion of certain contract phases or targeted milestones.  In the event of contract cancellation, the Company is generally entitled to payment for all work performed through the point of cancellation.  As of December 31, 2013, the Company had $4,251,373 in deferred revenues relating to contracts for services to be performed over periods ranging from 1 month to 5 years.  The Company had $2,866,356 in deferred revenues that are expected to be recognized in the next twelve fiscal months.

ADVERTISING

Advertising costs are expensed as incurred.  Advertising costs were $226,380 and $269,311 for the years ended December 31, 2013 and December 31, 2012, respectively and are included under selling, general and administrative expenses on our consolidated financial statements.

RESEARCH AND DEVELOPMENT EXPENSES

Software development costs are included in R&D and are expensed as incurred.  ASC 985.20, Software Industry Costs of Software to Be Sold, Leased or Marketed, requires the capitalization of certain development costs of software to be sold once technological feasibility is established, which the Company defines as completion to the point of marketability.  The capitalized cost is then amortized on a straight-line basis over the estimated product life.  To date, the period between achieving technological feasibility and the general availability of such software has been short and software development costs qualifying for capitalization have been immaterial.  Accordingly, the Company has not capitalized any software development costs under ASC 985.20.  During the years ended December 31, 2013 and December 31, 2012 we spent approximately $2,403,504 and $2,337,904 respectively, on R&D activities, which include costs associated with the development of our software products and services for our client’s projects and which are primarily comprised of salaries and related expenses for our software developers and consulting fees paid to third-party consultants.  R&D costs are primarily included under Salaries, benefits and related taxes in our Statement of Operations.

EMPLOYEE EQUITY INCENTIVE PLANS

The OmniComm Systems, Inc. 2009 Equity Incentive Plan (the “2009 Plan”) was approved at our Annual Meeting of Shareholders on July 10, 2009.  The 2009 Plan provides for the issuance of up to 7.5 million shares to employees, directors and key consultants in accordance with the terms of the 2009 Plan documents.  The predecessor plan, the OmniComm Systems, Inc., 1998 Stock Incentive Plan (the “1998 Plan”) expired on December 31, 2008.  The 1998 Plan provided for the issuance of up to 12.5 million shares in accordance with the terms of the 1998 Plan document.  Each plan is more fully described in “Note 15, Employee Equity Incentive Plans.”  The Company accounts for its employee equity incentive plans under ASC 718, Compensation – Stock Compensation which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions.

ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The Company currently uses the Black Scholes option pricing model to determine grant date fair value.

EARNINGS/(LOSS)  PER SHARE

The Company accounts for Earnings/(loss) Per Share using ASC 260 – Earnings per Share.  Unlike diluted earnings per share, basic earnings per share excludes any dilutive effects of options, warrants, and convertible securities.

INCOME TAXES

The Company accounts for income taxes in accordance ASC 740, Income Taxes.  ASC 740 has as its basic objective the recognition of current and deferred income tax assets and liabilities based upon all events that have been recognized in the financial statements as measured by the provisions of the enacted tax laws

Valuation allowances are established when necessary to reduce deferred tax assets to the estimated amount to be realized.  Income tax expense represents the tax payable for the current period and the change during the period in the deferred tax assets and liabilities.

IMPACT OF NEW ACCOUNTING STANDARDS

During fiscal 2013, we adopted the following new accounting pronouncements:

In December 2011, FASB issued Accounting Standards Update 2011-11, “Balance Sheet - Disclosures about Offsetting Assets and Liabilities” to enhance disclosure requirements relating to the offsetting of assets and liabilities on an entity's balance sheet. The update requires enhanced disclosures regarding assets and liabilities that are presented net or gross in the statement of financial position when the right of offset exists, or that are subject to an enforceable master netting arrangement. The new disclosure requirements relating to this update are retrospective and effective for annual and interim periods beginning on or after January 1, 2013. The update only requires additional disclosures, as such, the adoption of this standard did not have a material impact on our results of operations, cash flows or financial condition.

In January 2013, the FASB issued authoritative guidance on the presentation of amounts reclassified out of accumulated other comprehensive income. This guidance requires an entity to provide information about the amounts reclassified from accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the income statement or in the notes, significant amounts reclassified from accumulated other comprehensive income by the net income line item. Our adoption of this standard did not have an impact on our consolidated financial statements.

In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. This ASU amends ASC 740, Income Taxes, to require that an unrecognized tax benefit be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward; to the extent that a net operating loss carry forward, a similar tax loss, or a tax credit carryforward does not exist at the reporting date, the unrecognized tax benefit should be presented in the financial statements as a liability and not combined with deferred tax assets. ASU No. 2013-11 is effective for interim and annual periods beginning after December 15, 2013, with early adoption permitted. The Company will adopt ASU No. 2013-11 on January 1, 2014 and the adoption is not expected to have a material impact on its consolidated financial statements.

Accounting standards-setting organizations frequently issue new or revised accounting rules. We regularly review all new pronouncements to determine their impact, if any, on our financial statements.

Note_3_Going_Concern

Note 3 - Going Concern	12 Months Ended
	Dec. 31, 2013
Policy Text Block [Abstract]	'
Liquidity Disclosure [Policy Text Block]	'
	NOTE 3:                GOING CONCERN
	We have experienced net losses and negative cash flows from operations and have utilized debt and equity financings to help provide for our working capital, capital expenditure and R&D needs.  We will continue to require substantial funds to continue our R&D activities and to market, sell and commercialize our technology. We may need to raise substantial additional capital to fund our future operations.  Our capital requirements will depend on many factors, including the problems, delays, expenses and complications frequently encountered by companies developing and commercializing new technologies; the progress of our R&D activities; the rate of technological advances; determinations as to the commercial potential of our technology under development; the status of competitive technology; the establishment of collaborative relationships; the success of our sales and marketing programs; and other changes in economic, regulatory or competitive conditions in our planned business.
	Estimates about the adequacy of funding for our activities are based upon certain assumptions, including assumptions that the R&D programs relating to our technology can be conducted at projected costs and that progress towards the commercialization of our technology will be timely and successful.  There can be no assurance that changes in our R&D plans, acquisitions or other events will not result in accelerated or unexpected expenditures.
	To satisfy our capital requirements, we may seek additional financing through debt and equity financings. There can be no assurance that any such funding will be available to us on favorable terms or at all.  If adequate funds are not available when needed, we may be required to delay, scale back or eliminate some or all of our R&D and marketing programs.  If we are successful in obtaining additional financings, the terms of such financings may have the effect of diluting or adversely affecting the holdings or the rights of the holders of our common and preferred stock or result in increased interest expense in future periods.
	The ability of the Company to continue in existence is dependent on its having sufficient financial resources to bring products and services to market for marketplace acceptance.  As a result of our historical operating losses, negative cash flows and accumulated deficits for the period ending December 31, 2013 there is substantial doubt about the Company’s ability to continue as a going concern.
	The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note_4_Earnings_Loss_Per_Share

Note 4 - Earnings (Loss) Per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	NOTE 4                  EARNINGS/(LOSS) PER SHARE
	Basic earnings/(loss) per share were calculated using the weighted average number of shares outstanding of 87,969,202 and 86,522,332 for the years ended December 31, 2013 and December 31, 2012, respectively.
	Antidilutive shares aggregating 79,546,913 and 82,069,096 have been omitted from the calculation of dilutive earnings/(loss) per share for the years ended December 31, 2013 and December 31, 2012 respectively as the shares were antidilutive. Provided below is the reconciliation between numerators and denominators of the basic and diluted earnings/(loss) per shares:  There were no differences between basic and diluted earnings/(loss) per share.  The table below provides a reconciliation of anti-dilutive securities outstanding as of December 31, 2013 and December 31, 2012, respectively.
	Anti-Dilutive Security	31-Dec-13			December 31, 2012
	Preferred stock		2,750,149			2,750,149
	Employee stock options		5,745,000			10,452,500
	Warrants		44,728,873			43,212,873
	Convertible notes		24,620,000			24,620,000
	Shares issuable for accrued interest		1,702,891			1,033,574
	Total		79,546,913			82,069,096
	The employee stock options are exercisable at prices ranging from $0.045 to $0.69 per share.  The exercise price on the stock warrants range from $0.25 to $0.60 per share.  Shares issuable upon conversion of Convertible Debentures have conversion prices ranging from $0.25 to $0.50 per share.
	The Company’s convertible debt and convertible preferred stock have an anti-dilutive effect on net income/(loss) per share and were not included in the computation of diluted earnings/(loss) per share.
	For the year ended
		31-Dec-13								31-Dec-12
		Income (loss)			Shares		Per-share			Income (loss)			Shares		Per-share
		numerator			denominator		amount			numerator			denominator		amount
	Basic EPS	$	(3,367,603	)		87,969,202	$	(0.04	)	$	(8,062,487	)		86,522,332	$	(0.09	)
	Effect of dilutive securities - none		-0-			-0-		-0-			-0-			-0-		-0-
	Diluted EPS	$	(3,367,603	)		87,969,202	$	(0.04	)	$	(8,062,487	)		86,522,332	$	(0.09	)

Note_5_Property_and_Equipment_

Note 5 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	NOTE 5:                PROPERTY AND EQUIPMENT, NET
	Property and equipment consists of the following:
		31-Dec-13						31-Dec-12
		Cost		Accumulated depreciation		Net book		Cost		Accumulated depreciation		Net book		Estimated
						value						value		useful life
														(years)
	Computer & office equipment	$	1,822,098	$	1,326,256	$	495,842	$	1,519,617	$	1,181,451	$	338,166		5
	Leasehold improvements		93,812		75,735		18,077		92,686		68,044		24,642		5
	Computer software		1,556,497		1,477,801		78,696		1,502,524		1,403,705		98,819		3
	Office furniture		114,373		99,555		14,818		110,780		90,604		20,176		5
	Total	$	3,586,780	$	2,979,347	$	607,433	$	3,225,607	$	2,743,804	$	481,803
	Depreciation expense for the years ended December 31, 2013 and December 31, 2012 was $230,323 and $377,680, respectively.

Note_6_Intangible_Assets_At_Co

Note 6 - Intangible Assets, At Cost	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	NOTE 6:                INTANGIBLE ASSETS, AT COST
	Intangible assets consist of the following:
		31-Dec-13						31-Dec-12
	Asset	Cost		Accumulated amortization		Net book		Cost		Accumulated amortization		Net book		Estimated
						value						value		useful life
														(years)
	eClinical customer lists	$	1,392,701	$	1,392,701	$	-0-	$	1,392,701	$	1,392,701	$	-0-		3
	Promasys B.V. customer lists		136,253		1,514		134,739		-0-		-0-		-0-		15
	Promasys B.V. software code		72,943		2,431		70,512		-0-		-0-		-0-		5
	Promasys B.V. URLs/Website		68,814		3,823		64,991		-0-		-0-		-0-		3
		$	1,670,711	$	1,400,469	$	270,242	$	1,392,701	$	1,392,701	$	-0-
	Amortization expense was $7,720 and $232,117 for the years ended December 31, 2013 and December 31, 2012, respectively.
	Annual amortization expense for the Company’s intangible assets is as follows:
	2014	$	46,610
	2015		46,610
	2016		42,788
	2017		23,672
	2018 and thereafter		110,562
	Total	$	270,242

Note_7_Accounts_Payable_and_Ac

Note 7 - Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	NOTE 7:                ACCOUNTS PAYABLE AND ACCRUED EXPENSES
	Accounts payable and accrued expenses consist of the following:
	Account	31-Dec-13		31-Dec-12
	Accounts payable	$	724,421	$	665,139
	Accrued payroll and related costs		260,072		383,859
	Other accrued expenses		88,292		124,154
	Accrued interest		1,468,171		951,213
	Total accounts payable and accrued expenses	$	2,540,956	$	2,124,365

Note_8_Promasys_BV_Acquisition

Note 8 - Promasys B.V. Acquisition (Promasys B.V. [Member])	12 Months Ended
	Dec. 31, 2013
Promasys B.V. [Member]	'
Note 8 - Promasys B.V. Acquisition [Line Items]	'
Business Combination Disclosure [Text Block]	'
	NOTE 8:     PROMASYS B.V. ACQUISITION
	On November 11, 2013, with economic effect as of October 31, 2013, we acquired 100% of the capital stock of Promasys B.V., a privately held Netherlands company, from the 4 shareholders of Promasys B.V. pursuant to a share purchase agreement and as a result, Promasys B.V. became our wholly owned subsidiary. Promasys B.V. is involved in the development and marketing of software and services relating to clinical data management (“Business”).  Since its establishment in 2004, Promasys B.V. has built an international customer base, with a focus on the academic market and a strong presence in Asia. As consideration for the acquisition, we paid an aggregate of 435,998 euros (approximately $593,000) to one of the shareholders of Promasys B.V and issued an aggregate of 2,270,000 shares of our common stock to the other 3 shareholders of Promasys B.V. On the same day, and in connection with the share purchase agreement, we also entered into an employment agreement with one of the shareholders and a management agreement with the principal of a second shareholder pursuant to which, among other things, the individuals shall continue providing services to us as it relates to the Business. The foregoing description of the share purchase agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement which we have filed as Exhibit 10.71 to this Annual Report on Form 10K.
	In conjunction with the share purchase agreement of the capital stock of Promasys B.V., effective October 31, 2013, our Board of Directors appointed Dr. Adam F. Cohen to serve on our Board of Directors. It is expected that Dr. Cohen will be a member of the Compensation and Governance and Nominating Committees. Dr. Cohen, age 61, has no family relationships with any of the executive officers or directors of the Company. Dr. Cohen was a director of Promasys B. V. and held a 10% equity interest in Promasys B.V. prior to the acquisition. He received 790,000 shares of OmniComm’s common shares in exchange for his interest in Promasys B.V. Other than the acquisition of Promasys B.V. there have been no related party transactions in the past two years in which the Company or any of its subsidiaries was or is to be a party, in which Dr. Cohen had, or will have, a direct or indirect material interest.
	Dr. Cohen currently serves as the CEO of CHDR, a clinical research unit based in Leiden in the Netherlands. Dr. Cohen graduated in Pharmacy and Medicine from Leiden University. He subsequently joined the department of Clinical Pharmacology of the Wellcome Research Laboratories in Beckenham, UK where he obtained experience in early drug development. This work led to a PhD thesis about the development of an antihistamine (acrivastine) and an antiepileptic (lamotrigine). Further training in internal medicine was obtained at King’s College Hospital in London. Phase II-III drug development experience was obtained as European Clinical project leader for t-PA at Wellcome. He is a professor of Clinical Pharmacology at Leiden University and has a clinical attachment at the department of nephrology at Leiden University Medical Centre. He is author of more than two hundred publications about a wide range of clinical pharmacological subjects. He is executive editor of the British Journal of Clinical Pharmacology.
	We accounted for the acquisition of Promasys B.V as a business combination and accordingly accounted for the acquisition under Statement of Financial Accounting Standards No. 141, Business Combinations (“SFAS 141”) (Codified within ASC 805, Business Combinations). We allocate the purchase price to the assets acquired and the liabilities assumed based on their estimated fair values on the date of the acquisition. The difference between the fair value of the net assets acquired and the purchase price is recorded as goodwill. We record the operating results of the acquired business in our consolidated statements of operations from the date of acquisition.
	The table below summarizes the amounts of the assets acquired and liabilities assumed that were recognized at the acquisition date.
	Cash	$	215,571
	Receivables	$	216,287
	Property and equipment	$	2,178
	Identifiable intangibles	$	276,356
	Goodwill	$	671,689
	Total assets acquired	$	1,382,081
	Accounts payable	$	(170,339	)
	Deferred revenue	$	(229,353	)
	Net asssets acquired	$	982,389
	The below table provides unaudited pro-forma results as if the acquistion had occurred effective January 1, 2012.
		(Unaudited)
		For the year ended
		December 31,
		2013			2012
	Gross revenues	$	15,119,861		$	16,002,612
	Total expenses		18,145,210			23,988,611
	Net income (loss) before taxes	$	(3,025,349	)	$	(7,985,999	)
	Net income (loss) per share	$	(0.04	)	$	(0.09	)
	Weighted average number of shares outstanding
	Basic and Diluted		89,866,051			88,792,332

Note_9_Line_of_Credit_and_Note

Note 9 - Line of Credit and Notes Payable	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	NOTE 9:                LINES OF CREDIT AND NOTES PAYABLE
	On March 18, 2013, the Company entered into a $2,000,000 revolving line of credit with The Northern Trust Company guaranteed by Cornelis F. Wit, CEO and Director. Mr. Wit receives 2.0% interest on the assets pledged for the line of credit. On December 18, 2013 the Company renewed the Line of Credit and increased the available balance to $4,000,000. The line of credit matures on December 17, 2014 and carries a variable interest rate based on the prime rate. At December 31, 2013, $3,500,000 was outstanding on the line of credit at an interest rate of 2.25%.
	At December 31, 2013, the Company owed $5,667,865 in notes payable all of which are unsecured.  The table below provides details as to the terms and conditions of the notes payable.
					Ending
					principal		Non related party				Related party
	Origination	Maturity	Interest		December 31,				Long				Long
	date	date	rate		2013		Current		term		Current		term
	12/31/11	1/1/15		12%	$	1,600,000	$	-0-	$	-0-	$	-0-	$	1,600,000
	4/1/12	1/1/14		12%		17,500		17,500		-0-		-0-		-0-
	12/17/12	12/16/14		12%		20,000		20,000		-0-		-0-		-0-
	1/1/13	1/1/16		12%		529,000		-0-		-0-		-0-		529,000
	1/1/13	1/1/15		10%		308,561		-0-		308,561		-0-		-0-
	1/1/13	1/1/15		10%		123,425		-0-		123,425		-0-		-0-
	1/1/13	1/1/15		12%		45,000		-0-		45,000		-0-		-0-
	2/1/13	1/1/16		12%		20,000		-0-		-0-		-0-		20,000
	3/5/13	1/1/15		12%		137,500		-0-		137,500		-0-		-0-
	4/1/13	3/31/16		12%		2,866,879		-0-		-0-		-0-		2,866,879
	Discount on note payable							-0-		-0-		-0-		(447,666	)
	Total				$	5,667,865	$	37,500	$	614,486	$	-0-	$	4,568,213
	At December 31, 2012, the Company owed $5,138,866 in notes payable all of which are unsecured.  The table below provides details as to the terms and conditions of the notes payable.
					Ending
					principal		Non related party				Related party
	Origination	Maturity	Interest		December 31,				Long				Long
	date	date	rate		2012		Current		term		Current		term
	12/31/10	1/1/15		10%	$	308,562	$	-0-	$	308,562	$	-0-	$	-0-
	12/31/10	1/1/15		10%		123,425		-0-		123,425		-0-		-0-
	2/1/11	1/1/15		12%		137,500		-0-		137,500		-0-		-0-
	3/31/11	4/1/14		12%		2,866,879		-0-		-0-		-0-		2,866,879
	12/31/11	1/1/15		12%		1,600,000		-0-		-0-		-0-		1,600,000
	12/31/11	1/1/16		12%		20,000		-0-		-0-		-0-		20,000
	4/1/12	1/1/14		12%		17,500		-0-		17,500		-0-		-0-
	10/1/12	1/1/15		12%		45,000		-0-		45,000		-0-		-0-
	12/17/12	12/16/14		12%		20,000		-0-		20,000		-0-		-0-
	Discount on note payable							-0-		-0-		-0-		(656,524	)
	Total				$	5,138,866	$	-0-	$	651,987	$	-0-	$	3,830,355
	On January 1, 2013, the Company issued a promissory note in the principal amount of $529,000 and warrants to purchase 2,116,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of January 31, 2016 to our CEO and Director, Cornelis F. Wit. The note carries an interest rate of 12% per annum and is due on January 1, 2016.
	This issuance caused us to calculate and record a derivative liability for the warrant liability. The warrants were valued using the Black Scholes option pricing model. A value of $400,141 was calculated and allocated to the warrants and recorded as a liability to the issuance of the note payable. As a result of the liability we recorded a discount to the note payable. The carrying amount of the note at the time of issuance was $128,858. The warrant liability (discount) will be amortized over the 36 month duration of the note payable. The Company will continue to perform a fair value calculation periodically on the warrant liability and accordingly the warrant liability is increased or decreased based on the fair value calculation. The resulting increase or decrease is reflected in operations as an unrealized gain or loss on changes in derivative liabilities.
	On January 1, 2013 the Company issued promissory notes in the amount of $431,987 in exchange for existing promissory notes in the same amount. The promissory notes carry an interest rate of 10% and have a maturity date of January 1, 2015.
	On January 1, 2013 the Company issued a promissory note in the amount of $45,000 in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of January 1, 2015.
	On February 1, 2013 the Company issued a promissory note in the amount of $20,000 to our Chairman and CTO, Randall G. Smith, in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of January 1, 2016.
	On March 5, 2013 the Company issued a promissory note in the amount of $137,500 in exchange for a promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of January 1, 2015.
	On April 1, 2013 the Company issued a promissory note in the amount of $2,866,879 to our CEO and Director, Cornelis F. Wit, in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of March 31, 2016. The expiration date of the warrants associated with the original prommissory note was extended to March 31, 2016.

Note_10_Convertible_Notes_Paya

Note 10 - Convertible Notes Payable	12 Months Ended
	Dec. 31, 2013
Convertible Debt Disclosure [Abstract]	'
Convertible Debt Disclosure	'
	NOTE 10                CONVERTIBLE NOTES PAYABLE
	The following table summarizes the convertible debt outstanding as of December 31, 2013.
								Principal						Discount		Carrying		Carrying amount
								at				Total		at		amount at		Short term				Long term
	Date of	Maturity		Interest		Original		December		Allocated		discount		December		December		Related		Non		Related		Non related
	issuance	date		rate		principal		31, 2013		discount		amortized		31, 2013		31, 2013				related
	8/1/99	6/30/04			10%	$	862,500	$	75,000	$	-0-	$	-0-	$	-0-	$	75,000	$	-0-	$	75,000	$	-0-	$	-0-
	8/29/08	1/1/15			10%		150,000		150,000		135,600		135,600		-0-		150,000		-0-		-0-		150,000		-0-
	8/29/08	1/1/16			10%		2,120,000		1,770,000		1,916,480		1,916,480		-0-		1,770,000		-0-		-0-		1,770,000		-0-
	12/16/08	1/1/15			12%		100,000		100,000		27,515		27,515		-0-		100,000		-0-		-0-		-0-		100,000
	12/16/08	1/1/16			12%		160,000		160,000		44,024		44,024		-0-		160,000		-0-		-0-		160,000		-0-
	12/16/08	1/1/16			12%		200,000		200,000		55,030		55,030		-0-		200,000		-0-		-0-		-0-		200,000
	12/16/08	1/1/16			12%		4,615,000		4,520,000		1,243,681		1,243,681		-0-		4,520,000		-0-		-0-		4,505,000		15,000
	9/30/09	1/1/16			12%		1,400,000		1,200,000		526,400		526,400		-0-		1,200,000		-0-		-0-		1,100,000		100,000
	12/31/09	1/1/16			12%		1,490,000		1,490,000		935,720		935,720		-0-		1,490,000		-0-		-0-		1,440,000		50,000
	Total					$	11,097,500	$	9,665,000	$	4,884,450	$	4,884,450	$	-0-	$	9,665,000	$	-	$	75,000	$	9,125,000	$	465,000
	The following table summarizes the convertible debt outstanding as of December 31, 2012.
								Principal						Discount		Carrying		Carrying amount
								at				Total		at		amount at		Short term				Long term
	Date of	Maturity		Interest		Original		December		Allocated		discount		December		December		Related		Non related		Related		Non related
	issuance	date		rate		principal		31, 2012		discount		amortized		31, 2012		31, 2012
	8/1/99	6/30/04			10%	$	862,500	$	75,000	$	-0-	$	-0-	$	-0-	$	75,000	$	-0-	$	75,000	$	-0-	$	-0-
	8/29/08	1/1/15			10%		150,000		150,000		135,600		135,600		-0-		150,000		-0-		-0-		150,000		-0-
	8/29/08	1/1/16			10%		2,120,000		1,770,000		1,916,480		1,916,480		-0-		1,770,000		-0-		-0-		1,770,000		-0-
	12/16/08	12/16/13			12%		160,000		160,000		44,024		44,024		-0-		160,000		160,000		-0-		-0-		-0-
	12/16/08	1/1/14			12%		200,000		200,000		55,030		55,030		-0-		200,000		-0-		-0-		-0-		200,000
	12/16/08	1/1/15			12%		100,000		100,000		27,515		27,515		-0-		100,000		-0-		-0-		-0-		100,000
	12/16/08	1/1/16			12%		4,615,000		4,520,000		1,243,681		1,243,681		-0-		4,520,000		-0-		-0-		4,505,000		15,000
	9/30/09	1/1/16			12%		1,400,000		1,200,000		526,400		526,400		-0-		1,200,000		-0-		-0-		1,100,000		100,000
	12/31/09	1/1/16			12%		1,490,000		1,490,000		935,720		935,720		-0-		1,490,000		-0-		-0-		1,440,000		50,000
	Total					$	11,097,500	$	9,665,000	$	4,884,450	$	4,884,450	$	-0-	$	9,665,000	$	160,000	$	75,000	$	8,965,000	$	465,000
	10% Convertible Notes
	During 1999, the Company issued 10% Convertible Notes payable in the amount of $862,500 pursuant to a Confidential Private Placement Memorandum.  There were costs of $119,625 associated with this offering. The net proceeds to the Company were $742,875.  The notes bear interest at ten percent annually, payable semi-annually.  The notes were convertible after maturity, which was June 30, 2004, into shares of common stock of the Company at $1.25 per share. We are in default in the payment of principal and interest. As of December 31, 2013, approximately $787,500 of the Convertible Notes had been repaid in cash or converted into 1,495,179 shares of common stock of the Company leaving an outstanding principal balance of $75,000.  There was $109,748 of accrued interest at December 31, 2013.
	Secured Convertible Debentures
	On September 30, 2009, the Company sold an aggregate of $1,400,000 principal amount 12% Secured Convertible Debentures (the “Debentures”) and common stock purchase warrants (the “Warrants”) to purchase an aggregate of 5,600,000 shares of our common stock exercisable at a price of $0.25 per share for four years subsequent to the closing of the transaction to four accredited investors including our CEO and Director, Cornelis, F. Wit.   The Company received net proceeds of $1,400,000.  The Debentures, which bear interest at 12% per annum, matured on March 30, 2011. The Debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.25 per share.  On March 30, 2011, the Company repaid $200,000 of the outstanding principal amounts owed and extended $1,200,000 of the convertible notes until April 1, 2013, including $1,100,000 in convertible notes held by our CEO and Director, Cornelis F. Wit. The Company also extended the expiration date of the warrants associated with the September 2009 offering.  On February 22, 2013, the Company and two lenders extended $1,200,000 of the convertible notes until January 1, 2016, including $1,100,000 in convertible notes held by our CEO and Director, Cornelis F. Wit. The expiration date of the warrants associated with the September 2009 offering was also extended to January 1, 2016.
	Convertible Debentures
	On August 29, 2008, the Company sold $2,270,000 of convertible debentures and warrants to purchase an aggregate of 4,540,000 shares of our common stock to four accredited investors including our CEO and Director, Cornelis F. Wit, and one of our Directors. The convertible debentures, which bear interest at 10% per annum, were due on August 29, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share. On September 30, 2009, two Affiliates of the Company extended $1,920,000 of the convertible debentures until August 29, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. On February 22, 2013 the Company and Mr. van Kesteren extended the maturity date of $150,000 of the convertible debentures due to our Director, Guus van Kesteren to January 1, 2015. The expiration date of the warrants associated with the debentures was also extended to January 1, 2015. On February 22, 2013 the Company and Mr. Wit extended the maturity date of $1,770,000 of the convertible debentures due to our CEO and Director, Cornelis F. Wit, to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.
	On December 16, 2008, we sold $5,075,000 of convertible debentures and warrants to purchase an aggregate of 10,150,000 shares of our common stock to eleven accredited investors including our CEO and Director, Cornelis F. Wit, our COO and President, Stephen E. Johnson, our Chairman and CTO, Randall G. Smith, our CFO, Ronald T. Linares, and four of our Directors. The convertible debentures, which bear interest at 12% per annum, were due on December 16, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share. On September 30, 2009 Affiliates of the Company extended $4,980,000 of Convertible Notes until December 16, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. On February 22, 2013 the Company and the lenders agreed to extend the maturity date of $4,505,000 of the convertible debentures including $4,475,000 due to our CEO and Director, Cornelis F. Wit, $25,000 due to our COO and President, Stephen E. Johnson, and $5,000 due to our Chairman and CTO, Randall G. Smith, to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On February 27, 2013 the Company and Mr. Veatch extended the maturity date of $15,000 of convertible debentures issued to our former Director, Matthew Veatch, to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On March 6, 2013, the Company and one of the lenders agreed to extend the maturity date of $200,000 of convertible debentures to January 1, 2014. The expiration date of the warrants associated with the debentures was also extended to January 1, 2014. On March 12, 2013, the Company and one of the lenders agreed to extend the maturity date of $100,000 of convertible debentures to January 1, 2015. The expiration date of the warrants associated with the debentures was also extended to January 1, 2015. In December 2013, the Company and two lenders agreed to extend the maturity date of $360,000 of convertible debentures, including $160,000 due to our Director, Guus van Kesteren, to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.
	On December 31, 2009, the Company sold an aggregate of $1,490,000 principal amount 12% Convertible Debentures (the “Debentures”) and common stock purchase warrants (the “Warrants”) to purchase an aggregate of 5,960,000 shares of our common stock exercisable at a price of $0.25 per share for four years subsequent to the closing of the transaction to three accredited investors including our CEO and Director, Cornelis F. Wit.  The Company received net proceeds of $1,490,000.  The Debentures, which bear interest at 12% per annum, matured on June 30, 2011. The Debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.25 per share.  On September 30, 2011, the Company extended all $1,490,000 of the convertible notes until October 1, 2013, including $1,440,000 in convertible notes held by our CEO and Director, Cornelis F. Wit.  The Company also extended the expiration date of the warrants associated with the December 2009 offering until December 31, 2015.  On February 22, 2013, the Company extended all $1,490,000 of the convertible notes until January 1, 2016, including $1,440,000 in convertible notes held by our CEO and Director, Cornelis F. Wit.  The Company also extended the expiration date of the warrants associated with the December 2009 offering until January 1, 2016.
	The payments required at maturity under the Company’s outstanding convertible debt at December 31, 2013 are as follows:
	2014	$	75,000
	2015		250,000
	2016		9,340,000
	Total	$	9,665,000

Note_11_Fair_Value_Measurement

Note 11 - Fair Value Measurement	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	NOTE 11:              FAIR VALUE MEASUREMENT
	The Company measures the fair value of its assets and liabilities under the guidance of ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements. ASC 820 does not require any new fair value measurements, but its provisions apply to all other accounting pronouncements that require or permit fair value measurement.
	ASC 820 clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820 requires the Company to use valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows:
		•	Level 1: Observable inputs such as quoted prices for identical assets or liabilities in active markets;
		•	Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly such as quoted prices for similar assets or liabilities or market-corroborated inputs; and
		•	Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions about how market participants would price the assets or liabilities.
	The valuation techniques that may be used to measure fair value are as follows:
		A.	Market approach - Uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities
		B.	Income approach - Uses valuation techniques to convert future amounts to a single present amount based on current market expectations about those future amounts, including present value techniques, option-pricing models and excess earnings method
		C.	Cost approach - Based on the amount that currently would be required to replace the service capacity of an asset (replacement cost)
	The Company also adopted the provisions of ASC 825, Financial Instruments. ASC 825 allows companies to choose to measure eligible assets and liabilities at fair value with changes in value recognized in earnings. Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to re-measure any of its existing financial assets or liabilities under the provisions of this Statement and did not elect the fair value option for any financial assets and liabilities transacted in the years ended December 31, 2013 and December 31, 2012.
	The Company’s financial assets or liabilities subject to ASC 820 as of December 31, 2013 include the conversion feature and warrant liability associated with convertible debentures issued during fiscal 2008 and 2009, the warrants issued during 2011 and 2013 that are associated with notes payable that were issued to our CEO and Director, Cornelis F. Wit, and the value of Intellectual Property and a customer list associated with the acquisition of Promasys B. V. during 2013. The conversion feature and warrants were deemed to be derivatives (the “Derivative Instruments”) since a fixed conversion price cannot be determined for either of the Derivative Instruments due to anti-dilution provisions embedded in the offering documents for the convertible debentures. The derivative instruments were not issued for risk management purposes and as such are not designated as hedging instruments under the provisions of ASC 815 Disclosures about Derivative Instruments and Hedging Activities. See Note 10 – Convertible Notes Payable.
	Following is a description of the valuation methodologies used to determine the fair value of the Company’s financial assets including the general classification of such instruments pursuant to the valuation hierarchy.
	A summary as of December 31, 2013 of the fair value of liabilities measured at fair value on a recurring basis follows:
			Fair value at				Quoted prices in active markets for identical assets/ liabilities			Significant other			Significant
			December 31,							observable inputs			unobservable inputs
			2013				(Level 1)			(Level 2)			(Level 3)
	Derivatives: (1) (2)
	Conversion feature liability		$	3,126,206			$	-0-		$	-0-		$	3,126,206
	Warrant liability			5,943,977				-0-			-0-			5,943,977
	Total of derivative liabilities		$	9,070,183			$	-0-		$	-0-		$	9,070,183
	(1)   The fair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the year ended December 31, 2013
	(2)   The fair value at the measurement date is equal to their carrying value on the balance sheet
			Significant valuation assumptions of derivative instruments at December 31, 2013
	Risk free interest rate			0.12%	to	0.13%
	Dividend yield				0.00%
	Expected volatility			166.7%	to	217.1%
	Expected life (range in years)
	Conversion feature liability			1	to	2
	Warrant liability			1	to	2.25
	A summary as of December 31, 2013 of the fair value of assets measured at fair value on a non recurring basis follows:
			Carrying				Carrying			Quoted prices in active markets for identical assets/ liabilities			Significant other observable inputs		Significant unobservable inputs
			amount				amount
			December 31,				December 31,
			2012				2013			(Level 1)			(Level 2)		(Level 3)
	Acquired assets (3)
	Promasys B.V. customer lists (4)		$	-0-			$	134,739		$	-0-		$	-0-	$	136,253
	Promasys B.V. software code (4)			-0-				70,512			-0-			-0-		72,943
	Promasys B.V. URLs/website (4)			-0-				64,991			-0-			-0-		68,814
	Promasys B.V. goodwill (4)			-0-				675,710			-0-			-0-		675,710
			$	-0-			$	945,952		$	-0-		$	-0-	$	953,720
	(3)   The fair value of the Acquired Assets was estimated using the Income Approach with a discounted cash flow valuation methodology applied.
	(4)   The acquired Promasys B.V. software code, customer list and URLs/website are not measured on a recurring basis since their initial fair value has been deemed to have a finite life and is being amortized periodically. Instead the Company performs an impairment analysis on a quarterly basis in order to determine whether the carrying value of the assets reflects the fair value of the assets in a market based transaction.
	The Company’s goodwill and other identifiable intangible assets with indefinite lives are measured at fair value on a nonrecurring basis using significant unobservable inputs (Level 3).
	Goodwill and other identifiable intangible assets with indefinite lives are reviewed for impairment annually, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Long-lived assets and identifiable intangible assets are also reviewed for impairment whenever events or changes in circumstances indicate that amounts may not be recoverable. If the testing performed indicates that impairment has occurred, the Company will record a noncash impairment charge for the difference between the carrying amount of the goodwill or other intangible assets and the implied fair value of the goodwill or other intangible assets in the period the determination is made.
	The table below presents the fair value of the Goodwill as of December 31, 2013 and December 31, 2012.
			31-Dec-13				31-Dec-12
	(Level 3)
	Goodwill		$	675,710			$	-0-
	Other identifiable intangible assets, which are subject to amortization, are being amortized using the straight-line method over their estimated useful lives ranging from 3 to 15 years. The Impairment or Disposal of Long-Lived Asset subsection of the Property, Plant and Equipment Topic of the FASB ASC, requires us to test the recoverability of long-lived assets, including identifiable intangible assets with definite lives, whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. In testing for potential impairment, if the carrying value of the asset group exceeds the expected undiscounted cash flows, we must then determine the amount by which the fair value of those assets exceeds the carrying value and determine the amount of impairment, if any.
	A summary as of December 31, 2012 of the fair value of liabilities measured at fair value on a recurring basis follows:
			Fair value at December 31,				Quoted prices in active markets for identical assets/ liabilities			Significant other observable inputs			Significant unobservable inputs
			2012				(Level 1)			(Level 2)			(Level 3)
	Derivatives: (1) (2)
	Conversion feature liability		$	2,287,323			$	-0-		$	-0-		$	2,287,323
	Warrant liability			6,287,598				-0-			-0-			6,287,598
	Total of derivative liabilties		$	8,574,921			$	-0-		$	-0-		$	8,574,921
	(1) The fair value of the derivative instruments was estimated using the Black Scholes option pricing model with the following assumptions for the year ended December 31, 2012
	(2) The fair value at the measurement date is equal to their carrying value on the balance sheet
	Significant valuation assumptions of derivative instruments at December 31, 2012
	Risk free interest rate		0.18%	to	0.36%
	Dividend yield			0.00%
	Expected volatility		218.2%	to	259.10%
Expected life (range in years)
Conversion feature liability		0.25	to	0.96
Warrant liability		0.66	to	3.25
		Other income
		for the year ended
		31-Dec-13				31-Dec-12
The net amount of (losses) for the period included in earnings attributable to the unrealized loss from changes in derivative liabilities at the reporting date		$	(95,121	)		$	(6,123,302	)
Total unrealized (losses) included in earnings		$	(95,121	)		$	(6,123,302	)
The tables below set forth a summary of changes in fair value of the Company’s Level 3 financial liabilities at fair value for the years ended December 31, 2013 and December 31, 2012. The tables reflect gains and losses for all financial liabilities at fair value categorized as Level 3 as of December 31, 2013 and December 31, 2012.
		Level 3 financial assets and financial liabilities at fair value
		Balance,				Net realized			Net unrealized			Net		Net transfers		Balance,
		beginning				gains/(losses)			(gains)/losses			purchases,		in and/or out		end of
		of year							relating to			issuances		of Level 3		period
									instruments still			and
									held at the			settlements
									reporting date
Year ended December 31, 2013
Derivatives:
Conversion feature liability		$	2,287,323			$	-0-		$	838,883		$	-0-	$	-0-	$	3,126,206
Warrant liability			6,287,598				-0-			(743,762	)		400,141		-0-		5,943,977
Total of derivative liabilties		$	8,574,921			$	-0-		$	95,121		$	400,141	$	-0-	$	9,070,183
		Level 3 financial assets and financial liabilities at fair value
		Balance,				Net realized			Net unrealized			Net		Net transfers		Balance,
		beginning				gains/(losses)			(gains)/losses			purchases,		in and/or out		end of
		of year							relating to			issuances		of Level 3		period
									instruments still			and
									held at the			settlements
									reporting date
Year ended December 31, 2012
Derivatives:
Conversion feature liability		$	758,911			$	-0-		$	1,528,412		$	-0-	$	-0-	$	2,287,323
Warrant liability			1,692,708				-0-			4,594,890			-0-		-0-		6,287,598
Total of derivative liabilties		$	2,451,619			$	-0-		$	6,123,302		$	-0-	$	-0-	$	8,574,921

Note_12_Commitments_and_Contin

Note 12 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	NOTE 12:              COMMITMENTS AND CONTINGENCIES
	The Company currently leases office space under operating leases for its office locations and has several operating leases related to server and network co-location and disaster recovery for its operations.  The minimum future lease payments required under the Company’s operating leases at December 31, 2013 are as follows:
	2014	$	537,630
	2015		502,131
	2016		279,174
	2017		53,699
	2018		5,849
	Total	$	1,378,483
	In addition to annual base rental payments, the Company pays for the operating expenses associated with its leased office space and is responsible for any escalation in operating expenses as determined in the leases.  Rent expense was $894,121 and $881,503 for the years ended December 31, 2013 and December 31, 2012, respectively.
	The Company’s corporate office lease expires in September 2016.  The Company’s lease on its New Jersey field office expires in February 2016.   The Company currently operates its wholly-owned subsidiary, OmniComm Ltd., in the United Kingdom under the terms of a lease that expires in September 2016.  The Company currently operates its wholly-owned subsidiary, OmniComm Europe, GmbH, in Germany under the terms of a lease that expires in July 2015. The Company currently operates its wholly-owned subsidiary, Promasys B.V., in the Netherlands under the terms of a lease that expires in October 2018.
	LEGAL PROCEEDINGS
	From time to time the Company may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of December 31, 2013, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of our operations.
	PATENT LITIGATION SETTLEMENT
	On April 9, 2009, we entered into a Settlement and License Agreement with DataSci, LLC (“DataSci”) which relates to a lawsuit filed on September 18, 2008 in the United States District Court for the District of Maryland by DataSci against OmniComm alleging infringement of a U.S. Patent No. 6,496,827 B2 entitled “Methods and Apparatus for the Centralized Collection and Validation of Geographically Distributed Clinical Study Data with Verification of Input Data to the Distributed System” (“Licensed Patent”) claimed to be owned by DataSci. Pursuant to the agreement, the parties entered into a Stipulated Order of Dismissal of the lawsuit filed by DataSci and DataSci granted us a worldwide, non-exclusive non-transferable right and license under the Licensed Patent, the subject of the claim, and the right to sublicense TrialMaster on a Technology Transfer and Technology Transition basis. The license expressly excludes the right to make, use, sell, import, market, distribute, oversee the operation of, or service systems covered by, a claim (if any) of the Licensed Patent to the extent such systems are used for creating and managing source documentation and conducting remote data validation in clinical trial studies using a tablet PC with stylus, touch screen device, digitizing tablet, digitizer pen, or similar mobile processing device (“Digitizing Device”), wherein the source documentation is electronic and is completed using a Digitizing Device. Under the terms of the license, we are obligated to pay royalties quarterly for sales of Licensed Products, as defined therein,  from January 1, 2009 until the expiration of the Licensed Patent equal to two percent (2%) of OmniComm’s annual Gross Revenues or, alternatively, the annual minimum royalty payment(s), whichever is greater.  The remaining minimum royalty payments per year are as follows:
	2014	$	450,000
	2015		450,000
	2016		450,000
	2017		450,000
	Total	$	1,800,000
	In conjunction with the acquisition of the eResearch Technology, Inc. EDC assets, the Company entered into the First Amendment to Settlement and Licensing Agreement with DataSci, LLC in June 2009 to provide for license payments totaling $300,000 to DataSci over the next three years for the EDC assets acquired in that transaction.  The Company began making annual payments of $100,000 to DataSci beginning in July 2009 and has to-date made payments totaling $200,000.
	During the years ended December 31, 2013 and December 31, 2012, respectively, the Company recorded a charge to earnings of  $189,408 and $218,467 respectively,  which amounts represent (1) the amount of additional license expense incurred above the stipulated minimum in the DataSci License Agreement during the years ended December 31, 2013 and December 31, 2012 and (2) the accretion of the difference between the total stipulated annual minimum royalty payments and the recorded present value accrual of the annual minimum royalty payments.
	EMPLOYMENT AGREEMENTS
	In December 2013, we renewed an employment agreement with Mr. Cornelis F. Wit to serve as our Chief Executive Officer through December 31, 2014. As part of the renewal the employment agreement will renew for successive one-year terms unless the employment agreement is expressly cancelled by either Mr. Wit or the Company ninety days prior to the end of the term.  Mr. Wit receives an annual salary of $192,780 payable in cash and/or stock plus a bonus tied to our operating results. As part of the agreement incentive options are awardable under the agreement based upon sales and cash flow objectives.  In the event that we consummate a transaction with a third party resulting in the sale, merger, consolidation, reorganization or other business combination involving all or a majority of our business, assets or stock, whether effected in one transaction or a series of transactions due to the initiative of Mr. Wit (whether or not during the term of the agreement), Mr. Wit will receive a fee equal to 2% of the aggregate consideration.   The agreement also provides, among other things, for participation in employee benefits available to employees and executives.  Under the terms of the agreement, we may terminate Mr. Wit’s employment upon 30 days notice of a material breach and Mr. Wit may terminate the agreement under the same terms and conditions.  The employment agreement contains customary non-disclosure provisions, as well as a one year non-compete clause if Mr. Wit leaves the company voluntarily or a six month non-compete clause following his termination by us.
	In December 2013, we renewed our employment agreement with Mr. Randall Smith to serve as our Chief Technology Officer.  As part of the renewal the employment agreement will renew for successive one-year terms unless the employment agreement is expressly cancelled by either Mr. Smith or the Company ninety days prior to the end of the term. Under the terms of the agreement, as compensation for his services, Mr. Smith receives an annual salary of $305,235 to be paid in the form of cash and/or stock, as agreed upon by the parties, and he is eligible to receive a bonus based upon achieving technology related milestones.  The agreement also provides, among other things, for participation in employee benefit plans or programs applicable to employees and executives.  Under the terms of the agreement, we may terminate the employment of Mr. Smith upon 30 days notice of a material breach and Mr. Smith may terminate the agreement under the same terms and conditions.  If Mr. Smith is terminated by us for any reason other than for cause, we must pay him severance benefits equal to six month’s salary.  The employment agreement contains customary non-disclosure provisions, as well as a one year non-competition restriction following the termination of the agreement.
	In September 2013, we renewed our employment agreement with Mr. Stephen Johnson to serve as our President and Chief Operating Officer.  As part of the renewal the employment agreement will renew for successive one-year terms unless the employment agreement is expressly cancelled by either Mr. Johnson or the Company ninety days prior to the end of the term. Under the terms of this agreement, Mr. Johnson receives an annual salary of $305,235.   The agreement also provides, among other things, for participation in employee benefit plans or programs applicable to employees and executives.  Under the terms of the agreement, we may terminate the employment of Mr. Johnson upon 30 days notice of a material breach and Mr. Johnson may terminate the agreement under the same terms and conditions.  If Mr. Johnson is terminated by us for any reason other than for cause, we must pay him severance benefits equal to three month’s salary for every year of service up to a maximum of twelve months salary.  The employment agreement contains customary non-disclosure provisions as well as a one year non-compete clause if Mr. Johnson leaves the company voluntarily or a six month non-compete clause following his termination by us.

Note_13_Related_Party_Transact

Note 13 - Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 13:             RELATED PARTY TRANSACTIONS
	On February 1, 2013, our Chairman and CTO, Randall Smith, extended the maturity date of his $20,000 promissory note until January 1, 2016. The promissory note bears interest at 12% per annum. The note was originally issued on December 16, 2010 with a maturity date of December 31, 2011. On December 31, 2011, Mr. Smith extended the maturity date of his promissory note until April 1, 2013.
	On February 22, 2013, our Director, Guus van Kesteren, extended the maturity date of $150,000 of convertible debentures to January 1, 2015. The convertible debentures were originally issued in August 2008. The expiration date of the warrants associated with the debentures was also extended to January 1, 2015.
	On February 22, 2013, our COO and President, Stephen Johnson, extended the maturity date of $25,000 of convertible debentures to January 1, 2016. The convertible debentures were originally issued in December 2008. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.
	On February 22, 2013, our Chairman and CTO, Randall Smith, extended the maturity date of $5,000 of convertible debentures to January 1, 2016. The convertible debentures were originally issued in December 2008. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.
	On December 5, 2013, our Director, Guus van Kesteren, extended the maturity date of $160,000 of convertible debentures to January 1, 2016. The convertible debentures were originally issued in December 2008. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.
	As of December 31, 2013, we have an aggregate of $13,780,879 principal amount of convertible debentures and promissory notes outstanding to Cornelis F. Wit, our CEO and Director, and have issued certain warrants to Mr. Wit, as follows:
	●	In June 2008, Mr. Wit invested $510,000 in convertible notes. On August 29, 2008, Mr. Wit converted the $510,000 and invested an additional $1,260,000 in a private placement of convertible debentures and warrants to purchase 3,540,000 shares of our common stock. The convertible debentures, which bear interest at 10% per annum, were due on August 29, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share. On September 30, 2009, the Company and Mr. Wit extended the $1,770,000 of convertible debentures until August 29, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. On February 22, 2013, the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.
	●	In February 2008, Mr. Wit invested $150,000 in promissory notes and from September 2008 to December 2008, Mr. Wit invested $4,200,000 in convertible notes. On December 16, 2008, Mr. Wit converted the $4,350,000 into a private placement of convertible debentures and warrants to purchase 8,700,000 shares of our common stock. The convertible debentures, which bear interest at 12% per annum, were due on December 16, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share. On September 30, 2009, the Company and Mr. Wit extended the $4,350,000 of convertible debentures until December 16, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. In a private transaction on October 16, 2012, Mr. Wit purchased $125,000 of the December 2008 convertible debentures and the related 250,000 warrants from Mr. Ronald Linares, the Company’s former CFO. On February 22, 2013, the Company and Mr. Wit extended the maturity date of the $4,475,000 of convertible debentures to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.
	●	From July 2009 to September 2009, Mr. Wit invested $1,100,000 which amount was aggregated under the terms of one convertible note dated September 30, 2009.  On September 30, 2009, Mr. Wit agreed to convert this convertible note into a private placement of secured convertible debentures bearing interest at a rate of 12% per annum with a maturity date of March 30, 2011. The convertible debentures were convertible into 4,400,000 shares of common stock and Mr. Wit received 4,400,000 warrants to purchase common stock of the Company at a price of $0.25. On March 30, 2011, the Company and Mr. Wit extended the maturity date of his convertible note until April 1, 2013 in accordance with the terms of Amendment Number One To Securities Purchase Agreement. The Company also extended the expiration date of the 4,400,000 warrants issued with convertible note by two years to September 30, 2015. On February 22, 2013, the Company and Mr. Wit extended the maturity date of his convertible debentures to January 1, 2016 in accordance with the terms of Amendment Number Two To Securities Purchase Agreement. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.
	●	From October 2009 to December 2009, Mr. Wit invested $1,440,000, which amount was aggregated under the terms of one convertible note dated December 31, 2009. On December 31, 2009, Mr. Wit agreed to convert this Convertible Note into a private placement of unsecured convertible debentures bearing interest at a rate of 12% per annum, which Convertible Debentures were due on June 30, 2011. The Company and Mr. Wit extended the maturity date of his convertible note until October 1, 2013 in accordance with the terms of Amendment Number One To Securities Purchase Agreement. The Company also extended the expiration date of the 5,760,000 warrants issued with convertible note by two years to December 31, 2015. On February 22, 2013, the Company and Mr. Wit extended the maturity date of his convertible debentures to January 1, 2016 in accordance with the terms of Amendment Number Two To Securities Purchase Agreement. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.
	●	On March 31, 2011, the Company issued a note payable in the principal amount of $2,866,879 and warrants to purchase 11,467,517 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of March 31, 2016 to our CEO and Director, Cornelis F. Wit. The note accrues interest at a rate of 12% per annum and had a maturity date of April 1, 2014. On April 1, 2013, the Company and Mr. Wit extended the maturity date of the promissory note to March 31, 2016. The Promissory Note replaced the following Promissory Notes that had been previously issued:
		i.	Promissory Note issued on April 13, 2010 for $450,000 with a maturity date of December 31, 2011;
		ii.	Promissory Note issued on June 29, 2010 for $115,000 with a maturity date of December 31, 2011;
		iii.	Promissory Note issued on September 30, 2010 for $695,000 with a maturity date of December 31, 2011;
		iv.	Promissory Note issued on December 31, 2010 for $1,197,500 with a maturity date of December 31, 2011; and
		v.	Promissory Note issued on December 31, 2010 for $409,379 with a maturity date of April 01, 2012.
	●	On December 31, 2011, the Company issued a promissory note in the principal amount of $1,600,000 and warrants to purchase 6,400,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of December 31, 2015 to our CEO and Director, Cornelis F. Wit. The note carries an interest rate of 12% per annum and is due on January 1, 2015. The promissory note consolidates the amounts owed as detailed below:
		i.	Promissory Note issued on May 13, 2011 for $96,000 with a maturity date of January 01, 2013;
		ii.	Promissory Note issued on September 30, 2011 for $342,000 with a maturity date of April 01, 2014;
		iii.	Promissory Note issued on October 05, 2011 for $130,000 with a maturity date of April 01, 2014;
		iv.	Promissory Note issued on October 28, 2011 for $123,000 with a maturity date of April 01, 2014;
		v.	Promissory Note issued on October 31, 2011 for $82,000 with a maturity date of April 01, 2014;
		vi.	Promissory Note issued on November 23, 2011 for $60,000 with a maturity date of January 1, 2013; and
		vii.	Accrued and unpaid interest in the amount of $767,000.
	●	On January 1, 2013, the Company issued a promissory note in the principal amount of $529,000 and warrants to purchase 2,116,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of January 31, 2016 to our CEO and Director, Cornelis F. Wit. The note carries an interest rate of 12% per annum and is due on January 1, 2016.
	On March 18, 2013, the Company entered into a $2,000,000 revolving line of credit with The Northern Trust Company guaranteed by Cornelis F. Wit, our CEO and Director. Mr. Wit receives 2.0% interest on the assets pledged for the line of credit. On December 18, 2013 the Company renewed the Line of Credit and increased the available balance to $4,000,000. The line of credit matures on December 17, 2014 and carries a variable interest rate based on the prime rate. At December 31, 2013, $3,500,000 was outstanding on the line of credit at an interest rate of 2.25%.
	For the years December 31, 2013 and December 31, 2012 we incurred $2,339,702 and $2,108,749, respectively, in interest expense payable to related parties.

Note_14_Stockholders_Deficit

Note 14 - Stockholders' (Deficit)

12 Months Ended

Dec. 31, 2013

Stockholders' Equity Note [Abstract]

'

Stockholders' Equity Note Disclosure [Text Block]

'

NOTE 14:              STOCKHOLDERS’ (DEFICIT)

Our authorized capital stock consists of 250,000,000 shares of common stock, $.001 par value per share, and 10,000,000 shares of preferred stock, par value $.001 per share, of which 5,000,000 shares have been designated as 5% Series A Preferred, 230,000 shares have been designated as Series B Preferred Stock, 747,500 shares have been designated as Series C Preferred Stock and 250,000 shares have been designated as Series D Preferred Stock.

As of December 31, 2013 we had the following outstanding securities:

o

90,104,659 shares of common stock issued and outstanding;

o

44,728,873 warrants issued and outstanding to purchase shares of our common stock;

o

4,125,224 shares of our  Series A  Preferred Stock issued and outstanding,

o

-0- shares of our Series B  Preferred Stock issued and outstanding;

o

-0- shares of our Series C  Preferred Stock issued and outstanding;

o

250,000 Series D Preferred Stock issued and outstanding; and

o

$9,665,000 principal amount Convertible Debentures convertible into 24,620,000 shares of common stock.

Common Stock

Holders of common stock are entitled to one vote for each share on all matters submitted to a stockholder vote.  Holders of our voting securities do not have cumulative voting rights. Holders of common stock are entitled to share in all dividends that the Board of Directors, in its discretion, declares from legally available funds.  In the event of our liquidation, dissolution or winding up, subject to the preferences of the Series A Preferred Stockholders, each outstanding share of common stock entitles its holder to participate in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock.

Holders of common stock have no conversion, preemptive or other subscription rights, and there are no redemption provisions for the common stock.  The rights of the holders of common stock are subject to any rights that may be fixed for holders of preferred stock, when and if any preferred stock is outstanding.  All outstanding shares of common stock are duly authorized, validly issued, fully paid and non-assessable.

During 2013, we issued 1,225,000 restricted shares of our common stock to our senior management team and our Board of Directors. The restrictions on the shares lapse ratably over a 3 year period.  In 2013 we recognized $53,125 in compensation expense related to the share issuance.

In June 2013 a former employee exercised options granted to the employee during their employment. As a result of the exercise, 11,000 common shares were issued to the individual.

In November 2013, we issued 2,270,000 shares of our common in relation to our acquisition of Promasys B.V. We issued the shares to the Promasys B.V. shareholders who were all non US-persons/ non US-entities and the issuance of the shares to them occurred in an offshore transaction. The issuance of the 2,270,000 shares of common stock to the 3 shareholders of Promasys B.V pursuant to the share exchange agreement was exempt from registration under the Securities Act of 1933, as amended, pursuant to Regulation S thereof. (See Note 8)

Preferred stock

Our Board of Directors, without further stockholder approval, may issue preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. In addition, the Board of Directors may fix and determine all privileges and rights of the authorized preferred stock series including:

o

dividend and liquidation preferences,

o

voting rights,

o

conversion privileges, and

o

redemption terms.

Our Board of Directors may authorize the issuance of preferred stock which ranks senior to our common stock for the payment of dividends and the distribution of assets on liquidation.  In addition, our Board of Directors can fix limitations and restrictions, if any, upon the payment of dividends on our common stock to be effective while any shares of preferred stock are outstanding.

The following table presents the cumulative arrearage of undeclared dividends by class of preferred stock as of December 31, 2013 and December 31, 2012, respectively, and the per share amount by class of preferred stock.

Cumulative arrearage as of

Cumulative arrearage as of

December 31,

December 31,

Series of preferred stock

2013

2012

2013

2012

Series A

$

2,380,439

$

2,174,178

$

0.58

$

0.53

Series B

609,887

609,887

$

3.05

$

3.05

Series C

1,472,093

1,472,093

$

4.37

$

4.37

Total preferred stock arrearage

$

4,462,419

$

4,256,158

Series A Preferred Stock

In 1999, our Board of Directors designated 5,000,000 shares of our preferred stock as 5% Series A Convertible Preferred Stock (“Series A Preferred Stock”), of which 4,125,224 shares are issued and outstanding.

The designations, rights and preferences of the Series A Preferred include:

o

the shares are not redeemable,

o

each share of Series A Preferred Stock is convertible into shares of our common stock at any time at the option of the holder at a conversion price of $1.50 per share, or if not so converted after one year from issuance, at any time at our option if the closing bid price of our common stock has exceeded $3.00 for 20 consecutive trading days, our common stock is listed on The NASDAQ Stock Market or other national stock exchange, and the shares of common stock issuable upon conversion of the Series A Preferred Stock are registered under a registration statement,

o

the conversion price has certain anti-dilution protections for any stock splits, stock dividends, and corporate reorganizations, and certain other corporate transactions and issuances of securities at below the applicable conversion price per share.  The Series A Preferred Stockholders have waived their rights to an anti-dilution adjustment reducing their conversion price as a result of the issuance of the Series B Preferred Stock and Series C Preferred Stock,

o

the shares of Series A Preferred Stock pay a cumulative dividend at a rate of 5% per annum based on the stated value of $1.00 per share, payable when and as declared by the Board of Directors, or upon conversion or liquidation. Dividends on the Series A Preferred Stock have priority to our common stock and are junior to Series B Preferred Stock and Series C Preferred Stock.  At our option, dividends can be paid in cash or shares of common stock valued at the conversion price of the Series A Preferred Stock,

o

in the event of our liquidation or winding up, each share of Series A Preferred Stock has a liquidation preference equal to $1.00 per share, and

o

the holders of the Series A Preferred Stock are entitled to vote together with the holders of our common stock, on the basis of one vote for each share of common stock issuable upon the conversion of the Series A Preferred Stock.

There were cumulative arrearages of $2,380,439 and $2,174,178, or $0.58 and $0.53 per share, on the Series A Preferred Stock for undeclared dividends as of December 31, 2013 and December 31, 2012 respectively.

The Company has 235,000 shares of its 5% Series A Preferred stock that have been converted by the shareholders into shares of our common stock.  Pursuant to Delaware General Corporate Law, once the Company has a positive net worth, the cumulative dividends would be payable in either cash or in shares of our common stock upon the declaration of dividends by our board of directors.

In addition, the holders of the Series A Preferred Stock were granted certain demand and piggy-back registration rights for the shares of our common stock issuable upon the conversion of the Series A Preferred Stock.

Series B Preferred Stock

In August 2001, our Board of Directors designated 200,000 shares of our preferred stock as Series B Convertible Preferred Stock (“Series B Preferred Stock”). A Corrected Certificate of Designations was filed on February 7, 2002 with the Delaware Secretary of State increasing the number of shares authorized as Series B Preferred Stock to 230,000 shares, of which -0- shares are issued and outstanding.

The designations, rights and preferences of the Series B Preferred Stock include:

o

the stated value of each share is $10.00 per share,

o

the shares are not redeemable,

o

each share of Series B Preferred Stock is convertible into shares of our common stock at the option of the holder at any time commencing January 31, 2002 at the option of the holder at $0.25 per share, as adjusted, and the shares automatically convert, subject to limitations based on trading volume, into shares of our common stock at $0.25 per share at such time as we complete a public offering raising proceeds in excess of $25 million at an offering price of at least $0.75 per share.  We may require all outstanding shares of the Series B Preferred Stock to convert in the event the closing bid price of our common stock exceeds $0.50 for 20 consecutive trading days, and our common stock has been listed on The NASDAQ Stock Market or other comparable national stock exchange or the OTC Bulletin board and a registration statement registering the shares of common stock issuable upon conversion of the Series B Preferred Stock has been declared effective,

o

the conversion price has certain anti-dilution protections for any stock splits, stock dividends, and corporate reorganizations, and certain other corporate transactions and issuances of securities at below the applicable conversion price per share or market value of the common stock,

o

the shares of Series B Preferred Stock pay a cumulative dividend at a rate of 8% per annum based on the stated value of $10.00 per share, payable when and as declared by the Board of Directors, or upon conversion or liquidation.  At our option, dividends can be paid in cash or shares of common stock valued at the conversion price of the Series B Preferred Stock,

o

each share of Series B Preferred Stock will rank senior to our Series A Preferred and pari passu with our Series C Preferred Stock,

o

in the event of our liquidation or winding up, each share of Series B Preferred Stock has a liquidation preference equal to $10.00 per share plus accrued and unpaid dividends, and

o

the holders of the Series B Preferred Stock are entitled to vote, together with the holders of our common stock, on the basis of one vote for each share of common stock issuable upon the conversion of the Series B Preferred Stock,

There were cumulative arrearages of $609,887 and $609,887, or $3.05 and $3.05 per share, on the Series B Preferred Stock dividends as of December 31, 2013 and December 31, 2012, respectively.

The Company has 200,000 shares of its Series B Preferred stock that have been converted by the shareholders into shares of our common stock.  Pursuant to Delaware General Corporate Law, once the Company has a positive net worth, the cumulative dividends would be payable in either cash or in shares of our common stock upon the declaration of dividends by our board of directors.

In addition, the holders of the Series B Preferred Stock were granted certain mandatory and piggy-back registration rights for the shares of our common stock issuable upon the conversion of the Series B Preferred Stock and are entitled to vote one member to our Board of Directors.

Series C Preferred Stock

In March 2002, our Board of Directors designated 747,500 shares of our preferred stock as Series C Convertible Preferred Stock of which -0- shares are issued and outstanding.

The designations, rights and preferences of the Series C Preferred Stock include:

o

the stated value of each share is $10.00 per share,

o

the shares are not redeemable,

o

each share of Series C Preferred Stock is convertible at any time, at the option of the holder, into a number of shares of common stock determined by dividing the stated value per share of the Series C Preferred Stock by $0.25, which is the Series C Conversion Price.  The Series C Preferred Stock will automatically convert, subject to limitations based on trading volume, into shares of our common stock upon a public offering of our securities raising gross proceeds in excess of $25,000,000 at a per share price greater than 2.5 times the Series C Conversion Price per share, as adjusted for any stock split, stock dividend, recapitalization, or other similar transaction.  In addition, the Series C Preferred Stock will automatically convert into shares of our common stock at the Series C Conversion Price at such time as the closing bid price for our common stock has traded at two times the then prevailing Series C Conversion Price for a period of 20 consecutive trading days, provided that (i) a public trading market exists for our common stock on a national securities exchange, the NASDAQ Stock Market, or the over the counter market; and (ii) the Conversion Shares have been registered for resale and are not subject to any lock-up and the number of shares of the Series C Preferred Stock which can be converted in any 30-day period will be limited to the number of shares of common stock underlying the Series C  Preferred Stock equal to 10 times the average daily trading volume during the 20-day look-back period set forth above,

o

the conversion price  has certain anti-dilution protections for any stock splits, stock dividends, and corporate reorganizations, and certain other corporate transactions and issuances of securities at below the applicable conversion price per share or market value of the common stock,

o

the shares of Series C Preferred Stock pay a cumulative dividend at a rate of 8% per annum based on the stated value of $10.00 per share, payable when and as declared by the Board of Directors, or upon conversion or liquidation.  At our option, dividends can be paid in cash or shares of common stock valued at the conversion price of the Series C Preferred Stock,

o

each share of Series C Preferred Stock will rank pari passu with our Series B  Preferred Stock and senior to our Series A  Preferred Stock,

o

in the event of our liquidation or winding up, each share of Series C Preferred Stock  has a liquidation preference equal to $10.00 per share plus accrued and unpaid dividends, and

o

the holders of the Series C Preferred Stock are entitled to vote, together with the holders of our common stock, on the basis of one vote for each share of common stock issuable upon the conversion of the Series C Preferred Stock.

There were cumulative arrearages of $1,472,093 and $1,472,093, or $4.37 and $4.37 per share, on the Series C Preferred Stock for undeclared dividends as of December 31, 2013 and December 31, 2012, respectively.

The Company has 337,150 shares of its Series C Preferred stock that have been converted by the shareholders into shares of our common stock.  Pursuant to Delaware General Corporate Law, once the Company has a positive net worth, the cumulative dividends would be payable in either cash or in shares of our common stock upon the declaration of dividends by our board of directors.

In addition, the holders of the Series C Preferred Stock were granted certain mandatory and piggy-back registration rights covering the shares of our common stock issuable upon the conversion of the Series C Preferred Stock and are entitled to vote two members to our Board of Directors.

Series D Preferred Stock

In November 2010, our Board of Directors designated 250,000 shares of our preferred stock as Series D Convertible Preferred Stock of which 250,000 shares are issued and outstanding.

The designations, rights and preferences of the Series D Preferred Stock include:

o

the stated value of the Series D Preferred is $0.001 per share,

o

the Series D Preferred has no rights to receive dividend distributions or to participate in any dividends declared by the Corporation to or for the benefit of the holders of its common stock,

o

the shares of Series D Preferred are not convertible into or exchangeable for any other security of the Corporation,

o

except as provided in Series D Preferred Designation, in the case of the death or disability of Series D Preferred holder, the Series D Preferred is not redeemable without the prior express written consent of the holders of the majority of the voting power of all then outstanding shares of such Series D Preferred. In the event any shares of Series D Preferred are redeemed pursuant, the shares redeemed will automatically be canceled and returned to the status of authorized but unissued shares of preferred stock,

o

each share of Series D Preferred entitles the holder to Four Hundred (400) votes.  With respect to such vote, the holder is entitled to notice of any stockholders' meeting in accordance with the bylaws of the Company, and is entitled to vote, together as a single class with holders of common stock and any other series of preferred stock then outstanding, with respect to any question or matter upon which holders of common stock have the right to vote.  The Series D Preferred will also entitle the holders to vote the shares as a separate class as set forth herein and as required by law. In the event of any stock split, stock dividend or reclassification of the Corporation's common stock, the number of votes which attach to each share of Series D Preferred shall be adjusted in the same proportion as any adjustment to the number of outstanding shares of common stock. The shares of Series D Preferred present at a meeting of the Company’s shareholders shall vote in the same percentage as all voting shares voted for each director at the Company’s shareholder meeting in connection with the election or removal of directors to or from the Corporation’s Board of Directors,

o

in the event of the liquidation, dissolution or winding up of the affairs of the Corporation, whether voluntary or involuntary, the holders of shares of the Series D Preferred then outstanding are entitled to receive before holders of shares of common stock receive any amounts, out of the remaining assets of the Corporation available for distribution to its stockholders, an amount equal to $0.001 per share,

o

so long as any shares of Series D Preferred are outstanding, the Company cannot without first obtaining the written approval of the holders of at least a majority of the voting power of the then outstanding shares of such Series D Preferred Stock (i) alter or change the rights, preferences or privileges of the Series D Preferred, or (ii) increase or decrease the total number of authorized shares of Series D Preferred Stock,

o

the holders of the Series D Preferred are not entitled to rights to subscribe for, purchase or receive any part of any new or additional shares of any class, whether now or hereinafter authorized, or of bonds or debentures, or other evidences of indebtedness convertible into or exchangeable for shares of any class,

o

the Company has a thirty (30) day “right of first refusal” in which to match the terms and conditions set forth in any bona fide offer received by holders of the Series D Preferred Stock.  The Company must purchase all of those shares of Series D Preferred offered by the holder of the Series D Preferred Stock, and

o

the holders of Series D Preferred cannot, directly or indirectly, transfer any shares of Series D Preferred.  Any such purported transfer shall be of no force or effect and shall not be recognized by the Company.

The following table presents preferred dividends accreted for the years ended December 31, 2013 and December 31, 2012, respectively, and the per share effect of the preferred dividends if their effect was not anti-dilutive.

Dividends accreted

Dividends per share

year ended December 31,

year ended December 31,

2013

2012

2013

2012

Preferred stock dividends in arrears Series A

$

206,261

$

229,517

$

0.05

$

0.056

Preferred stock dividends in arrears Series B

$

-0-

$

-0-

$

-0-

$

-0-

Preferred stock dividends in arrears Series C

$

-0-

$

-0-

$

-0-

$

-0-

Warrants Issued for Services and in Capital Transactions

The following tables summarize all warrants issued to consultants and warrants issued as part of convertible debt transactions for the year ended December 31, 2013 and December 31, 2012, and the related changes during these years.

December 31, 2013 warrants outstanding

December 31, 2013 warrants exercisable

Range of exercise price

Number outstanding at

Weighted average

Weighted average

Number exercisable at

Weighted average

31-Dec-13

remaining contractual life

exercise price

31-Dec-13

exercise price

$

0.25

–

0.6

44,728,873

2.05

$

0.36

44,728,873

$

0.36

December 31, 2012 warrants outstanding

December 31, 2012 warrants exercisable

Range of exercise price

Number outstanding at

Weighted average

Weighted average

Number exercisable at

Weighted average

31-Dec-12

remaining contractual life

exercise price

31-Dec-12

exercise price

$

0.25

–

0.6

43,412,873

2.32

$

0.36

43,412,873

$

0.36

Warrants

Balance at December 31, 2012

43,412,873

Issued

2,116,000

Exercised

-0-

Expired/forfeited

(800,000

)

Balance at December 31, 2013

44,728,873

Warrants exercisable at December 31, 2013

44,728,873

Weighted average fair value of warrants granted during 2013

$

0.19

Other Comprehensive (Loss)

Due to the availability of net operating losses and related deferred tax valuations, there is no tax effect associated with any component of other comprehensive (loss).  The following table lists the beginning balance, yearly activity and ending balance of the components of accumulated other comprehensive (loss).

Foreign currency translation

Accumulated other comprehensive (loss)

Balance December 31, 2011

$

(53,714

)

$

(53,714

)

2012 Activity

(15,378

)

(15,378

)

Balance at December 31, 2012

(69,092

)

(69,092

)

2013 Activity

(18,512

)

(18,512

)

Balance at December 31, 2013

$

(87,604

)

$

(87,604

)

Note_15_Employee_Equity_Incent

Note 15 - Employee Equity Incentive Plans	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	NOTE 15:              EMPLOYEE EQUITY INCENTIVE PLANS
	Stock Option Plan
	Description of 2009 Equity Incentive Plan
	In 2009, the Company’s Board of Directors and shareholders approved the 2009 Equity Incentive Plan of OmniComm Systems, Inc. (the “2009 Plan”).  The 2009 Plan provides for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units.  Pursuant to the 2009 Plan, 7,500,000 shares of the Company’s common stock are authorized for issuance.
	The maximum term for any option grant under the 2009 Plan is ten years from the date of the grant; however, options granted under the 2009 Plan will generally expire five years from the date of grant for most employees, officers and directors of the Company.  Options granted to employees generally vest either upon grant or in two installments.  The first vesting, which is equal to 50% of the granted stock options, occurs upon completion of one full year of employment from the date of grant and the second vesting occurs on the second anniversary of the employee’s employment.  The vesting period typically begins on the date of hire for new employees and on the date of grant for existing employees.
	As of December 31, 2013, there were 3,991,000 outstanding options and 1,225,000 restricted stock shares that have been granted under the 2009 Plan.  At December 31, 2013, there were 2,284,000 shares available for grant as options or other forms of share-based compensation under the 2009 Plan.
	Description of 1998 Stock Incentive Plan
	In 1998, the Company’s Board of Directors and shareholders approved the 1998 Stock Incentive Plan of OmniComm Systems, Inc. (the “1998 Plan”).  The 1998 Plan provides for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units.  Pursuant to the 1998 Plan, 12,500,000 shares of the Company’s common stock were authorized for issuance.  The 1998 Plan expired as of December 31, 2008.  As of December 31, 2013, there were 1,754,000 outstanding options that have been granted under the 1998 Plan.
	The following table summarizes the stock option activity for the Company’s equity incentive plans:
			Number of shares				Weighted average exercise price				Weighted average remaining contractual term				Aggregate intrinsic value
							(per share)				(in years)
	Outstanding at December 31, 2011			11,158,000			$	0.37				2.52			$	-0-
	Granted			425,000				0.12
	Exercised			(265,000	)			0.2
	Forfeited/cancelled/expired			(865,500	)			0.43
	Outstanding at December 31, 2012			10,452,500				0.36				1.68			$	149,598
	Granted			350,000				0.17
	Exercised			(100,000	)			0.18
	Forfeited/cancelled/expired			(4,957,500	)			0.42
	Outstanding at December 31, 2013			5,745,000			$	0.29				1.7			$	93,945
	Vested and exercisable at December 31, 2013			4,924,166			$	0.32				1.42			$	67,737
	The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company’s closing stock price at fiscal year-end and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2013.
	The total number of shares vested and the fair value of shares vested for the years ended December 31, 2013 and December 31, 2012, respectively, was:
			Number of options				Fair value of
			vested				options vested
	Fair value of options vesting during the year ended December 31, 2013			768,833			$	35,384
	Fair value of options vesting during the year ended December 31, 2012			816,333			$	75,656
	Cash received from stock option exercises for the years ended December 31, 2013 and December 31, 2012 was $-0- and $-0-, respectively. Due to the Company’s net loss position, no income tax benefit has been realized during the years ended December 31, 2013 and December 31, 2012.
	The following table summarizes information concerning options outstanding at December 31, 2013:
	Awards breakdown by price range at December 31, 2013
					Outstanding												Vested
	Strike price				Outstanding				Weighted				Weighted				Vested stock		Weighted		Weighted
	range ($)				stock options				average				average				options		average		average vested
									remaining				outstanding						remaining		strike price
									contractual life				strike price						vested
																			contractual life
	0	to	0.2			3,251,000				2.16			$	0.15				2,530,166		1.86	$	0.16
	0.21	to	0.29			750,000				1.64				0.25				650,000		1.2		0.25
	0.3	to	0.49			110,000				0.98				0.38				110,000		0.98		0.38
	0.5	to	0.7			1,634,000				0.87				0.59				1,634,000		0.87		0.59
	0	to	0.7			5,745,000				1.7			$	0.29				4,924,166		1.42	$	0.32
	The following table summarizes information concerning options outstanding at December 31, 2012:
	Awards breakdown by price range at December 31, 2012
					Outstanding												Vested
	Strike price				Outstanding				Weighted				Weighted				Vested stock		Weighted		Weighted
	range ($)				stock options				average				average				options		average		average vested
									remaining				outstanding						remaining		strike price
									contractual life				strike price						vested
																			contractual life
	0	to	0.2			3,428,500				3.02			$	0.15				2,035,083		2.5	$	0.17
	0.21	to	0.29			2,550,000				1.18				0.26				2,550,000		1.18		0.26
	0.3	to	0.49			755,000				0.79				0.45				755,000		0.79		0.45
	0.5	to	0.7			3,719,000				0.97				0.6				3,719,000		0.97		0.6
	0	to	0.7			10,452,500				1.68			$	0.36				9,059,083		1.36	$	0.39
	The weighted average fair value (per share) of options granted during the years ended December 31, 2013, and December 31, 2012 using the Black Scholes option-pricing model was $0.17 and $0.11, respectively.
	Basis for Fair Value Estimate of Share-Based Payments
	Based on analysis of its historical volatility, the Company expects that the future volatility of its share price is likely to be similar to the historical volatility the Company experienced since the Company’s commercialization activities were initiated during the second half of 2000. The Company used a volatility calculation utilizing the Company’s own historical volatility to estimate its future volatility for purposes of valuing the share-based payments granted during fiscal 2013 and 2012. Actual volatility, and future changes in estimated volatility, may differ substantially from the Company’s current estimates.
	The Company utilizes the historical data available regarding employee and director exercise activity to calculate an expected life of the options. The table below presents the weighted average expected life in years of options granted under the Plan as described above. The risk-free rate of the stock options is based on the U.S. Treasury yield curve in effect at the time of grant, which corresponds with the expected term of the option granted.
	The fair value of share-based payments was estimated using the Black Scholes option pricing model with the following assumptions for grants made during the periods indicated.
			Stock option assumptions for the year ended
	Stock option assumptions		31-Dec-13				31-Dec-12
	Risk-free interest rate			0.58%				0.36%
	Expected dividend yield			0.00%				0.00%
Expected volatility			202.70%				192.30%
Expected life of options (in years)			5				5
The following table summarizes weighted average grant date fair value activity for the Company incentive stock plans:
		Weighted average grant date fair value
		2013				2012
Stock options granted during the year ended December 31,		$	0.17			$	0.11
Stock options vested during the year ended December 31,		$	0.11			$	0.09
Stock options forfeited during the year ended December 31,		$	0.29			$	0.32
A summary of the status of the Company’s non-vested shares underlying stock options as of December 31, 2013, and changes during the year ended December 31, 2013 is as follows:
		Shares underlying stock options				Weighted average grant date fair value
Nonvested shares at January 1, 2013			1,393,417			$	0.1
Nonvested shares at December 31, 2013			820,834			$	0.13
As of December 31, 2013, approximately $69,577 of total unrecognized compensation cost related to unvested stock options is expected to be recognized over a weighted-average period of 0.90 years.

Note_16_Income_Taxes

Note 16 - Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	NOTE 16:              INCOME TAXES
	A reconciliation of income tax expense and the amount computed by applying the statutory federal income tax rate to the income before provision for income taxes is as follows:
		31-Dec-13			31-Dec-12
	Federal statutory rate applied to loss before income taxes	$	(1,154,195	)	$	(2,923,533	)
	Increase/(decrease) in income taxes results from:
	Current tax expense		94,122			63,814
	Non deductible expenses		296,783			2,509,532
	Change in deferred assets		71,274			82,209
	Change in valuation allowance		786,138			331,792
	Income tax expense	$	94,122		$	63,814
	The components of income tax expense (benefit) for the years ended:
		31-Dec-13			31-Dec-12
	Current tax expense:	$	94,122		$	63,814
	Deferred tax expense/(benefit):
	Bad debt allowance		7,100			21,913
	Operating loss carryforward		(864,512	)		(435,914	)
	Patent litigation settlement		71,274			82,209
			(786,138	)		(331,792	)
	Valuation allowance		786,138			331,792
	Total tax expense	$	94,122		$	63,814
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities are as follows:
		31-Dec-13			31-Dec-12
	Amortization of intangibles	$	283,698		$	283,698
	Bad debt allowance		23,615			30,715
	Patent litigation liability accrual		315,408			386,682
	Operating loss carryforwards		18,220,482			17,355,970
	Gross deferred tax assets		18,843,203			18,057,065
	Valuation allowance		(18,843,203	)		(18,057,065	)
	Net deferred tax liability/(asset)	$	-0-		$	-0-
	The Company has net operating loss carry forwards (NOL) for income tax purposes of approximately $50,666,197.  This loss is allowed to be offset against future income until the year 2033 when the NOL’s will expire.  Other timing differences relate to depreciation and amortization for the stock acquisition of Education Navigator in 1998.  The tax benefits relating to all timing differences have been fully reserved for in the valuation allowance account due to the substantial losses incurred through December 31, 2013.  The change in the valuation allowance for the year ended December 31, 2013 was an increase of $786,138. The Company's tax returns for the prior three years remain subject to examination by major tax jurisdictions.

Note_17_Subsequent_Events

Note 17 - Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	NOTE 17:              SUBSEQUENT EVENTS
	On January 1, 2014 the Company issued a promissory note payable in the amount of $980,000 and 3,920,000 common stock purchase warrants (“Warrants”) to our CEO and Director, Cornelis F. Wit, in exchange for accrued interest in the amount of $980,000. The note carries an interest rate of 12% per annum and matures on April 1, 2017. The Warrants are exercisable until April 1, 2017 at an exercise price of $0.25.
	Subsequent to December 31, 2013 the Company drew an additional $500,000 on its line of credit.
	In January 2014, we paid in full a prommissory note with a principal balance of $17,500 that carried an interest rate of 12%.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

'

Basis of Accounting, Policy [Policy Text Block]

'

BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION

The Company’s accounts include those of all its wholly-owned subsidiaries, which are more fully described in the Company’s Annual Report filed on Form 10-K with the Securities and Exchange Commission, and have been prepared in conformity with (i) accounting principles generally accepted in the United States of America; and (ii) the rules and regulations of the United States Securities and Exchange Commission.  All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated in consolidation.

Use of Estimates, Policy [Policy Text Block]

'

ESTIMATES IN FINANCIAL STATEMENTS

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and footnotes thereto.  Significant estimates incorporated in our financial statements include the recorded allowance for doubtful accounts, the estimate of the appropriate amortization period of our intangible assets, the evaluation of whether our intangible assets have suffered any impairment, the allocation of revenues under multiple-element customer contracts, royalty-based patent liabilities, the value of derivatives associated with debt issued by the Company and the valuation of any corresponding discount to the issuance of our debt.  Actual results may differ from those estimates.

Reclassification, Policy [Policy Text Block]

'

RECLASSIFICATIONS

Certain reclassifications have been made in the 2012 financial statements to conform to the 2013 presentation.  These reclassifications did not have any effect on our net loss or shareholders’ deficit.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

'

FOREIGN CURRENCY TRANSLATION

The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830-30, Foreign Currency Matters—Translation of Financial Statements. The reporting currency for the Company is the U.S. dollar. The functional currency of the Company’s subsidiaries, OmniComm Europe GmbH in Germany, OmniComm Spain S.L. in Spain and Promasys B.V. in the Netherlands is the Euro. The functional currency of the Company's subsidiary, OmniComm Ltd. in the United Kingdom is the British Pound Sterling. Accordingly, the assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using the exchange rate in effect at each balance sheet date. Revenue and expense accounts of the Company’s foreign subsidiaries are translated using an average rate of exchange during the period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income (loss) as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are primarily related to intercompany accounts that have been determined to be temporary in nature and accordingly, are recorded directly to the statement of operations.  We record translation gains and losses in accumulated other comprehensive income as a component of stockholders’ equity. We recorded a translation loss of $18,512 for the year ended December 31, 2013 and a translation loss of $15,378 for the year ended December 31, 2012.

Revenue Recognition, Policy [Policy Text Block]

'

REVENUE RECOGNITION POLICY

The Company derives revenues from software licenses and services of its EDC products and services which can be purchased on a stand-alone basis. License revenues are derived principally from the sale of term licenses for the following software products offered by the Company: TrialMaster, TrialOne, Promasys and eClinical Suite (the “EDC Software”). Service revenues are derived principally from the Company's delivery of the hosted solutions of its TrialMaster and eClinical Suite software products, and consulting services and customer support, including training, for all of the Company's products.

The Company recognizes revenues when all of the following conditions are satisfied: (1) there is persuasive evidence of an arrangement; (2) the product or service has been provided to the customer; (3) the collection of fees is probable; and (4) the amount of fees to be paid by the customer is fixed or determinable.

The Company operates in one reportable segment which is the delivery of EDC Software and services to clinical trial sponsors.  The Company segregates its revenues based on the activity cycle used to generate its revenues.  Accordingly, revenues are currently generated through four main activities. These activities include hosted applications, licensing, professional services and maintenance-related services.

Hosted Application Revenues

The Company offers its TrialMaster and eClinical Suite software products as hosted application solutions delivered through a standard Web-browser, with customer support and training services. To date, hosted applications revenues have been primarily related to TrialMaster.

Revenues resulting from TrialMaster and eClinical Suite application hosting services consist of three components of services for each clinical trial: the first component is comprised of application set up, including design of electronic case report forms and edit checks, installation and server configuration of the system.  The second component involves application hosting and related support services as well as billable change orders which consist of amounts billed to customers for functionality changes made. The third stage involves services required to close out, or lock, the database for the clinical trial.

Fees charged and costs incurred for the trial system design, set up and implementation are amortized and recognized ratably over the estimated hosting period.  Work performed outside the original scope of work is contracted for separately as an additional fee and is generally recognized ratably over the remaining term of the hosting period. Fees for the first and third stages of the service are billed based upon milestones.  Revenues earned upon completion of a contractual milestone are deferred and recognized over the estimated remaining hosting period.   Fees for application hosting and related services in the second stage are generally billed quarterly in advance.  Revenues resulting from hosting services for the eClinical Suite products consist of installation and server configuration, application hosting and related support services. Services for this offering are generally charged as a fixed fee payable on a quarterly or annual basis. Revenues are recognized ratably over the period of the service.

Licensing Revenues

The Company's software license revenues are earned from the sale of off-the-shelf software.  From time-to-time a client might require significant modification or customization subsequent to delivery to the customer.  The Company generally enters into software term licenses for its EDC Software products with its customers for 3 to 5 year periods, although customers have entered into both longer and shorter term license agreements.  These arrangements typically include multiple elements: software license, consulting services and customer support. The Company bills its customers in accordance with the terms of the underlying contract. Generally, the Company bills license fees in advance for each billing cycle of the license term which typically is either on a quarterly or annual basis. Payment terms are generally net 30 days.

In the past the Company has sold perpetual licenses for EDC Software products in certain situations to existing customers with the option to purchase customer support, and may in the future do so for new customers based on customer requirements or market conditions. The Company has established vendor specific objective evidence of fair value for the customer support. Accordingly, license revenues are recognized upon delivery of the software and when all other revenue recognition criteria are met. Customer support revenues are recognized ratably over the term of the underlying support arrangement.  The Company generates customer support and maintenance revenues from its perpetual license customer base.

Professional Services

The Company may also enter into arrangements to provide consulting services separate from a license arrangement. In these situations, revenue is recognized on a time-and-materials basis. Professional services can be deemed to be as essential to the functionality of the software at inception and typically are for initial trial configuration, implementation planning, loading of software, building simple interfaces and running test data and documentation of procedures.  Subsequent additions or extensions to license terms do not generally include additional professional services.

Maintenance Revenues

Maintenance includes telephone-based help desk support and software maintenance. The Company generally bundles customer support with the software license for the entire term of the arrangement. As a result, the Company generally recognizes revenues for both maintenance and software licenses ratably over the term of the software license and support arrangement. The Company allocates the revenues recognized for these arrangements to the different elements based on management's estimate of the relative fair value of each element.  The Company generally invoices each of the elements based on separately quoted amounts and thus has a fairly accurate estimate of the relative fair values of each of the invoiced revenue elements.

The fees associated with each business activity for the years ended December 31, 2013 and December 31, 2012, respectively are:

For the year ended

Revenue activity

31-Dec-13

31-Dec-12

Set-up fees

$

3,369,670

$

4,990,378

Change orders

475,680

249,673

Maintenance

4,584,594

5,270,913

Software licenses

2,911,509

3,364,324

Professional services

2,207,181

996,081

Hosting

783,206

680,894

Total

$

14,331,840

$

15,552,263

Cost of Sales, Policy [Policy Text Block]

'

COST OF REVENUES

Cost of revenues primarily consists of costs related to hosting, maintaining and supporting the Company’s application suite and delivering professional services and support. These costs include salaries, benefits, bonuses and stock-based compensation for the Company’s professional services staff. Cost of revenues also includes outside service provider cost.  Cost of revenues is expensed as incurred.

Cash and Cash Equivalents, Policy [Policy Text Block]

'

CASH AND CASH EQUIVALENTS

Cash equivalents consist of highly liquid, short-term investments with maturities of 90 days or less.  The carrying amount reported in the accompanying consolidated balance sheets approximates fair value.

Receivables, Policy [Policy Text Block]

'

ACCOUNTS RECEIVABLE

Accounts receivable are judged as to collectability by management and an allowance for bad debts is established as necessary. The allowance is based on an evaluation of the collectability of accounts receivable and prior bad debt experience.  The Company had recorded an allowance for uncollectible accounts receivable of $65,341 and $84,210 as of December 31, 2013 and December 31, 2012, respectively.

The following table summarizes activity in the Company's allowance for doubtful accounts for the years presented.

December 31, 2013

December 31, 2012

Beginning of period

$

84,210

$

142,444

Bad debt expense

11,131

(58,234

)

Write-offs

(30,000

)

-0-

End of period

$

65,341

$

84,210

Concentration Risk, Credit Risk, Policy [Policy Text Block]

'

CONCENTRATION OF CREDIT RISK

Cash and cash equivalents and restricted cash are deposited with major financial institutions and, at times, such balances with any one financial institution may be in excess of FDIC-insured limits. As of December 31, 2013, $793,016 was deposited in excess of FDIC-insured limits.  Management believes the risk in these situations to be minimal.

Except as follows, the Company has no significant off balance sheet risk or credit risk concentrations. Financial instruments that subject the Company to potential credit risks are principally cash equivalents and accounts receivable. Concentrated credit risk with respect to accounts receivable is limited to creditworthy customers. The Company's customers are principally located in the United States and Europe.   The Company is directly affected by the overall financial condition of the pharmaceutical, biotechnology and medical device industries and management believes that credit risk exists and that any credit risk the Company faces has been adequately reserved for as of December 31, 2013.  The Company maintains an allowance for doubtful accounts based on accounts past due according to contractual terms and historical collection experience. Actual losses when incurred are charged to the allowance. The Company's losses related to collection of accounts receivable have consistently been within management's expectations.  As of December 31, 2013, the Company believes no additional credit risk exists beyond the amounts provided for in our allowance for uncollectible accounts.  The Company evaluates its allowance for uncollectable accounts on a monthly basis based on a specific review of receivable aging and the period that any receivables are beyond the standard payment terms. The Company does not require collateral from its customers in order to mitigate credit risk.

One customer accounted for 11% during the year ended December 31, 2013 or approximately $1,551,100, respectively. One customer accounted for 19% and another accounted for 16% of our revenues during the year ended December 31, 2012 or approximately $2,909,300 and $2,503,100, respectively.  The following table summarizes the number of customers who individually comprise greater than 10% of total revenue and/or total accounts receivable and their aggregate percentage of the Company's total revenue and gross accounts receivable for the years presented.

Revenues

Accounts Receivable

For the years ended

Number of

Percentage of

Number of

Percentage of accounts

customers

total revenues

customers

receivable

31-Dec-13

1

11%

2

23%

31-Dec-12

2

35%

3

54%

The table below provides revenues from European customers for the years ended December 31, 2013 and December 31, 2012, respectively.

European revenues

For the year ended

31-Dec-13

31-Dec-12

European revenues

% of Total revenues

European revenues

% of Total revenues

$

1,847,305

12.90%

$

1,545,730

9.90%

The Company serves all of its hosting customers from third-party web hosting facilities located in the United States. The Company does not control the operation of these facilities, and they are vulnerable to damage or interruption. The Company maintains redundant systems that can be used to provide service in the event the third-party web hosting facilities become unavailable, although in such circumstances, the Company's service may be interrupted during the transition.

Property, Plant and Equipment, Policy [Policy Text Block]

'

PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost.  Additions and betterments are capitalized; maintenance and repairs are expensed as incurred.  Depreciation is calculated using the straight-line method over the asset’s estimated useful life, which is 5 years for leasehold improvements, computers, equipment and furniture and 3 years for software.  Gains or losses on disposal are charged to operations.

Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]

'

ASSET IMPAIRMENT

Acquisitions and Intangible Assets

We account for acquisitions in accordance with ASC 805, Business Combinations (“ASC 805”) and ASC 350, Intangibles- Goodwill and Other (“ASC 350”). The acquisition method of accounting requires that assets acquired and liabilities assumed be recorded at their fair values on the date of a business acquisition. Our consolidated financial statements and results of operations reflect an acquired business from the completion date of an acquisition.

The judgments that we make in determining the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact net income in periods following an asset acquisition. We generally use either the income, cost or market approach to aid in our conclusions of such fair values and asset lives. The income approach presumes that the value of an asset can be estimated by the net economic benefit to be received over the life of the asset, discounted to present value. The cost approach presumes that an investor would pay no more for an asset than its replacement or reproduction cost. The market approach estimates value based on what other participants in the market have paid for reasonably similar assets. Although each valuation approach is considered in valuing the assets acquired, the approach ultimately selected is based on the characteristics of the asset and the availability of information.

Long-lived Assets

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount and the asset’s residual value, if any. In turn, measurement of an impairment loss requires a determination of fair value, which is based on the best information available. We use quoted market prices when available and independent appraisals and management estimates of future operating cash flows, as appropriate, to determine fair value.

Revenue Recognition, Deferred Revenue [Policy Text Block]

'

DEFERRED REVENUE

Deferred revenue represents cash advances received in excess of revenue earned on on-going contracts.  Payment terms vary with each contract but may include an initial payment at the time the contract is executed, with future payments dependent upon the completion of certain contract phases or targeted milestones.  In the event of contract cancellation, the Company is generally entitled to payment for all work performed through the point of cancellation.  As of December 31, 2013, the Company had $4,251,373 in deferred revenues relating to contracts for services to be performed over periods ranging from 1 month to 5 years.  The Company had $2,866,356 in deferred revenues that are expected to be recognized in the next twelve fiscal months.

Advertising Costs, Policy [Policy Text Block]

'

ADVERTISING

Advertising costs are expensed as incurred.  Advertising costs were $226,380 and $269,311 for the years ended December 31, 2013 and December 31, 2012, respectively and are included under selling, general and administrative expenses on our consolidated financial statements.

Research, Development, and Computer Software, Policy [Policy Text Block]

'

RESEARCH AND DEVELOPMENT EXPENSES

Software development costs are included in R&D and are expensed as incurred.  ASC 985.20, Software Industry Costs of Software to Be Sold, Leased or Marketed, requires the capitalization of certain development costs of software to be sold once technological feasibility is established, which the Company defines as completion to the point of marketability.  The capitalized cost is then amortized on a straight-line basis over the estimated product life.  To date, the period between achieving technological feasibility and the general availability of such software has been short and software development costs qualifying for capitalization have been immaterial.  Accordingly, the Company has not capitalized any software development costs under ASC 985.20.  During the years ended December 31, 2013 and December 31, 2012 we spent approximately $2,403,504 and $2,337,904 respectively, on R&D activities, which include costs associated with the development of our software products and services for our client’s projects and which are primarily comprised of salaries and related expenses for our software developers and consulting fees paid to third-party consultants.  R&D costs are primarily included under Salaries, benefits and related taxes in our Statement of Operations.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

'

EMPLOYEE EQUITY INCENTIVE PLANS

The OmniComm Systems, Inc. 2009 Equity Incentive Plan (the “2009 Plan”) was approved at our Annual Meeting of Shareholders on July 10, 2009.  The 2009 Plan provides for the issuance of up to 7.5 million shares to employees, directors and key consultants in accordance with the terms of the 2009 Plan documents.  The predecessor plan, the OmniComm Systems, Inc., 1998 Stock Incentive Plan (the “1998 Plan”) expired on December 31, 2008.  The 1998 Plan provided for the issuance of up to 12.5 million shares in accordance with the terms of the 1998 Plan document.  Each plan is more fully described in “Note 15, Employee Equity Incentive Plans.”  The Company accounts for its employee equity incentive plans under ASC 718, Compensation – Stock Compensation which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions.

ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The Company currently uses the Black Scholes option pricing model to determine grant date fair value.

Earnings Per Share, Policy [Policy Text Block]

'

EARNINGS/(LOSS)  PER SHARE

The Company accounts for Earnings/(loss) Per Share using ASC 260 – Earnings per Share.  Unlike diluted earnings per share, basic earnings per share excludes any dilutive effects of options, warrants, and convertible securities.

Income Tax, Policy [Policy Text Block]

'

INCOME TAXES

The Company accounts for income taxes in accordance ASC 740, Income Taxes.  ASC 740 has as its basic objective the recognition of current and deferred income tax assets and liabilities based upon all events that have been recognized in the financial statements as measured by the provisions of the enacted tax laws

Valuation allowances are established when necessary to reduce deferred tax assets to the estimated amount to be realized.  Income tax expense represents the tax payable for the current period and the change during the period in the deferred tax assets and liabilities.

New Accounting Pronouncements, Policy [Policy Text Block]

'

IMPACT OF NEW ACCOUNTING STANDARDS

During fiscal 2013, we adopted the following new accounting pronouncements:

In December 2011, FASB issued Accounting Standards Update 2011-11, “Balance Sheet - Disclosures about Offsetting Assets and Liabilities” to enhance disclosure requirements relating to the offsetting of assets and liabilities on an entity's balance sheet. The update requires enhanced disclosures regarding assets and liabilities that are presented net or gross in the statement of financial position when the right of offset exists, or that are subject to an enforceable master netting arrangement. The new disclosure requirements relating to this update are retrospective and effective for annual and interim periods beginning on or after January 1, 2013. The update only requires additional disclosures, as such, the adoption of this standard did not have a material impact on our results of operations, cash flows or financial condition.

In January 2013, the FASB issued authoritative guidance on the presentation of amounts reclassified out of accumulated other comprehensive income. This guidance requires an entity to provide information about the amounts reclassified from accumulated other comprehensive income by component. In addition, an entity is required to present, either on the face of the income statement or in the notes, significant amounts reclassified from accumulated other comprehensive income by the net income line item. Our adoption of this standard did not have an impact on our consolidated financial statements.

In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. This ASU amends ASC 740, Income Taxes, to require that an unrecognized tax benefit be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward; to the extent that a net operating loss carry forward, a similar tax loss, or a tax credit carryforward does not exist at the reporting date, the unrecognized tax benefit should be presented in the financial statements as a liability and not combined with deferred tax assets. ASU No. 2013-11 is effective for interim and annual periods beginning after December 15, 2013, with early adoption permitted. The Company will adopt ASU No. 2013-11 on January 1, 2014 and the adoption is not expected to have a material impact on its consolidated financial statements.

Accounting standards-setting organizations frequently issue new or revised accounting rules. We regularly review all new pronouncements to determine their impact, if any, on our financial statements.

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Revenue Recognition, Multiple-deliverable Arrangements [Table Text Block]	'
			For the year ended
	Revenue activity		31-Dec-13				31-Dec-12
	Set-up fees		$	3,369,670			$	4,990,378
	Change orders			475,680				249,673
	Maintenance			4,584,594				5,270,913
	Software licenses			2,911,509				3,364,324
	Professional services			2,207,181				996,081
	Hosting			783,206				680,894
	Total		$	14,331,840			$	15,552,263
Allowance for Credit Losses on Financing Receivables [Table Text Block]	'
			December 31, 2013				December 31, 2012
	Beginning of period		$	84,210			$	142,444
	Bad debt expense			11,131				(58,234	)
	Write-offs			(30,000	)			-0-
	End of period		$	65,341			$	84,210
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	'
			Revenues								Accounts Receivable
	For the years ended		Number of				Percentage of				Number of			Percentage of accounts
			customers				total revenues				customers			receivable
	31-Dec-13			1				11%				2			23%
	31-Dec-12			2				35%				3			54%
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	'
		European revenues
		For the year ended
		31-Dec-13								31-Dec-12
		European revenues				% of Total revenues				European revenues			% of Total revenues
		$	1,847,305				12.90%			$	1,545,730			9.90%

Note_4_Earnings_Loss_Per_Share1

Note 4 - Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	Anti-Dilutive Security	31-Dec-13			December 31, 2012
	Preferred stock		2,750,149			2,750,149
	Employee stock options		5,745,000			10,452,500
	Warrants		44,728,873			43,212,873
	Convertible notes		24,620,000			24,620,000
	Shares issuable for accrued interest		1,702,891			1,033,574
	Total		79,546,913			82,069,096
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	For the year ended
		31-Dec-13								31-Dec-12
		Income (loss)			Shares		Per-share			Income (loss)			Shares		Per-share
		numerator			denominator		amount			numerator			denominator		amount
	Basic EPS	$	(3,367,603	)		87,969,202	$	(0.04	)	$	(8,062,487	)		86,522,332	$	(0.09	)
	Effect of dilutive securities - none		-0-			-0-		-0-			-0-			-0-		-0-
	Diluted EPS	$	(3,367,603	)		87,969,202	$	(0.04	)	$	(8,062,487	)		86,522,332	$	(0.09	)

Note_5_Property_and_Equipment_1

Note 5 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		31-Dec-13						31-Dec-12
		Cost		Accumulated depreciation		Net book		Cost		Accumulated depreciation		Net book		Estimated
						value						value		useful life
														(years)
	Computer & office equipment	$	1,822,098	$	1,326,256	$	495,842	$	1,519,617	$	1,181,451	$	338,166		5
	Leasehold improvements		93,812		75,735		18,077		92,686		68,044		24,642		5
	Computer software		1,556,497		1,477,801		78,696		1,502,524		1,403,705		98,819		3
	Office furniture		114,373		99,555		14,818		110,780		90,604		20,176		5
	Total	$	3,586,780	$	2,979,347	$	607,433	$	3,225,607	$	2,743,804	$	481,803

Note_6_Intangible_Assets_At_Co1

Note 6 - Intangible Assets, At Cost (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
		31-Dec-13						31-Dec-12
	Asset	Cost		Accumulated amortization		Net book		Cost		Accumulated amortization		Net book		Estimated
						value						value		useful life
														(years)
	eClinical customer lists	$	1,392,701	$	1,392,701	$	-0-	$	1,392,701	$	1,392,701	$	-0-		3
	Promasys B.V. customer lists		136,253		1,514		134,739		-0-		-0-		-0-		15
	Promasys B.V. software code		72,943		2,431		70,512		-0-		-0-		-0-		5
	Promasys B.V. URLs/Website		68,814		3,823		64,991		-0-		-0-		-0-		3
		$	1,670,711	$	1,400,469	$	270,242	$	1,392,701	$	1,392,701	$	-0-
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	2014	$	46,610
	2015		46,610
	2016		42,788
	2017		23,672
	2018 and thereafter		110,562
	Total	$	270,242

Note_7_Accounts_Payable_and_Ac1

Note 7 - Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
	Account	31-Dec-13		31-Dec-12
	Accounts payable	$	724,421	$	665,139
	Accrued payroll and related costs		260,072		383,859
	Other accrued expenses		88,292		124,154
	Accrued interest		1,468,171		951,213
	Total accounts payable and accrued expenses	$	2,540,956	$	2,124,365

Note_8_Promasys_BV_Acquisition1

Note 8 - Promasys B.V. Acquisition (Tables)	12 Months Ended
	Dec. 31, 2013
Note 8 - Promasys B.V. Acquisition (Tables) [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	'
	Cash	$	215,571
	Receivables	$	216,287
	Property and equipment	$	2,178
	Identifiable intangibles	$	276,356
	Goodwill	$	671,689
	Total assets acquired	$	1,382,081
	Accounts payable	$	(170,339	)
	Deferred revenue	$	(229,353	)
	Net asssets acquired	$	982,389
Promasys B.V. [Member]	'
Note 8 - Promasys B.V. Acquisition (Tables) [Line Items]	'
Business Acquisition, Pro Forma Information [Table Text Block]	'
		(Unaudited)
		For the year ended
		December 31,
		2013			2012
	Gross revenues	$	15,119,861		$	16,002,612
	Total expenses		18,145,210			23,988,611
	Net income (loss) before taxes	$	(3,025,349	)	$	(7,985,999	)
	Net income (loss) per share	$	(0.04	)	$	(0.09	)
	Weighted average number of shares outstanding
	Basic and Diluted		89,866,051			88,792,332

Note_9_Line_of_Credit_and_Note1

Note 9 - Line of Credit and Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
					Ending
					principal		Non related party				Related party
	Origination	Maturity	Interest		December 31,				Long				Long
	date	date	rate		2013		Current		term		Current		term
	12/31/11	1/1/15		12%	$	1,600,000	$	-0-	$	-0-	$	-0-	$	1,600,000
	4/1/12	1/1/14		12%		17,500		17,500		-0-		-0-		-0-
	12/17/12	12/16/14		12%		20,000		20,000		-0-		-0-		-0-
	1/1/13	1/1/16		12%		529,000		-0-		-0-		-0-		529,000
	1/1/13	1/1/15		10%		308,561		-0-		308,561		-0-		-0-
	1/1/13	1/1/15		10%		123,425		-0-		123,425		-0-		-0-
	1/1/13	1/1/15		12%		45,000		-0-		45,000		-0-		-0-
	2/1/13	1/1/16		12%		20,000		-0-		-0-		-0-		20,000
	3/5/13	1/1/15		12%		137,500		-0-		137,500		-0-		-0-
	4/1/13	3/31/16		12%		2,866,879		-0-		-0-		-0-		2,866,879
	Discount on note payable							-0-		-0-		-0-		(447,666	)
	Total				$	5,667,865	$	37,500	$	614,486	$	-0-	$	4,568,213
					Ending
					principal		Non related party				Related party
	Origination	Maturity	Interest		December 31,				Long				Long
	date	date	rate		2012		Current		term		Current		term
	12/31/10	1/1/15		10%	$	308,562	$	-0-	$	308,562	$	-0-	$	-0-
	12/31/10	1/1/15		10%		123,425		-0-		123,425		-0-		-0-
	2/1/11	1/1/15		12%		137,500		-0-		137,500		-0-		-0-
	3/31/11	4/1/14		12%		2,866,879		-0-		-0-		-0-		2,866,879
	12/31/11	1/1/15		12%		1,600,000		-0-		-0-		-0-		1,600,000
	12/31/11	1/1/16		12%		20,000		-0-		-0-		-0-		20,000
	4/1/12	1/1/14		12%		17,500		-0-		17,500		-0-		-0-
	10/1/12	1/1/15		12%		45,000		-0-		45,000		-0-		-0-
	12/17/12	12/16/14		12%		20,000		-0-		20,000		-0-		-0-
	Discount on note payable							-0-		-0-		-0-		(656,524	)
	Total				$	5,138,866	$	-0-	$	651,987	$	-0-	$	3,830,355

Note_10_Convertible_Notes_Paya1

Note 10 - Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2013
Note 10 - Convertible Notes Payable (Tables) [Line Items]	'
Schedule of Maturities of Long-term Debt [Table Text Block]	'
	2014	$	75,000
	2015		250,000
	2016		9,340,000
	Total	$	9,665,000
Convertible Debt [Member]	'
Note 10 - Convertible Notes Payable (Tables) [Line Items]	'
Schedule of Long-term Debt Instruments [Table Text Block]	'
								Principal						Discount		Carrying		Carrying amount
								at				Total		at		amount at		Short term				Long term
	Date of	Maturity		Interest		Original		December		Allocated		discount		December		December		Related		Non		Related		Non related
	issuance	date		rate		principal		31, 2013		discount		amortized		31, 2013		31, 2013				related
	8/1/99	6/30/04			10%	$	862,500	$	75,000	$	-0-	$	-0-	$	-0-	$	75,000	$	-0-	$	75,000	$	-0-	$	-0-
	8/29/08	1/1/15			10%		150,000		150,000		135,600		135,600		-0-		150,000		-0-		-0-		150,000		-0-
	8/29/08	1/1/16			10%		2,120,000		1,770,000		1,916,480		1,916,480		-0-		1,770,000		-0-		-0-		1,770,000		-0-
	12/16/08	1/1/15			12%		100,000		100,000		27,515		27,515		-0-		100,000		-0-		-0-		-0-		100,000
	12/16/08	1/1/16			12%		160,000		160,000		44,024		44,024		-0-		160,000		-0-		-0-		160,000		-0-
	12/16/08	1/1/16			12%		200,000		200,000		55,030		55,030		-0-		200,000		-0-		-0-		-0-		200,000
	12/16/08	1/1/16			12%		4,615,000		4,520,000		1,243,681		1,243,681		-0-		4,520,000		-0-		-0-		4,505,000		15,000
	9/30/09	1/1/16			12%		1,400,000		1,200,000		526,400		526,400		-0-		1,200,000		-0-		-0-		1,100,000		100,000
	12/31/09	1/1/16			12%		1,490,000		1,490,000		935,720		935,720		-0-		1,490,000		-0-		-0-		1,440,000		50,000
	Total					$	11,097,500	$	9,665,000	$	4,884,450	$	4,884,450	$	-0-	$	9,665,000	$	-	$	75,000	$	9,125,000	$	465,000
								Principal						Discount		Carrying		Carrying amount
								at				Total		at		amount at		Short term				Long term
	Date of	Maturity		Interest		Original		December		Allocated		discount		December		December		Related		Non related		Related		Non related
	issuance	date		rate		principal		31, 2012		discount		amortized		31, 2012		31, 2012
	8/1/99	6/30/04			10%	$	862,500	$	75,000	$	-0-	$	-0-	$	-0-	$	75,000	$	-0-	$	75,000	$	-0-	$	-0-
	8/29/08	1/1/15			10%		150,000		150,000		135,600		135,600		-0-		150,000		-0-		-0-		150,000		-0-
	8/29/08	1/1/16			10%		2,120,000		1,770,000		1,916,480		1,916,480		-0-		1,770,000		-0-		-0-		1,770,000		-0-
	12/16/08	12/16/13			12%		160,000		160,000		44,024		44,024		-0-		160,000		160,000		-0-		-0-		-0-
	12/16/08	1/1/14			12%		200,000		200,000		55,030		55,030		-0-		200,000		-0-		-0-		-0-		200,000
	12/16/08	1/1/15			12%		100,000		100,000		27,515		27,515		-0-		100,000		-0-		-0-		-0-		100,000
	12/16/08	1/1/16			12%		4,615,000		4,520,000		1,243,681		1,243,681		-0-		4,520,000		-0-		-0-		4,505,000		15,000
	9/30/09	1/1/16			12%		1,400,000		1,200,000		526,400		526,400		-0-		1,200,000		-0-		-0-		1,100,000		100,000
	12/31/09	1/1/16			12%		1,490,000		1,490,000		935,720		935,720		-0-		1,490,000		-0-		-0-		1,440,000		50,000
	Total					$	11,097,500	$	9,665,000	$	4,884,450	$	4,884,450	$	-0-	$	9,665,000	$	160,000	$	75,000	$	8,965,000	$	465,000

Note_11_Fair_Value_Measurement1

Note 11 - Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2013
Note 11 - Fair Value Measurement (Tables) [Line Items]	'
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	'
		Fair value at				Quoted prices in active markets for identical assets/ liabilities			Significant other			Significant
		December 31,							observable inputs			unobservable inputs
		2013				(Level 1)			(Level 2)			(Level 3)
	Derivatives: (1) (2)
	Conversion feature liability	$	3,126,206			$	-0-		$	-0-		$	3,126,206
	Warrant liability		5,943,977				-0-			-0-			5,943,977
	Total of derivative liabilities	$	9,070,183			$	-0-		$	-0-		$	9,070,183
		Fair value at December 31,				Quoted prices in active markets for identical assets/ liabilities			Significant other observable inputs			Significant unobservable inputs
		2012				(Level 1)			(Level 2)			(Level 3)
	Derivatives: (1) (2)
	Conversion feature liability	$	2,287,323			$	-0-		$	-0-		$	2,287,323
	Warrant liability		6,287,598				-0-			-0-			6,287,598
	Total of derivative liabilties	$	8,574,921			$	-0-		$	-0-		$	8,574,921
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	'
		Significant valuation assumptions of derivative instruments at December 31, 2013
	Risk free interest rate		0.12%	to	0.13%
	Dividend yield			0.00%
	Expected volatility		166.7%	to	217.1%
	Expected life (range in years)
	Conversion feature liability		1	to	2
	Warrant liability		1	to	2.25
	Significant valuation assumptions of derivative instruments at December 31, 2012
	Risk free interest rate	0.18%	to	0.36%
	Dividend yield		0.00%
	Expected volatility	218.2%	to	259.10%
	Expected life (range in years)
	Conversion feature liability	0.25	to	0.96
	Warrant liability	0.66	to	3.25
Schedule of Goodwill [Table Text Block]	'
		31-Dec-13				31-Dec-12
	(Level 3)
	Goodwill	$	675,710			$	-0-
Promasys B.V. [Member]	'
Note 11 - Fair Value Measurement (Tables) [Line Items]	'
Fair Value Measurements, Nonrecurring [Table Text Block]	'
		Carrying				Carrying			Quoted prices in active markets for identical assets/ liabilities			Significant other observable inputs		Significant unobservable inputs
		amount				amount
		December 31,				December 31,
		2012				2013			(Level 1)			(Level 2)		(Level 3)
	Acquired assets (3)
	Promasys B.V. customer lists (4)	$	-0-			$	134,739		$	-0-		$	-0-	$	136,253
	Promasys B.V. software code (4)		-0-				70,512			-0-			-0-		72,943
	Promasys B.V. URLs/website (4)		-0-				64,991			-0-			-0-		68,814
	Promasys B.V. goodwill (4)		-0-				675,710			-0-			-0-		675,710
		$	-0-			$	945,952		$	-0-		$	-0-	$	953,720
Fair Value, Inputs, Level 3 [Member]	'
Note 11 - Fair Value Measurement (Tables) [Line Items]	'
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	'
		Level 3 financial assets and financial liabilities at fair value
		Balance,				Net realized			Net unrealized			Net		Net transfers		Balance,
		beginning				gains/(losses)			(gains)/losses			purchases,		in and/or out		end of
		of year							relating to			issuances		of Level 3		period
									instruments still			and
									held at the			settlements
									reporting date
	Year ended December 31, 2013
	Derivatives:
	Conversion feature liability	$	2,287,323			$	-0-		$	838,883		$	-0-	$	-0-	$	3,126,206
	Warrant liability		6,287,598				-0-			(743,762	)		400,141		-0-		5,943,977
	Total of derivative liabilties	$	8,574,921			$	-0-		$	95,121		$	400,141	$	-0-	$	9,070,183
		Level 3 financial assets and financial liabilities at fair value
		Balance,				Net realized			Net unrealized			Net		Net transfers		Balance,
		beginning				gains/(losses)			(gains)/losses			purchases,		in and/or out		end of
		of year							relating to			issuances		of Level 3		period
									instruments still			and
									held at the			settlements
									reporting date
	Year ended December 31, 2012
	Derivatives:
	Conversion feature liability	$	758,911			$	-0-		$	1,528,412		$	-0-	$	-0-	$	2,287,323
	Warrant liability		1,692,708				-0-			4,594,890			-0-		-0-		6,287,598
	Total of derivative liabilties	$	2,451,619			$	-0-		$	6,123,302		$	-0-	$	-0-	$	8,574,921
Unrealized (Losses) [Member]	'
Note 11 - Fair Value Measurement (Tables) [Line Items]	'
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	'
		Other income
		for the year ended
		31-Dec-13				31-Dec-12
	The net amount of (losses) for the period included in earnings attributable to the unrealized loss from changes in derivative liabilities at the reporting date	$	(95,121	)		$	(6,123,302	)
	Total unrealized (losses) included in earnings	$	(95,121	)		$	(6,123,302	)

Note_12_Commitments_and_Contin1

Note 12 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	2014	$	537,630
	2015		502,131
	2016		279,174
	2017		53,699
	2018		5,849
	Total	$	1,378,483
Schedule of Minimum Royalty Payments [Table Text Block]	'
	2014	$	450,000
	2015		450,000
	2016		450,000
	2017		450,000
	Total	$	1,800,000

Note_14_Stockholders_Deficit_T

Note 14 - Stockholders' (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2013
Note 14 - Stockholders' (Deficit) (Tables) [Line Items]	'
Schedule of Dividends in Arrears [Table Text Block]	'
			Cumulative arrearage as of								Cumulative arrearage as of
			December 31,								December 31,
	Series of preferred stock		2013				2012				2013				2012
	Series A		$	2,380,439			$	2,174,178			$	0.58			$	0.53
	Series B			609,887				609,887			$	3.05			$	3.05
	Series C			1,472,093				1,472,093			$	4.37			$	4.37
	Total preferred stock arrearage		$	4,462,419			$	4,256,158
Schedule of Dividends Payable [Table Text Block]	'
			Dividends accreted								Dividends per share
			year ended December 31,								year ended December 31,
			2013				2012				2013				2012
	Preferred stock dividends in arrears Series A		$	206,261			$	229,517			$	0.05			$	0.056
	Preferred stock dividends in arrears Series B		$	-0-			$	-0-			$	-0-			$	-0-
	Preferred stock dividends in arrears Series C		$	-0-			$	-0-			$	-0-			$	-0-
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	December 31, 2013 warrants outstanding														December 31, 2013 warrants exercisable
	Range of exercise price				Number outstanding at		Weighted average				Weighted average				Number exercisable at				Weighted average
					31-Dec-13		remaining contractual life				exercise price				31-Dec-13				exercise price
	$	0.25	–	0.6	44,728,873			2.05			$	0.36				44,728,873			$	0.36
	December 31, 2012 warrants outstanding																December 31, 2012 warrants exercisable
	Range of exercise price				Number outstanding at				Weighted average				Weighted average				Number exercisable at				Weighted average
					31-Dec-12				remaining contractual life				exercise price				31-Dec-12				exercise price
	$	0.25	–	0.6		43,412,873				2.32			$	0.36				43,412,873			$	0.36
Schedule of Share-based Compensation, Activity [Table Text Block]	'
			Weighted average grant date fair value
			2013				2012
	Stock options granted during the year ended December 31,		$	0.17			$	0.11
	Stock options vested during the year ended December 31,		$	0.11			$	0.09
	Stock options forfeited during the year ended December 31,		$	0.29			$	0.32
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'
			Foreign currency translation				Accumulated other comprehensive (loss)
	Balance December 31, 2011		$	(53,714	)		$	(53,714	)
	2012 Activity			(15,378	)			(15,378	)
	Balance at December 31, 2012			(69,092	)			(69,092	)
	2013 Activity			(18,512	)			(18,512	)
	Balance at December 31, 2013		$	(87,604	)		$	(87,604	)
Warrant [Member]	'
Note 14 - Stockholders' (Deficit) (Tables) [Line Items]	'
Schedule of Share-based Compensation, Activity [Table Text Block]	'
	Warrants
	Balance at December 31, 2012			43,412,873
	Issued			2,116,000
	Exercised			-0-
	Expired/forfeited			(800,000	)
	Balance at December 31, 2013			44,728,873
	Warrants exercisable at December 31, 2013			44,728,873
	Weighted average fair value of warrants granted during 2013		$	0.19

Note_15_Employee_Equity_Incent1

Note 15 - Employee Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
			Number of shares				Weighted average exercise price				Weighted average remaining contractual term				Aggregate intrinsic value
							(per share)				(in years)
	Outstanding at December 31, 2011			11,158,000			$	0.37				2.52			$	-0-
	Granted			425,000				0.12
	Exercised			(265,000	)			0.2
	Forfeited/cancelled/expired			(865,500	)			0.43
	Outstanding at December 31, 2012			10,452,500				0.36				1.68			$	149,598
	Granted			350,000				0.17
	Exercised			(100,000	)			0.18
	Forfeited/cancelled/expired			(4,957,500	)			0.42
	Outstanding at December 31, 2013			5,745,000			$	0.29				1.7			$	93,945
	Vested and exercisable at December 31, 2013			4,924,166			$	0.32				1.42			$	67,737
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	'
			Number of options				Fair value of
			vested				options vested
	Fair value of options vesting during the year ended December 31, 2013			768,833			$	35,384
	Fair value of options vesting during the year ended December 31, 2012			816,333			$	75,656
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	Awards breakdown by price range at December 31, 2013
					Outstanding												Vested
	Strike price				Outstanding				Weighted				Weighted				Vested stock		Weighted		Weighted
	range ($)				stock options				average				average				options		average		average vested
									remaining				outstanding						remaining		strike price
									contractual life				strike price						vested
																			contractual life
	0	to	0.2			3,251,000				2.16			$	0.15				2,530,166		1.86	$	0.16
	0.21	to	0.29			750,000				1.64				0.25				650,000		1.2		0.25
	0.3	to	0.49			110,000				0.98				0.38				110,000		0.98		0.38
	0.5	to	0.7			1,634,000				0.87				0.59				1,634,000		0.87		0.59
	0	to	0.7			5,745,000				1.7			$	0.29				4,924,166		1.42	$	0.32
	Awards breakdown by price range at December 31, 2012
					Outstanding												Vested
	Strike price				Outstanding				Weighted				Weighted				Vested stock		Weighted		Weighted
	range ($)				stock options				average				average				options		average		average vested
									remaining				outstanding						remaining		strike price
									contractual life				strike price						vested
																			contractual life
	0	to	0.2			3,428,500				3.02			$	0.15				2,035,083		2.5	$	0.17
	0.21	to	0.29			2,550,000				1.18				0.26				2,550,000		1.18		0.26
	0.3	to	0.49			755,000				0.79				0.45				755,000		0.79		0.45
	0.5	to	0.7			3,719,000				0.97				0.6				3,719,000		0.97		0.6
	0	to	0.7			10,452,500				1.68			$	0.36				9,059,083		1.36	$	0.39
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
			Stock option assumptions for the year ended
	Stock option assumptions		31-Dec-13				31-Dec-12
	Risk-free interest rate			0.58%				0.36%
	Expected dividend yield			0.00%				0.00%
	Expected volatility			202.70%				192.30%
	Expected life of options (in years)			5				5
Schedule of Share-based Compensation, Activity [Table Text Block]	'
			Weighted average grant date fair value
			2013				2012
	Stock options granted during the year ended December 31,		$	0.17			$	0.11
	Stock options vested during the year ended December 31,		$	0.11			$	0.09
	Stock options forfeited during the year ended December 31,		$	0.29			$	0.32
Schedule of Nonvested Share Activity [Table Text Block]	'
			Shares underlying stock options				Weighted average grant date fair value
	Nonvested shares at January 1, 2013			1,393,417			$	0.1
	Nonvested shares at December 31, 2013			820,834			$	0.13

Note_16_Income_Taxes_Tables

Note 16 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		31-Dec-13			31-Dec-12
	Federal statutory rate applied to loss before income taxes	$	(1,154,195	)	$	(2,923,533	)
	Increase/(decrease) in income taxes results from:
	Current tax expense		94,122			63,814
	Non deductible expenses		296,783			2,509,532
	Change in deferred assets		71,274			82,209
	Change in valuation allowance		786,138			331,792
	Income tax expense	$	94,122		$	63,814
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
		31-Dec-13			31-Dec-12
	Current tax expense:	$	94,122		$	63,814
	Deferred tax expense/(benefit):
	Bad debt allowance		7,100			21,913
	Operating loss carryforward		(864,512	)		(435,914	)
	Patent litigation settlement		71,274			82,209
			(786,138	)		(331,792	)
	Valuation allowance		786,138			331,792
	Total tax expense	$	94,122		$	63,814
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
		31-Dec-13			31-Dec-12
	Amortization of intangibles	$	283,698		$	283,698
	Bad debt allowance		23,615			30,715
	Patent litigation liability accrual		315,408			386,682
	Operating loss carryforwards		18,220,482			17,355,970
	Gross deferred tax assets		18,843,203			18,057,065
	Valuation allowance		(18,843,203	)		(18,057,065	)
	Net deferred tax liability/(asset)	$	-0-		$	-0-

Note_1_Organization_and_Nature1

Note 1 - Organization and Nature of Operations (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Disclosure Text Block [Abstract]	'	'
Research and Development Expense	$2,403,504	$2,337,904

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Jul. 10, 2009

Dec. 31, 2008

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Customer 1 [Member]

Customer 1 [Member]

Customer 1 [Member]

Customer 1 [Member]

Customer 2 [Member]

Customer 2 [Member]

Leasehold Improvements, Computers, Equipment and Furniture [Member]

Computer Software, Intangible Asset [Member]

2009 Plan [Member]

1998 Plan [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Minimum [Member]

Maximum [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax

($18,512)

($15,378)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Reportable Segments

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of Software License

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'5 years

Allowance for Doubtful Accounts Receivable, Current

65,341

84,210

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash, Uninsured Amount

793,016

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration Risk, Percentage

'

'

11.00%

19.00%

'

'

16.00%

'

'

'

'

'

11.00%

35.00%

'

'

Revenues

14,331,840

15,552,263

'

'

1,551,100

2,909,300

'

2,503,100

'

'

'

'

'

'

'

'

Property, Plant and Equipment, Useful Life

'

'

'

'

'

'

'

'

'5 years

'3 years

'

'

'

'

'

'

Deferred Revenue

4,251,373

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative, Term of Contract

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 month

'5 years

Deferred Revenue, Current

2,866,356

3,732,240

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Advertising Expense

226,380

269,311

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and Development Expense

$2,403,504

$2,337,904

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)

'

'

'

'

'

'

'

'

'

'

7,500,000

12,500,000

'

'

'

'

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Revenue by Business Activity (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]	'	'
Revenues	$14,331,840	$15,552,263
Set-up Fees [Member]	'	'
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]	'	'
Revenues	3,369,670	4,990,378
Change Orders [Member]	'	'
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]	'	'
Revenues	475,680	249,673
Maintenance [Member]	'	'
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]	'	'
Revenues	4,584,594	5,270,913
Software Licenses [Member]	'	'
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]	'	'
Revenues	2,911,509	3,364,324
Professional Services [Member]	'	'
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]	'	'
Revenues	2,207,181	996,081
Hosting [Member]	'	'
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]	'	'
Revenues	$783,206	$680,894

Note_2_Summary_of_Significant_4

Note 2 - Summary of Significant Accounting Policies (Details) - Allowance for Doubtful Account Summary (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Allowance for Doubtful Account Summary [Abstract]	'	'
Beginning of period	$84,210	$142,444
Bad debt expense	11,131	-58,234
Write-offs	-30,000	0
End of period	$65,341	$84,210

Note_2_Summary_of_Significant_5

Note 2 - Summary of Significant Accounting Policies (Details) - Customer Concentration (Customer Concentration Risk [Member])	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Sales [Member]	'	'
Concentration Risk [Line Items]	'	'
Number of Customers	1	2
Percentage of Concentration Risk	11.00%	35.00%
Accounts Receivable [Member]	'	'
Concentration Risk [Line Items]	'	'
Number of Customers	2	3
Percentage of Concentration Risk	23.00%	54.00%

Note_2_Summary_of_Significant_6

Note 2 - Summary of Significant Accounting Policies (Details) - Revenue from European Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 2 - Summary of Significant Accounting Policies (Details) - Revenue from European Operations [Line Items]	'	'
	$14,331,840	$15,552,263
Reportable Geographical Components [Member] | Europe [Member]	'	'
Note 2 - Summary of Significant Accounting Policies (Details) - Revenue from European Operations [Line Items]	'	'
	$1,847,305	$1,545,730
Geographic Concentration Risk [Member] | Europe [Member] | Sales [Member]	'	'
Note 2 - Summary of Significant Accounting Policies (Details) - Revenue from European Operations [Line Items]	'	'
	12.90%	9.90%

Note_4_Earnings_Loss_Per_Share2

Note 4 - Earnings (Loss) Per Share (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 4 - Earnings (Loss) Per Share (Details) [Line Items]	'	'
Weighted Average Number of Shares Outstanding, Basic (in Shares)	87,969,202	86,522,332
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)	79,546,913	82,069,096
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$0.05	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$0.69	'
Lower Range Limit [Member]	'	'
Note 4 - Earnings (Loss) Per Share (Details) [Line Items]	'	'
Investment Warrants, Exercise Price	$0.25	'
Upper Range Limit [Member]	'	'
Note 4 - Earnings (Loss) Per Share (Details) [Line Items]	'	'
Investment Warrants, Exercise Price	$0.60	'
Lower Range Limit [Member]	'	'
Note 4 - Earnings (Loss) Per Share (Details) [Line Items]	'	'
Debt Instrument, Convertible, Conversion Price	$0.25	'
Upper Range Limit [Member]	'	'
Note 4 - Earnings (Loss) Per Share (Details) [Line Items]	'	'
Debt Instrument, Convertible, Conversion Price	$0.50	'

Note_4_Earnings_Loss_Per_Share3

Note 4 - Earnings (Loss) Per Share (Details) - Reconciliation Of Anti-Dilutive Securities	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Security	79,546,913	82,069,096
Shares Of Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Security	2,750,149	2,750,149
Equity Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Security	5,745,000	10,452,500
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Security	44,728,873	43,212,873
Convertible Debt Securities [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Security	24,620,000	24,620,000
Shares Issuable For Accrued Interest [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Security	1,702,891	1,033,574

Note_4_Earnings_Loss_Per_Share4

Note 4 - Earnings (Loss) Per Share (Details) - Computation Of Diluted Earnings Per Share (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Computation Of Diluted Earnings Per Share [Abstract]	'	'
Basic EPS	($3,367,603)	($8,062,487)
Basic EPS (in Shares)	87,969,202	86,522,332
Basic EPS (in Dollars per share)	($0.04)	($0.09)
Effect of dilutive securities - none	0	0
Effect of dilutive securities - none	0	0
Effect of dilutive securities - none (in Dollars per share)	$0	$0
Diluted EPS	($3,367,603)	($8,062,487)
Diluted EPS (in Shares)	87,969,202	86,522,332
Diluted EPS (in Dollars per share)	($0.04)	($0.09)

Note_5_Property_and_Equipment_2

Note 5 - Property and Equipment, Net (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]	'	'
Depreciation	$230,323	$377,680

Note_5_Property_and_Equipment_3

Note 5 - Property and Equipment, Net (Details) - Property And Equipment (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Cost	$3,586,780	$3,225,607
Accumulated Depreciation	2,979,347	2,743,804
Net Book Value	607,433	481,803
Computer And Office Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	1,822,098	1,519,617
Accumulated Depreciation	1,326,256	1,181,451
Net Book Value	495,842	338,166
Estimated Useful Lives	'5 years	'
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	93,812	92,686
Accumulated Depreciation	75,735	68,044
Net Book Value	18,077	24,642
Estimated Useful Lives	'5 years	'
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	1,556,497	1,502,524
Accumulated Depreciation	1,477,801	1,403,705
Net Book Value	78,696	98,819
Estimated Useful Lives	'3 years	'
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost	114,373	110,780
Accumulated Depreciation	99,555	90,604
Net Book Value	$14,818	$20,176
Estimated Useful Lives	'5 years	'

Note_6_Intangible_Assets_At_Co2

Note 6 - Intangible Assets, At Cost (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Disclosure Text Block [Abstract]	'	'
Amortization of Intangible Assets	$7,720	$232,117

Note_6_Intangible_Assets_At_Co3

Note 6 - Intangible Assets, At Cost (Details) - Intangible Assets (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	$1,670,711	$1,392,701
Accumulated Amortization	1,400,469	1,392,701
Net Book value	270,242	0
eClinical Customer List [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	1,392,701	1,392,701
Accumulated Amortization	1,392,701	1,392,701
Net Book value	0	0
Estimated Useful Lives	'3 years	'
Promasys B.V. Customer List [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	136,253	0
Accumulated Amortization	1,514	0
Net Book value	134,739	0
Estimated Useful Lives	'15 years	'
Promasys B.V. Software Code [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	72,943	0
Accumulated Amortization	2,431	0
Net Book value	70,512	0
Estimated Useful Lives	'5 years	'
Promasys B.V. URLs/Website [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Cost	68,814	0
Accumulated Amortization	3,823	0
Net Book value	$64,991	$0
Estimated Useful Lives	'3 years	'

Note_6_Intangible_Assets_At_Co4

Note 6 - Intangible Assets, At Cost (Details) - Intangible Assets, Future Amortization Expense (USD $)	Dec. 31, 2013
Intangible Assets, Future Amortization Expense [Abstract]	'
2014	$46,610
2015	46,610
2016	42,788
2017	23,672
2018 and thereafter	110,562
Total	$270,242

Note_7_Accounts_Payable_and_Ac2

Note 7 - Accounts Payable and Accrued Expenses (Details) - Accounts Payable And Accrued Expenses (USD $)	Dec. 31, 2013	Dec. 31, 2012
Accounts Payable And Accrued Expenses [Abstract]	'	'
Accounts payable	$724,421	$665,139
Accrued payroll and related costs	260,072	383,859
Other accrued expenses	88,292	124,154
Accrued interest	1,468,171	951,213
Total accounts payable and accrued expenses	$2,540,956	$2,124,365

Note_8_Promasys_BV_Acquisition2

Note 8 - Promasys B.V. Acquisition (Details)	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2013	Nov. 11, 2013	Nov. 11, 2013	Nov. 11, 2013	Oct. 31, 2013	Nov. 11, 2013
			Promasys B.V. [Member]	Promasys B.V. [Member]	Shareholder 1 [Member]	Shareholder 1 [Member]	Dr. Adam F. Cohen [Member]	Promasys B.V. [Member]
			Dr. Adam F. Cohen [Member]		Promasys B.V. [Member]	Promasys B.V. [Member]	Promasys B.V. [Member]
					USD ($)	EUR (€)
Note 8 - Promasys B.V. Acquisition (Details) [Line Items]	'	'	'	'	'	'	'	'
Sale of Stock, Percentage of Ownership after Transaction	'	'	'	100.00%	'	'	'	'
Payments to Acquire Businesses, Gross	'	'	'	'	$593,000	€ 435,998	'	'
Common Stock, Shares, Issued	90,104,659	86,598,659	'	'	'	'	790,000	2,270,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	'	'	10.00%	'	'	'	'	'

Note_8_Promasys_BV_Acquisition3

Note 8 - Promasys B.V. Acquisition (Details) - Net Assets Acquired in Acquisition (USD $)	Dec. 31, 2013	Dec. 31, 2012
Net Assets Acquired in Acquisition [Abstract]	'	'
Cash	$215,571	'
Receivables	216,287	'
Property and equipment	2,178	'
Identifiable intangibles	276,356	'
Goodwill	675,710	0
Total assets acquired	1,382,081	'
Accounts payable	-170,339	'
Deferred revenue	-229,353	'
Net asssets acquired	$982,389	'

Note_8_Promasys_BV_Acquisition4

Note 8 - Promasys B.V. Acquisition (Details) - Pro Forma Information (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Pro Forma Information [Abstract]	'	'
Gross revenues	$15,119,861	$16,002,612
Total expenses	18,145,210	23,988,611
Net income (loss) before taxes	($3,025,349)	($7,985,999)
Net income (loss) per share (in Dollars per share)	($0.04)	($0.09)
Basic and Diluted (in Shares)	89,866,051	88,792,332

Note_9_Line_of_Credit_and_Note2

Note 9 - Line of Credit and Notes Payable (Details) (USD $)	Dec. 31, 2013	Dec. 18, 2013	Mar. 18, 2013	Dec. 31, 2012	Jan. 02, 2013	Jan. 02, 2013	Jan. 02, 2013	Feb. 02, 2013	Mar. 05, 2013	Apr. 02, 2013
					Promissory Note 1 [Member]	Promissory Note 2 [Member]	Promissory Note 3 [Member]	Promissory Note 4 [Member]	Promissory Note 5 [Member]	Promissory Note 6 [Member]
Note 9 - Line of Credit and Notes Payable (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	$4,000,000	$2,000,000	'	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	2.00%	'	12.00%	10.00%	12.00%	12.00%	12.00%	12.00%
Line of Credit Facility, Amount Outstanding	3,500,000	'	'	'	'	'	'	'	'	'
Line of Credit Facility, Interest Rate at Period End	2.25%	'	'	'	'	'	'	'	'	'
Unsecured Debt	5,667,865	'	'	5,138,866	'	'	'	'	'	'
Debt Instrument, Face Amount	'	'	'	'	529,000	431,987	45,000	20,000	137,500	2,866,879
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	'	'	'	'	2,116,000	'	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Share)	'	'	'	'	0.25	'	'	'	'	'
Derivative Liability	'	'	'	'	400,141	'	'	'	'	'
Notes Payable	$5,667,865	'	'	$5,138,866	$128,858	'	'	'	'	'
Debt Instrument, Convertible, Remaining Discount Amortization Period	'	'	'	'	'36 months	'	'	'	'	'

Note_9_Line_of_Credit_and_Note3

Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable (USD $)

Dec. 31, 2013

Mar. 18, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Non-Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Note Payable 2013 1[Member]

Note Payable 2013 2 [Member]

Note Payable 2013 3 [Member]

Note Payable 2013 4 [Member]

Note Payable 2013 5[Member]

Note Payable 2013 6 [Member]

Note Payable 2013 7[Member]

Note Payable 2013 8[Member]

Note Payable 2013 9 [Member]

Note Payable 2013 10 [Member]

Note Payable 1 [Member]

Note Payable 2 [Member]

Note Payable 3 [Member]

Note Payable 4 [Member]

Note Payable 5 [Member]

Note Payable 6 [Member]

Note Payable 7 [Member]

Note Payable 8 [Member]

Note Payable 9 [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Long Term [Member]

Note Payable 2013 1[Member]

Note Payable 2013 2 [Member]

Note Payable 2013 3 [Member]

Note Payable 2013 4 [Member]

Note Payable 2013 5[Member]

Note Payable 2013 6 [Member]

Note Payable 2013 7[Member]

Note Payable 2013 8[Member]

Note Payable 2013 9 [Member]

Note Payable 2013 10 [Member]

Note Payable 1 [Member]

Note Payable 2 [Member]

Note Payable 3 [Member]

Note Payable 4 [Member]

Note Payable 5 [Member]

Note Payable 6 [Member]

Note Payable 7 [Member]

Note Payable 8 [Member]

Note Payable 9 [Member]

Note Payable 2013 1[Member]

Note Payable 2013 2 [Member]

Note Payable 2013 3 [Member]

Note Payable 2013 4 [Member]

Note Payable 2013 5[Member]

Note Payable 2013 6 [Member]

Note Payable 2013 7[Member]

Note Payable 2013 8[Member]

Note Payable 2013 9 [Member]

Note Payable 2013 10 [Member]

Note Payable 1 [Member]

Note Payable 2 [Member]

Note Payable 3 [Member]

Note Payable 4 [Member]

Note Payable 5 [Member]

Note Payable 6 [Member]

Note Payable 7 [Member]

Note Payable 8 [Member]

Note Payable 9 [Member]

Note Payable 2013 1[Member]

Note Payable 2013 2 [Member]

Note Payable 2013 3 [Member]

Note Payable 2013 4 [Member]

Note Payable 2013 5[Member]

Note Payable 2013 6 [Member]

Note Payable 2013 7[Member]

Note Payable 2013 8[Member]

Note Payable 2013 9 [Member]

Note Payable 2013 10 [Member]

Note Payable 1 [Member]

Note Payable 2 [Member]

Note Payable 3 [Member]

Note Payable 4 [Member]

Note Payable 5 [Member]

Note Payable 6 [Member]

Note Payable 7 [Member]

Note Payable 8 [Member]

Note Payable 9 [Member]

Note Payable 2013 1[Member]

Note Payable 2013 2 [Member]

Note Payable 2013 3 [Member]

Note Payable 2013 4 [Member]

Note Payable 2013 5[Member]

Note Payable 2013 6 [Member]

Note Payable 2013 7[Member]

Note Payable 2013 8[Member]

Note Payable 2013 9 [Member]

Note Payable 2013 10 [Member]

Note Payable 1 [Member]

Note Payable 2 [Member]

Note Payable 3 [Member]

Note Payable 4 [Member]

Note Payable 5 [Member]

Note Payable 6 [Member]

Note Payable 7 [Member]

Note Payable 8 [Member]

Note Payable 9 [Member]

Note 9 - Line of Credit and Notes Payable (Details) - Notes Payable [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturity date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1-Jan-15

1-Jan-14

16-Dec-14

1-Jan-16

1-Jan-15

1-Jan-15

1-Jan-15

1-Jan-16

1-Jan-15

31-Mar-16

1-Jan-15

1-Jan-15

1-Jan-15

1-Apr-14

1-Jan-15

1-Jan-16

1-Jan-14

1-Jan-15

16-Dec-14

Interest rate

'

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

12.00%

12.00%

12.00%

10.00%

10.00%

12.00%

12.00%

12.00%

12.00%

10.00%

10.00%

12.00%

12.00%

12.00%

12.00%

12.00%

12.00%

12.00%

Ending principal

$5,667,865

'

$5,138,866

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,600,000

$17,500

$20,000

$529,000

$308,561

$123,425

$45,000

$20,000

$137,500

$2,866,879

$308,562

$123,425

$137,500

$2,866,879

$1,600,000

$20,000

$17,500

$45,000

$20,000

Non related party current

37,500

'

0

0

17,500

20,000

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

37,500

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non related party long term

614,486

'

651,987

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

0

308,561

123,425

45,000

0

137,500

0

308,562

123,425

137,500

0

0

0

17,500

45,000

20,000

614,486

651,987

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related party current

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related party long term

4,568,213

'

3,830,355

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,600,000

0

0

529,000

0

0

0

20,000

0

2,866,879

0

0

0

2,866,879

1,600,000

20,000

0

0

0

4,568,213

3,830,355

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non related party current-Discount on note payable

447,666

'

656,524

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

447,666

656,524

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non related party long term-Discount on note payable

447,666

'

656,524

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

447,666

656,524

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related party current-Discount on note payable

447,666

'

656,524

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

447,666

656,524

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related party long term-Discount on note payable

($447,666)

'

($656,524)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

($447,666)

($656,524)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_10_Convertible_Notes_Paya2

Note 10 - Convertible Notes Payable (Details) (USD $)

Dec. 31, 2013

Mar. 18, 2013

Feb. 22, 2013

Dec. 05, 2013

Feb. 22, 2013

Mar. 30, 2011

Dec. 31, 2013

Feb. 22, 2013

Sep. 30, 2009

Mar. 12, 2013

Mar. 06, 2013

Feb. 22, 2013

Sep. 30, 2009

Feb. 22, 2013

Feb. 22, 2013

Feb. 22, 2013

Feb. 22, 2013

Dec. 31, 2013

Feb. 22, 2013

Sep. 30, 2011

Sep. 30, 2011

Feb. 22, 2013

Feb. 22, 2013

Mar. 30, 2011

Dec. 31, 2013

Dec. 31, 1999

Jun. 30, 2004

Mar. 30, 2011

Sep. 30, 2009

Dec. 16, 2008

Aug. 29, 2008

Dec. 31, 2009

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Chief Executive Officer 2 [Member]

Chief Executive Officer 2 [Member]

Chief Operating Officer1[Member]

Chief Technology Officer1 [Member]

Director Guus Van Kesteren [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Director [Member]

CEO and Director Cornelis F. Wit [Member]

Director [Member]

Director [Member]

Convertible Note Payable 1 [Member]

Convertible Note Payable 1 [Member]

Convertible Note Payable 1 [Member]

Convertible Note Payable 4 [Member]

Convertible Note Payable 4 [Member]

Convertible Debentures [Member]

Convertible Debentures [Member]

Convertible Note Payable 5 [Member]

Former Director Mathew Veatech [Member]

Director Guus Van Kesteren [Member]

Convertible Note Payable 4 [Member]

Convertible Note Payable 4 [Member]

Convertible Debentures [Member]

Convertible Debentures [Member]

Convertible Debentures [Member]

Convertible Debenture4 [Member]

Convertible Debenture4 [Member]

Convertible Debenture4 [Member]

Convertible Debenture4 [Member]

Convertible Debentures [Member]

Convertible Debenture4 [Member]

Convertible Debentures [Member]

Convertible Debentures [Member]

Convertible Debenture 5 [Member]

Convertible Note Payable 5 [Member]

Convertible Note Payable 5 [Member]

Convertible Note Payable 5 [Member]

Convertible Note Payable 5 [Member]

Convertible Note Payable 4 [Member]

Convertible Note Payable 4 [Member]

Convertible Debentures [Member]

Convertible Debentures [Member]

Note 10 - Convertible Notes Payable (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

12.00%

12.00%

10.00%

12.00%

Convertible Notes Payable

$9,665,000

'

$15,000

$160,000

$1,200,000

$1,200,000

$360,000

$150,000

$1,920,000

$100,000

$200,000

$4,505,000

$4,980,000

$1,770,000

$4,475,000

$25,000

$5,000

$160,000

$1,490,000

$1,490,000

$1,440,000

$1,440,000

$1,100,000

$1,100,000

'

$862,500

'

'

$1,400,000

$5,075,000

$2,270,000

$1,490,000

Debt Issuance Cost

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

119,625

'

'

'

'

'

'

Proceeds from Issuance of Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

742,875

'

'

'

'

'

1,490,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.25

'

$0.25

$0.50

$0.50

$0.25

Debt Conversion, Converted Instrument, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

787,500

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,495,179

'

'

'

'

'

'

'

Long-term Debt, Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

'

'

'

'

'

'

'

Interest Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

109,748

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,600,000

10,150,000

4,540,000

5,960,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.25

'

'

0.25

Proceeds from Issuance of Secured Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,400,000

'

'

'

Repayments of Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$200,000

'

'

'

'

Note_10_Convertible_Notes_Paya3

Note 10 - Convertible Notes Payable (Details) - Convertible Debt (USD $)

Dec. 31, 2013

Mar. 18, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Related Party [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Convertible Notes Payable [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Principal Outstanding [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Allocated Discount [Member]

Convertible Notes Payable 10% $862,500 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $4,915,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Total [Member]

Total [Member]

Convertible Note Payable 10% $862,500 [Member]

Convertible Notes Payable 12% 4,520,000 [Member]

Convertible Notes Payable 10% $862,500 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $4,915,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Total [Member]

Convertible Note Payable 10% $862,500 [Member]

Convertible Notes Payable 12% 4,520,000 [Member]

Convertible Notes Payable 10% $862,500 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $4,915,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Total [Member]

Total [Member]

Convertible Note Payable 10% $862,500 [Member]

Convertible Notes Payable 12% 4,520,000 [Member]

Convertible Notes Payable 10% $862,500 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $4,915,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Total [Member]

Total [Member]

Convertible Note Payable 10% $862,500 [Member]

Convertible Notes Payable 12% 4,520,000 [Member]

Convertible Notes Payable 10% $862,500 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $4,915,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Total [Member]

Total [Member]

Convertible Note Payable 10% $862,500 [Member]

Convertible Notes Payable 12% 4,520,000 [Member]

Convertible Notes Payable 10% $862,500 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $4,915,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Total [Member]

Total [Member]

Convertible Note Payable 10% $862,500 [Member]

Convertible Notes Payable 12% 4,520,000 [Member]

Convertible Notes Payable 10% $862,500 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $150,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 10% $2,120,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $100,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $160,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $200,000 [Member]

Convertible Notes Payable 12% $4,915,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,400,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Convertible Notes Payable 12% $1,490,000 [Member]

Total [Member]

Total [Member]

Convertible Note Payable 10% $862,500 [Member]

Convertible Notes Payable 12% 4,520,000 [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maturity Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30-Jun-04

1-Jan-15

1-Jan-15

1-Jan-16

1-Jan-16

1-Jan-15

1-Jan-15

1-Jan-16

16-Dec-13

1-Jan-16

1-Jan-14

1-Jan-16

1-Jan-16

1-Jan-16

1-Jan-16

1-Jan-16

'

'

30-Jun-04

1-Jan-16

Interest Rate

'

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

10.00%

10.00%

10.00%

10.00%

12.00%

12.00%

12.00%

12.00%

12.00%

12.00%

12.00%

12.00%

12.00%

12.00%

12.00%

'

'

10.00%

12.00%

Original Principal

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$862,500

$150,000

$150,000

$2,120,000

$2,120,000

$100,000

$100,000

$160,000

$160,000

$200,000

$200,000

$4,615,000

$1,400,000

$1,400,000

$1,490,000

$1,490,000

$11,097,500

$11,097,500

$862,500

$4,615,000

Principal at Period End

9,665,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

150,000

150,000

1,770,000

1,770,000

100,000

100,000

160,000

160,000

200,000

200,000

4,520,000

1,200,000

1,200,000

1,490,000

1,490,000

9,665,000

9,665,000

75,000

4,520,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

150,000

150,000

1,770,000

1,770,000

100,000

100,000

160,000

160,000

200,000

200,000

4,520,000

1,200,000

1,200,000

1,490,000

1,490,000

9,665,000

9,665,000

75,000

4,520,000

Allocated Discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

135,600

135,600

1,916,480

1,916,480

27,515

27,515

44,024

44,024

55,030

55,030

1,243,681

526,400

526,400

935,720

935,720

4,884,450

4,884,450

0

1,243,681

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortized Discount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

135,600

135,600

1,916,480

1,916,480

27,515

27,515

44,024

44,024

55,030

55,030

1,243,681

526,400

526,400

935,720

935,720

4,884,450

4,884,450

0

1,243,681

Discount at Period End

447,666

'

656,524

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Carrying Amount at Period End

9,665,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

150,000

150,000

1,770,000

1,770,000

100,000

100,000

160,000

160,000

200,000

200,000

4,520,000

1,200,000

1,200,000

1,490,000

1,490,000

9,665,000

9,665,000

75,000

4,520,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

150,000

150,000

1,770,000

1,770,000

100,000

100,000

160,000

160,000

200,000

200,000

4,520,000

1,200,000

1,200,000

1,490,000

1,490,000

9,665,000

9,665,000

75,000

4,520,000

Short Term Related

75,000

'

75,000

0

0

0

0

0

0

0

0

160,000

0

0

0

0

0

0

0

160,000

0

0

75,000

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

75,000

75,000

75,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Short Term Non Related

75,000

'

75,000

0

0

0

0

0

0

0

0

160,000

0

0

0

0

0

0

0

160,000

0

0

75,000

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

75,000

75,000

75,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long Term Related

465,000

'

465,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

150,000

150,000

1,770,000

1,770,000

0

0

160,000

0

0

0

4,505,000

1,100,000

1,100,000

1,440,000

1,440,000

9,125,000

8,965,000

0

4,505,000

0

0

0

0

0

100,000

100,000

0

0

200,000

200,000

15,000

100,000

100,000

50,000

50,000

465,000

465,000

0

15,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long Term Non Related

$465,000

'

$465,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

$150,000

$150,000

$1,770,000

$1,770,000

$0

$0

$160,000

$0

$0

$0

$4,505,000

$1,100,000

$1,100,000

$1,440,000

$1,440,000

$9,125,000

$8,965,000

$0

$4,505,000

$0

$0

$0

$0

$0

$100,000

$100,000

$0

$0

$200,000

$200,000

$15,000

$100,000

$100,000

$50,000

$50,000

$465,000

$465,000

$0

$15,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_10_Convertible_Notes_Paya4

Note 10 - Convertible Notes Payable (Details) - Convertible Debt Maturity Payments (USD $)	Dec. 31, 2013
Note 10 - Convertible Notes Payable (Details) - Convertible Debt Maturity Payments [Line Items]	'
Total	$9,665,000
Convertible Debt [Member]	'
Note 10 - Convertible Notes Payable (Details) - Convertible Debt Maturity Payments [Line Items]	'
2014	75,000
2015	250,000
2016	$9,340,000

Note_11_Fair_Value_Measurement2

Note 11 - Fair Value Measurement (Details)	12 Months Ended
	Dec. 31, 2013
Minimum [Member]	'
Note 11 - Fair Value Measurement (Details) [Line Items]	'
Finite-Lived Intangible Asset, Useful Life	'3 years
Maximum [Member]	'
Note 11 - Fair Value Measurement (Details) [Line Items]	'
Finite-Lived Intangible Asset, Useful Life	'15 years

Note_11_Fair_Value_Measurement3

Note 11 - Fair Value Measurement (Details) - Fair Value of Liabilities Measured on a Recurring Basis (Fair Value, Measurements, Recurring [Member], USD $)	Dec. 31, 2013		Dec. 31, 2012
Derivatives: (1) (2)	'		'
Derivative Liabilities	$9,070,183	[1],[2]	$8,574,921	[1],[3]
Conversion Feature Liability [Member] | Fair Value, Inputs, Level 1 [Member]	'		'
Derivatives: (1) (2)	'		'
Derivative Liabilities	0	[1],[2]	0	[1],[3]
Conversion Feature Liability [Member] | Fair Value, Inputs, Level 2 [Member]	'		'
Derivatives: (1) (2)	'		'
Derivative Liabilities	0	[1],[2]	0	[1],[3]
Conversion Feature Liability [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Derivatives: (1) (2)	'		'
Derivative Liabilities	3,126,206	[1],[2]	2,287,323	[1],[3]
Conversion Feature Liability [Member]	'		'
Derivatives: (1) (2)	'		'
Derivative Liabilities	3,126,206	[1],[2]	2,287,323	[1],[3]
Warrant Liability [Member] | Fair Value, Inputs, Level 1 [Member]	'		'
Derivatives: (1) (2)	'		'
Derivative Liabilities	0	[1],[2]	0	[1],[3]
Warrant Liability [Member] | Fair Value, Inputs, Level 2 [Member]	'		'
Derivatives: (1) (2)	'		'
Derivative Liabilities	0	[1],[2]	0	[1],[3]
Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Derivatives: (1) (2)	'		'
Derivative Liabilities	5,943,977	[1],[2]	6,287,598	[1],[3]
Warrant Liability [Member]	'		'
Derivatives: (1) (2)	'		'
Derivative Liabilities	5,943,977	[1],[2]	6,287,598	[1],[3]
Fair Value, Inputs, Level 1 [Member]	'		'
Derivatives: (1) (2)	'		'
Derivative Liabilities	0	[1],[2]	0	[1],[3]
Fair Value, Inputs, Level 2 [Member]	'		'
Derivatives: (1) (2)	'		'
Derivative Liabilities	0	[1],[2]	0	[1],[3]
Fair Value, Inputs, Level 3 [Member]	'		'
Derivatives: (1) (2)	'		'
Derivative Liabilities	$9,070,183	[1],[2]	$8,574,921	[1],[3]
[1]	The fair value at the measurement date is equal to their carrying value on the balance sheet
[2]	The fair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the year ended December 31, 2013
[3]	The fair value of the derivative instruments was estimated using the Black Scholes option pricing model with the following assumptions for the year ended December 31, 2012

Note_11_Fair_Value_Measurement4

Note 11 - Fair Value Measurement (Details) - Fair Value Assumptions	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Dividend yield	0.00%	0.00%
Conversion Feature Liability [Member] | Minimum [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Expected Life	'1 year	'3 months
Conversion Feature Liability [Member] | Maximum [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Expected Life	'2 years	'350 days
Warrant Liability [Member] | Minimum [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Expected Life	'1 year	'240 days
Warrant Liability [Member] | Maximum [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Expected Life	'2 years 3 months	'3 years 3 months
Minimum [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Risk free interest rate	0.12%	0.18%
Expected volatility	166.70%	218.20%
Maximum [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Risk free interest rate	0.13%	0.36%
Expected volatility	217.10%	259.10%

Note_11_Fair_Value_Measurement5

Note 11 - Fair Value Measurement (Details) - Fair Value of Assets Aquired on NonRecurring Basis (USD $)	Dec. 31, 2013		Dec. 31, 2012
Note 11 - Fair Value Measurement (Details) - Fair Value of Assets Aquired on NonRecurring Basis [Line Items]	'		'
Promasys B.V. goodwill (4)	$675,710		$0
	1,382,081		'
Fair Value, Measurements, Nonrecurring [Member] | Promasys B.V. [Member] | Fair Value, Inputs, Level 1 [Member]	'		'
Note 11 - Fair Value Measurement (Details) - Fair Value of Assets Aquired on NonRecurring Basis [Line Items]	'		'
Promasys B.V. customer lists (4)	0	[1]	'
Promasys B.V. software code (4)	0	[1]	'
Promasys B.V. URLs/website (4)	0	[1]	'
Promasys B.V. goodwill (4)	0	[1]	'
	0		'
Fair Value, Measurements, Nonrecurring [Member] | Promasys B.V. [Member] | Fair Value, Inputs, Level 2 [Member]	'		'
Note 11 - Fair Value Measurement (Details) - Fair Value of Assets Aquired on NonRecurring Basis [Line Items]	'		'
Promasys B.V. customer lists (4)	0	[1]	'
Promasys B.V. software code (4)	0	[1]	'
Promasys B.V. URLs/website (4)	0	[1]	'
Promasys B.V. goodwill (4)	0	[1]	'
	0		'
Fair Value, Measurements, Nonrecurring [Member] | Promasys B.V. [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Note 11 - Fair Value Measurement (Details) - Fair Value of Assets Aquired on NonRecurring Basis [Line Items]	'		'
Promasys B.V. customer lists (4)	136,253	[1]	'
Promasys B.V. software code (4)	72,943	[1]	'
Promasys B.V. URLs/website (4)	68,814	[1]	'
Promasys B.V. goodwill (4)	675,710	[1]	'
	953,720		'
Fair Value, Measurements, Nonrecurring [Member] | Promasys B.V. [Member]	'		'
Note 11 - Fair Value Measurement (Details) - Fair Value of Assets Aquired on NonRecurring Basis [Line Items]	'		'
Promasys B.V. customer lists (4)	134,739	[1]	0	[1]
Promasys B.V. software code (4)	70,512	[1]	0	[1]
Promasys B.V. URLs/website (4)	64,991	[1]	0	[1]
Promasys B.V. goodwill (4)	675,710	[1]	0	[1]
	945,952		0
Promasys B.V. [Member] | Fair Value, Inputs, Level 3 [Member]	'		'
Note 11 - Fair Value Measurement (Details) - Fair Value of Assets Aquired on NonRecurring Basis [Line Items]	'		'
Promasys B.V. goodwill (4)	$675,710		$0
[1]	The acquired Promasys B.V. software code, customer list and URLs/website are not measured on a recurring basis since their initial fair value has been deemed to have a finite life and is being amortized periodically. Instead the Company performs an impairment analysis on a quarterly basis in order to determine whether the carrying value of the assets reflects the fair value of the assets in a market based transaction.

Note_11_Fair_Value_Measurement6

Note 11 - Fair Value Measurement (Details) - Fair Value of Goodwill (USD $)	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Line Items]	'	'
Goodwill	$675,710	$0
Promasys B.V. [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Goodwill [Line Items]	'	'
Goodwill	$675,710	$0

Note_11_Fair_Value_Measurement7

Note 11 - Fair Value Measurement (Details) - Unrealized Gain or Loss Included in Earnings (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Unrealized Gain or Loss Included in Earnings [Abstract]	'	'
The net amount of (losses) for the period included in earnings attributable to the unrealized loss from changes in derivative liabilities at the reporting date	($95,121)	($6,123,302)
Total unrealized (losses) included in earnings	($95,121)	($6,123,302)

Note_11_Fair_Value_Measurement8

Note 11 - Fair Value Measurement (Details) - Change in Level 3 Financial Liabilities Fair Value (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Derivatives:	'	'
Balance, Beginning of year	$8,574,921	$2,451,619
Net Realized Gains/(Losses)	0	0
Net Unrealized (gains)/losses relating to instruments still held at the reporting date	95,121	6,123,302
Net purchases, issuances and settlements	400,141	0
Net transfers in and/or out of Level 3	0	0
Balance, end of period	9,070,183	8,574,921
Conversion Feature Liability [Member]	'	'
Derivatives:	'	'
Balance, Beginning of year	2,287,323	758,911
Net Realized Gains/(Losses)	0	0
Net Unrealized (gains)/losses relating to instruments still held at the reporting date	838,883	1,528,412
Net purchases, issuances and settlements	0	0
Net transfers in and/or out of Level 3	0	0
Balance, end of period	3,126,206	2,287,323
Warrant Liability [Member]	'	'
Derivatives:	'	'
Balance, Beginning of year	6,287,598	1,692,708
Net Realized Gains/(Losses)	0	0
Net Unrealized (gains)/losses relating to instruments still held at the reporting date	-743,762	4,594,890
Net purchases, issuances and settlements	400,141	0
Net transfers in and/or out of Level 3	0	0
Balance, end of period	$5,943,977	$6,287,598

Note_12_Commitments_and_Contin2

Note 12 - Commitments and Contingencies (Details) (USD $)	1 Months Ended		12 Months Ended		54 Months Ended	1 Months Ended
	Jul. 31, 2009	Jun. 30, 2009	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Sep. 30, 2013
						Chief Executive Officer [Member]	Chief Technology Officer [Member]	Chief Operating Officer [Member]
Note 12 - Commitments and Contingencies (Details) [Line Items]	'	'	'	'	'	'	'	'
Operating Leases, Rent Expense	'	'	$894,121	$881,503	'	'	'	'
Patent Royalty Percentage Obligation	'	'	2.00%	'	'	'	'	'
License Payments	100,000	300,000	'	'	200,000	'	'	'
Other Expenses	'	'	189,408	218,467	'	'	'	'
Salaries, Wages and Officers' Compensation	'	'	'	'	'	192,780	'	'
Fee as Percentage of Aggregate Consideration	'	'	2.00%	'	'	'	'	'
Officers' Compensation	'	'	'	'	'	'	$305,235	$305,235

Note_12_Commitments_and_Contin3

Note 12 - Commitments and Contingencies (Details) - Future Minimum Lease Payments (USD $)	Dec. 31, 2013
Future Minimum Lease Payments [Abstract]	'
2014	$537,630
2015	502,131
2016	279,174
2017	53,699
2018	5,849
Total	$1,378,483

Note_12_Commitments_and_Contin4

Note 12 - Commitments and Contingencies (Details) - Minimum Royalty Payments Per Year (USD $)	Dec. 31, 2013
Minimum Royalty Payments Per Year [Abstract]	'
2014	$450,000
2015	450,000
2016	450,000
2017	450,000
Total	$1,800,000

Note_13_Related_Party_Transact1

Note 13 - Related Party Transactions (Details) (USD $)

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 18, 2013

Mar. 18, 2013

Dec. 05, 2013

Dec. 31, 2013

Feb. 22, 2013

Sep. 30, 2009

Mar. 12, 2013

Mar. 06, 2013

Feb. 22, 2013

Sep. 30, 2009

Oct. 06, 2012

Dec. 31, 2013

Dec. 31, 2008

Dec. 16, 2010

Aug. 29, 2008

Feb. 14, 2008

Dec. 16, 2008

Feb. 22, 2013

Sep. 30, 2009

Sep. 30, 2009

Dec. 31, 2009

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Oct. 05, 2011

Dec. 31, 2011

Dec. 18, 2013

Dec. 31, 2013

Dec. 31, 2012

Mar. 18, 2013

Dec. 31, 2013

Mar. 31, 2011

Sep. 30, 2009

Aug. 29, 2008

Dec. 31, 2013

Feb. 22, 2013

Sep. 30, 2009

Dec. 16, 2008

Feb. 29, 2008

Dec. 31, 2011

Dec. 16, 2008

Aug. 29, 2008

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Extended Maturity [Member]

Purchased From Chief Financial Officer [Member]

Issued December 2008 [Member]

Issued December 2008 [Member]

Issued December 16, 2010 [Member]

Issued Feb 14, 2010 [Member]

Issued Feb 14, 2010 [Member]

Issued June 10, 2008 [Member]

Convertible Debenture4 [Member]

Aggregated September 30, 2009 [Member]

Aggregated September 30, 2009 [Member]

Aggregated December 31, 2009 [Member]

Issued April 13, 2010 [Member]

Issued June 29, 2010 [Member]

Issued September 30, 2010 [Member]

Issued December 31, 2010 [Member]

Issued December 31, 2010 2 [Member]

Issued August 16, 2011 [Member]

Issued August 19, 2011 [Member]

Issued August 25, 2011 [Member]

Issued September 2, 2011 [Member]

Issued September 15, 2011 [Member]

Issued September 28, 2011 [Member]

Issued October 5, 2011 [Member]

Issued December 31, 2011 [Member]

Issued September 30, 2011 [Member]

Excluding Interest Expense From Derivatives [Member]

Excluding Interest Expense From Derivatives [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer 5 [Member]

Chief Executive Officer 5 [Member]

Chief Executive Officer 5 [Member]

Chief Executive Officer 5 [Member]

Chief Executive Officer 5 [Member]

Chief Executive Officer 5 [Member]

Chief Executive Officer 5 [Member]

CEO and Director Cornelis F. Wit [Member]

Convertible Debentures [Member]

Convertible Debentures [Member]

Director Guus Van Kesteren [Member]

Convertible Debentures [Member]

Convertible Debentures [Member]

Convertible Debentures [Member]

Convertible Debenture4 [Member]

Convertible Debenture4 [Member]

Convertible Debenture4 [Member]

Convertible Debenture4 [Member]

Chief Executive Officer 5 [Member]

Board of Directors Chairman [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer 5 [Member]

Chief Executive Officer [Member]

Chief Executive Officer 2 [Member]

Chief Executive Officer 2 [Member]

Chief Executive Officer 2 [Member]

Chief Executive Officer [Member]

Chief Executive Officer 2 [Member]

Chief Executive Officer 5 [Member]

Chief Executive Officer 5 [Member]

Chief Executive Officer 5 [Member]

Chief Executive Officer 5 [Member]

Chief Executive Officer 5 [Member]

Chief Executive Officer 5 [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Convertible Debenture4 [Member]

Convertible Debentures [Member]

Note 13 - Related Party Transactions (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Original Debt, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$20,000

'

'

'

'

'

'

'

'

$450,000

$115,000

$695,000

$1,197,500

$409,379

$96,000

$342,000

$130,000

$123,000

$82,000

$60,000

'

'

$4,000,000

'

'

'

'

'

'

'

$3,500,000

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

2.00%

'

'

'

'

'

'

'

'

'

'

12.00%

'

10.00%

'

12.00%

'

12.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

'

'

12.00%

'

'

'

'

'

'

'

12.00%

12.00%

10.00%

Due to Related Parties, Current

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Expense, Related Party

2,339,702

2,108,749

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,339,702

2,108,749

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes Payable, Related Parties

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

510,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

767,000

529,000

'

'

'

'

13,780,879

2,866,879

'

'

'

'

'

'

150,000

1,600,000

'

'

Convertible Notes Payable

9,665,000

'

'

'

160,000

360,000

150,000

1,920,000

100,000

200,000

4,505,000

4,980,000

125,000

'

'

'

'

'

4,350,000

4,475,000

1,100,000

'

1,440,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,350,000

1,260,000

'

1,770,000

1,770,000

'

4,200,000

'

5,075,000

2,270,000

Debt Conversion, Converted Instrument, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

510,000

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

8,700,000

'

'

0.25

'

'

'

'

'

'

'

'

'

'

'

'

'

2,116,000

'

'

'

'

'

11,467,517

'

3,540,000

'

'

'

'

'

6,400,000

10,150,000

4,540,000

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.50

'

'

'

$0.50

'

'

$0.50

$0.50

Debt Instrument, Convertible, Number of Equity Instruments

24,620,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and Rights Outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,400,000

5,760,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.25

'

'

'

'

'

0.25

'

'

'

'

'

'

'

0.25

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

$4,000,000

$2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related Party Transaction, Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Basis Spread on Variable Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.25%

'

'

'

'

'

'

'

Note_14_Stockholders_Deficit_D

Note 14 - Stockholders' (Deficit) (Details) (USD $)

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 1999

Dec. 31, 2013

Dec. 31, 2012

Feb. 07, 2002

Aug. 31, 2001

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Nov. 30, 2013

Nov. 11, 2013

Restricted Stock [Member]

Common Stock [Member]

Common Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series D Preferred Stock [Member]

Series D Preferred Stock [Member]

Convertible Series B Preferred Stock [Member]

Senior Management and Board of Director [Member]

Promasys B.V. [Member]

Promasys B.V. [Member]

Note 14 - Stockholders' (Deficit) (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

'

250,000,000

250,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Par or Stated Value Per Share (in Dollars per share)

'

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized

'

10,000,000

10,000,000

'

'

'

5,000,000

5,000,000

5,000,000

230,000

230,000

230,000

200,000

747,500

747,500

250,000

250,000

'

'

'

'

Preferred Stock, Par or Stated Value Per Share (in Dollars per share)

'

$0.00

$0.00

'

'

'

$0.00

$0.00

'

$0.00

$0.00

'

'

$0.00

$0.00

$0.00

$0.00

'

'

'

'

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

'

'

5.00%

'

5.00%

8.00%

'

'

'

8.00%

'

'

'

'

'

'

'

Common Stock, Shares, Issued

'

90,104,659

86,598,659

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,270,000

Common Stock, Shares, Outstanding

'

90,104,659

86,598,659

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

'

44,728,873

43,412,873

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Issued

'

'

'

'

'

'

4,125,224

4,125,224

'

0

0

'

'

0

0

250,000

250,000

'

'

'

'

Preferred Stock, Shares Outstanding

'

'

'

'

'

'

4,125,224

4,125,224

'

0

0

'

'

0

0

250,000

250,000

'

'

'

'

Convertible Debt (in Dollars)

'

$9,665,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Number of Equity Instruments

'

24,620,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Restricted Stock Award, Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,225,000

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense (in Dollars)

'

'

'

53,125

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

11,000

'

'

'

11,000

75,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Acquisitions

'

'

'

'

2,270,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,270,000

'

Convertible Preferred Stock, Conversion Price (in Dollars per share)

'

'

'

'

'

'

$1.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Conversion Term

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Stock Price Trigger (in Dollars per share)

'

'

'

'

'

'

$3

'

'

$0.50

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Threshold Consecutive Trading Days

'

'

'

'

'

'

'20 days

'

'

'20 years

'

'

'

'20 years

'

'

'

'

'

'

'

Share Price (in Dollars per share)

'

'

'

'

$0.25

'

$1

'

'

$10

'

'

'

$0.25

'

'

'

$0.75

'

'

'

Preferred Stock, Liquidation Preference Per Share (in Dollars per share)

'

'

'

'

'

'

$1

'

'

$10

'

'

'

$10

'

$0.00

'

'

'

'

'

Preferred Stock, Voting Rights

'

'

'

'

'

'

'one

'

'

'one

'

'

'

'one

'

'(400)

'

'

'

'

'

Preferred Stock, Amount of Preferred Dividends in Arrears (in Dollars)

'

4,462,419

4,256,158

'

'

'

2,380,439

2,174,178

'

609,887

609,887

'

'

1,472,093

1,472,093

'

'

'

'

'

'

Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears (in Dollars per share)

'

'

'

'

'

'

$0.58

$0.53

'

$3.05

$3.05

'

'

$4.37

$4.37

'

'

'

'

'

'

Conversion of Stock, Shares Converted

'

'

'

'

'

'

235,000

'

'

200,000

'

'

'

337,150

'

'

'

'

'

'

'

Convertible Preferred Stock, Public Offering Proceeds Threshold (in Dollars)

'

'

'

'

'

'

'

'

'

$25,000,000

'

'

'

$25,000,000

'

'

'

'

'

'

'

Preferred Stock Stated Value Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

'

'

'

'

'

'

'

Convertible Preferred Stock, Offering Price Threshold Ratio

'

'

'

'

'

'

'

'

'

'

'

'

'

2.5

'

'

'

'

'

'

'

Convertible Preferred Stock, Threshold Ratio of Stock Price Trigger

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

Note_14_Stockholders_Deficit_D1

Note 14 - Stockholders' (Deficit) (Details) - Cumulative Arrearage of Undeclared Dividends (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 14 - Stockholders' (Deficit) (Details) - Cumulative Arrearage of Undeclared Dividends [Line Items]	'	'
Preferred Stock, Dividend, Cumulative Arrearage	$4,462,419	$4,256,158
Series A Preferred Stock [Member]	'	'
Note 14 - Stockholders' (Deficit) (Details) - Cumulative Arrearage of Undeclared Dividends [Line Items]	'	'
Preferred Stock, Dividend, Cumulative Arrearage	2,380,439	2,174,178
Preferred Stock, Dividend, Cumulative Arrearage (in Dollars per share)	$0.58	$0.53
Series B Preferred Stock [Member]	'	'
Note 14 - Stockholders' (Deficit) (Details) - Cumulative Arrearage of Undeclared Dividends [Line Items]	'	'
Preferred Stock, Dividend, Cumulative Arrearage	609,887	609,887
Preferred Stock, Dividend, Cumulative Arrearage (in Dollars per share)	$3.05	$3.05
Series C Preferred Stock [Member]	'	'
Note 14 - Stockholders' (Deficit) (Details) - Cumulative Arrearage of Undeclared Dividends [Line Items]	'	'
Preferred Stock, Dividend, Cumulative Arrearage	$1,472,093	$1,472,093
Preferred Stock, Dividend, Cumulative Arrearage (in Dollars per share)	$4.37	$4.37

Note_14_Stockholders_Deficit_D2

Note 14 - Stockholders' (Deficit) (Details) - Dividends Payable (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Series A Preferred Stock [Member]	'	'
Dividends Payable [Line Items]	'	'
Dividends accreted	$206,261	$229,517
Divideds accreted per share	$0.05	$0.06
Series B Preferred Stock [Member]	'	'
Dividends Payable [Line Items]	'	'
Dividends accreted	0	0
Divideds accreted per share	$0	$0
Series C Preferred Stock [Member]	'	'
Dividends Payable [Line Items]	'	'
Dividends accreted	$0	$0
Divideds accreted per share	$0	$0

Note_14_Stockholders_Deficit_D3

Note 14 - Stockholders' (Deficit) (Details) - Warrants (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]	'	'
Number of Warrants Outstanding	44,728,873	43,412,873
Number of Warrants Exercisable	44,728,873	'
Exercise Price Range $0.25 to $0.60 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Number of Warrants Outstanding	44,728,873	43,412,873
Weighted Average Remaining Contractual Life	'2 years 18 days	'2 years 116 days
Weighted Average Exercise Price	$0.36	$0.36
Number of Warrants Exercisable	44,728,873	43,412,873
Weighted Average Exercise Price	$0.36	$0.36
Exercise Price Range $0.25 to $0.60 [Member] | Minimum [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Range of Exercise Price	0.25	0.25
Exercise Price Range $0.25 to $0.60 [Member] | Maximum [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Range of Exercise Price	0.6	0.6

Note_14_Stockholders_Deficit_D4

Note 14 - Stockholders' (Deficit) (Details) - Warrants Activity (USD $)	12 Months Ended
	Dec. 31, 2013
Warrants Activity [Abstract]	'
Balance at December 31, 2012	43,412,873
Issued (in Dollars)	$2,116,000
Exercised	0
Expired/forfeited	-800,000
Balance at December 31, 2013	44,728,873
Warrants exercisable at December 31, 2013	44,728,873
Weighted average fair value of warrants granted during 2013 (in Dollars)	$0.19

Note_14_Stockholders_Deficit_D5

Note 14 - Stockholders' (Deficit) (Details) - Accumulated Other Comprehensive Gain (Loss) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accumulated Other Comprehensive Gain (Loss) [Abstract]	'	'	'
Foreign Currency Translation	($87,604)	($69,092)	($53,714)
Accumulated other comprehensive income (loss)	-87,604	-69,092	-53,714
Foreign Currency Translation	-18,512	-15,378	'
Accumulated other comprehensive income (loss)	($18,512)	($15,378)	'

Note_15_Employee_Equity_Incent2

Note 15 - Employee Equity Incentive Plans (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 15 - Employee Equity Incentive Plans (Details) [Line Items]	'	'
Proceeds from Stock Options Exercised (in Dollars)	$0	$0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$0.17	$0.11
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)	$69,577	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'328 days	'
Restricted Stock [Member]	'	'
Note 15 - Employee Equity Incentive Plans (Details) [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number	1,225,000	'
Equity Incentive Plan 2009 [Member]	'	'
Note 15 - Employee Equity Incentive Plans (Details) [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	7,500,000	'
Vesting Percentage Year 1	50.00%	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,991,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	2,284,000	'
Stock Incentive Plan 1998 [Member]	'	'
Note 15 - Employee Equity Incentive Plans (Details) [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	12,500,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,754,000	'
Equity Incentive Plan 2009 [Member]	'	'
Note 15 - Employee Equity Incentive Plans (Details) [Line Items]	'	'
Stock Option Expiration Term	'5 years	'
Equity Incentive Plan 2009 [Member] | Maximum [Member]	'	'
Note 15 - Employee Equity Incentive Plans (Details) [Line Items]	'	'
Stock Option Grant Term	'10 years	'

Note_15_Employee_Equity_Incent3

Note 15 - Employee Equity Incentive Plans (Details) - Stock Option Activity (USD $)	1 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2011	Dec. 31, 2010
			Beginning of Period [Member]	End of Period [Member]	End of Period [Member]
Note 15 - Employee Equity Incentive Plans (Details) - Stock Option Activity [Line Items]	'	'	'	'	'
Outstanding at December 31, 2011	'	'	11,158,000	10,452,500	'
Outstanding at December 31, 2011	'	'	$0.37	$0.36	'
Outstanding at December 31, 2011	'	'	'2 years 189 days	'1 year 255 days	'1 year 248 days
Outstanding at December 31, 2011	'	'	$0	$149,598	'
Number of shares	'	'	'	5,745,000	10,452,500
Weighted average exercise price (per share)	'	'	'	$0.29	$0.36
Weighted average remaining contractual term (in years)	'	'	'2 years 189 days	'1 year 255 days	'1 year 248 days
Aggregate intrinsic value	'	'	'	93,945	149,598
Vested and exercisable at December 31, 2013	'	4,924,166	'	'	'
Vested and exercisable at December 31, 2013	'	$0.32	'	'	'
Vested and exercisable at December 31, 2013	'	'1 year 153 days	'	'	'
Vested and exercisable at December 31, 2013	'	$67,737	'	'	'
Number of shares	'	'	425,000	350,000	'
Weighted average exercise price (per share)	'	'	$0.12	$0.17	'
Number of shares	11,000	'	-265,000	-100,000	'
Weighted average exercise price (per share)	'	'	$0.20	$0.18	'
Number of shares	'	'	-865,500	-4,957,500	'
Weighted average exercise price (per share)	'	'	$0.43	$0.42	'

Note_15_Employee_Equity_Incent4

Note 15 - Employee Equity Incentive Plans (Details) - Vested Shares (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Vested Shares [Abstract]	'	'
Number of options vested	768,833	816,333
Fair value of options vested	$35,384	$75,656

Note_15_Employee_Equity_Incent5

Note 15 - Employee Equity Incentive Plans (Details) - Stock Options Oustanding (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Outstanding [Member] | Range 0 - .20 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Outstanding Stock Options (in Shares)	3,251,000	3,428,500
Weighted Average Remaining Contractual Life	'2 years 58 days	'3 years 7 days
Weighted Average Outstanding Strike Price	$0.15	$0.15
Outstanding [Member] | Range .21-.29 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Outstanding Stock Options (in Shares)	750,000	2,550,000
Weighted Average Remaining Contractual Life	'1 year 233 days	'1 year 65 days
Weighted Average Outstanding Strike Price	$0.25	$0.26
Outstanding [Member] | Range .30 -.49 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Outstanding Stock Options (in Shares)	110,000	755,000
Weighted Average Remaining Contractual Life	'357 days	'288 days
Weighted Average Outstanding Strike Price	$0.38	$0.45
Outstanding [Member] | Range .50 -.70 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Outstanding Stock Options (in Shares)	1,634,000	3,719,000
Weighted Average Remaining Contractual Life	'317 days	'354 days
Weighted Average Outstanding Strike Price	$0.59	$0.60
Outstanding [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Outstanding Stock Options (in Shares)	5,745,000	10,452,500
Weighted Average Remaining Contractual Life	'1 year 255 days	'1 year 248 days
Weighted Average Outstanding Strike Price	$0.29	$0.36
Vested [Member] | Range 0 - .20 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Outstanding Stock Options (in Shares)	2,530,166	2,035,083
Weighted Average Remaining Contractual Life	'1 year 313 days	'2 years 6 months
Weighted Average Outstanding Strike Price	$0.16	$0.17
Vested [Member] | Range .21-.29 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Outstanding Stock Options (in Shares)	650,000	2,550,000
Weighted Average Remaining Contractual Life	'1 year 73 days	'1 year 65 days
Weighted Average Outstanding Strike Price	$0.25	$0.26
Vested [Member] | Range .30 -.49 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Outstanding Stock Options (in Shares)	110,000	755,000
Weighted Average Remaining Contractual Life	'357 days	'288 days
Weighted Average Outstanding Strike Price	$0.38	$0.45
Vested [Member] | Range .50 -.70 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Outstanding Stock Options (in Shares)	1,634,000	3,719,000
Weighted Average Remaining Contractual Life	'317 days	'354 days
Weighted Average Outstanding Strike Price	$0.59	$0.60
Vested [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Outstanding Stock Options (in Shares)	4,924,166	9,059,083
Weighted Average Remaining Contractual Life	'1 year 153 days	'1 year 131 days
Weighted Average Outstanding Strike Price	$0.32	$0.39
Range 0 - .20 [Member] | Minimum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Strike Price Range	$0	$0
Range 0 - .20 [Member] | Maximum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Strike Price Range	$0.20	$0.20
Range .21-.29 [Member] | Minimum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Strike Price Range	$0.21	$0.21
Range .21-.29 [Member] | Maximum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Strike Price Range	$0.29	$0.29
Range .30 -.49 [Member] | Minimum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Strike Price Range	$0.30	$0.30
Range .30 -.49 [Member] | Maximum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Strike Price Range	$0.49	$0.49
Range .50 -.70 [Member] | Minimum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Strike Price Range	$0.50	$0.50
Range .50 -.70 [Member] | Maximum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Strike Price Range	$0.70	$0.70
Minimum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Strike Price Range	$0	$0
Maximum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Strike Price Range	$0.70	$0.70

Note_15_Employee_Equity_Incent6

Note 15 - Employee Equity Incentive Plans (Details) - Fair Value Assumptions of Share-Based Payments	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value Assumptions of Share-Based Payments [Abstract]	'	'
Risk-free interest rate	0.58%	0.36%
Expected dividend yield	0.00%	0.00%
Expected volatility	202.70%	192.30%
Expected life of options (in years)	'5 years	'5 years

Note_15_Employee_Equity_Incent7

Note 15 - Employee Equity Incentive Plans (Details) - Weighted Average Grant Date Fair Value Activity (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Weighted Average Grant Date Fair Value Activity [Abstract]	'	'
Stock options granted during the year ended December 31,	$0.17	$0.11
Stock options vested during the year ended December 31,	$0.11	$0.09
Stock options forfeited during the year ended December 31,	$0.29	$0.32

Note_15_Employee_Equity_Incent8

Note 15 - Employee Equity Incentive Plans (Details) - Status of Non-Vested Shares (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 15 - Employee Equity Incentive Plans (Details) - Status of Non-Vested Shares [Line Items]	'	'
Weighted average grant date fair value	$0.11	$0.09
End of Period [Member]	'	'
Note 15 - Employee Equity Incentive Plans (Details) - Status of Non-Vested Shares [Line Items]	'	'
Shares underlying stock options	1,393,417	'
Weighted average grant date fair value	$0.10	'
Beginning of Year [Member]	'	'
Note 15 - Employee Equity Incentive Plans (Details) - Status of Non-Vested Shares [Line Items]	'	'
Shares underlying stock options	820,834	'
Weighted average grant date fair value	$0.13	'

Note_16_Income_Taxes_Details

Note 16 - Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Operating Loss Carryforwards	$50,666,197
Valuation Allowance, Deferred Tax Asset, Change in Amount	$786,138

Note_16_Income_Taxes_Details_R

Note 16 - Income Taxes (Details) - Reconciliation of Income Tax Expense (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Reconciliation of Income Tax Expense [Abstract]	'	'
Federal statutory rate applied to loss before income taxes	($1,154,195)	($2,923,533)
Current tax expense	94,122	63,814
Non deductible expenses	296,783	2,509,532
Change in deferred assets	71,274	82,209
Change in valuation allowance	786,138	331,792
Income tax expense	$94,122	$63,814

Note_16_Income_Taxes_Details_T

Note 16 - Income Taxes (Details) - The Components of Income Tax Expense (Benefit) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 16 - Income Taxes (Details) - The Components of Income Tax Expense (Benefit) [Line Items]	'	'
Current tax expense:	$94,122	$63,814
Deferred tax expense/(benefit):	'	'
Deferred tax expense (benefit)	-786,138	-331,792
Valuation allowance	786,138	331,792
Total tax expense	94,122	63,814
Bad Debt Allowance [Member]	'	'
Deferred tax expense/(benefit):	'	'
Deferred tax expense (benefit)	7,100	21,913
Operating Loss Carryforward [Member]	'	'
Deferred tax expense/(benefit):	'	'
Deferred tax expense (benefit)	-864,512	-435,914
Patent Litigation Settlement [Member]	'	'
Deferred tax expense/(benefit):	'	'
Deferred tax expense (benefit)	$71,274	$82,209

Note_16_Income_Taxes_Details_D

Note 16 - Income Taxes (Details) - Deferred Taxes Assets and Liabilities (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred Taxes Assets and Liabilities [Abstract]	'	'
Amortization of intangibles	$283,698	$283,698
Bad debt allowance	23,615	30,715
Patent litigation liability accrual	315,408	386,682
Operating loss carryforwards	18,220,482	17,355,970
Gross deferred tax assets	18,843,203	18,057,065
Valuation allowance	-18,843,203	-18,057,065
Net deferred tax liability/(asset)	$0	$0

Note_17_Subsequent_Events_Deta

Note 17 - Subsequent Events (Details) (USD $)	12 Months Ended			0 Months Ended				0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Mar. 18, 2013	Jan. 02, 2014	Jan. 02, 2014	Jan. 02, 2014	Jan. 02, 2014	Jan. 02, 2014	Dec. 31, 2011
				Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	CEO and Director Cornelis F. Wit [Member]
				Accrued and Unpaid Interest [Member]	CEO and Director Cornelis F. Wit [Member]	CEO and Director Cornelis F. Wit [Member]	Promissory Note Repaid [Member]
				CEO and Director Cornelis F. Wit [Member]	Promissory Notes Issued [Member]
Note 17 - Subsequent Events (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Debt Instrument, Face Amount	'	'	'	'	$980,000	'	$17,500	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	'	'	'	'	'	3,920,000	'	'	6,400,000
Related Party Transaction, Amounts of Transaction	'	'	'	980,000	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	2.00%	'	'	12.00%	12.00%	'	12.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)	'	'	'	'	'	0.25	'	'	0.25
Proceeds from Lines of Credit	$3,500,000	$0	'	'	'	'	'	$500,000	'